Micro-RNAS that control myosin expression and myofiber identity by Olson, Eric N. & van Rooij, Eva
a2) United States Patent
Olsonet al.
(0) Patent No.:
(45) Date of Patent:
US008962588B2
US 8,962,588 B2
*Feb. 24, 2015
 
(54)
(71)
(72)
(73)
(*)
(21)
(22)
(65)
(63)
(60)
(51)
(52)
(58)
(56)
7,232,806 B2
2005/0059005 Al
2005/0261218 Al
2006/0019286 Al
2006/0185027 Al
2007/0287179 Al
2007/0292878 Al
2008/0050744 Al
2008/0176766 Al
2008/0214437 Al
2009/0137504 Al
2009/0143326 Al
2009/0286969 Al
2009/0291906 Al
2009/0291907 Al
2009/0293148 Al
2009/0317369 Al
MICRO-RNAS THAT CONTROL MYOSIN
EXPRESSION AND MYOFIBER IDENTITY
Applicant: The Board of Regents, The University
of Texas System, Austin, TX (US)
Inventors: Erie N. Olson, Dallas, TX (US); Eva
van Rooij, Utrecht (NL)
Assignee: The Board of Regents, The University
of Texas System, Austin, TX (US)
Notice: Subject to any disclaimer, the term ofthis
patent is extended or adjusted under 35
U.S.C. 154(b) by 147 days.
This patent is subject to a terminal dis-
claimer.
Appl. No.: 13/796,884
Filed: Mar. 12, 2013
Prior Publication Data
US 2013/0245092 Al Sep. 19, 2013
Related U.S. Application Data
Continuation of application No. 12/671,436, filed as
application No. PCT/US2008/071837 on Jul. 31,
2008, now Pat. No. 8,481,507.
Provisional application No. 60/952,911, filed on Jul.
31, 2007, provisional application No. 60/980,113,
filed on Oct. 15, 2007, provisional application No.
60/980,3 14,filed on Oct. 16, 2007.
Int. Cl.
CIN 15/11
C07H 21/02
CO7H 21/04
US. Cl.
USPC oonccc eesereeeeeneneenes 514/44 A; 536/24.5
Field of Classification Search
None
See application file for complete search history.
(2006.01)(2006.01)(2006.01)
References Cited
U.S. PATENT DOCUMENTS
6/2007
3/2005
11/2005
1/2006
8/2006
12/2007
12/2007
2/2008
7/2008
9/2008
5/2009
6/2009
11/2009
11/2009
11/2009
11/2009
12/2009
Tuschlet al.
Tuschlet al.
Esauetal.
Horvitz et al.
Bartel et al.
Tuschlet al.
Raymond
Brownetal.
Brownetal.
Mohapatraetal.
Echwaldet al.
Obadet al.
Esauetal.
Esauetal.
Esauetal.
Renet al.
Hosodaetal.
2009/0326049 Al
2010/0029003 Al
2010/0280094 Al
12/2009 Aristarkhovet al.
2/2010 Bartel et al.
11/2010 Beuvinketal.
FOREIGN PATENT DOCUMENTS
EP 1777301 A2 4/2007
EP 1959012 A2 8/2008
EP 2113567 Al 11/2009
JP 2004-522411 7/2004
JP 2006-502693 1/2006
JP 2006-101790 4/2006
WO WO 02/10453 A2 2/2002
WO WO 03/065993 A2 8/2003
WO WO 2005/013901 A2 2/2005
WO WO 2005/017145 Al 2/2005
WO WO 2005/078096 A2 8/2005
WO WO 2005/078139 A2 8/2005
WO WO 2005/079397 A2 9/2005
WO WO 2005/118806 A2 =12/2005
WO WO 2006/013561 A2 2/2006
WO WO 2006/047454 A2 5/2006
WO WO 2006/063356 Al 6/2006
WO WO 2006/111512 Al 10/2006
WO WO 2006/137941 A2 12/2006
WO WO 2007/000668 A2 1/2007
WO WO 2007/035684 A2 3/2007
WO WO 2007/070483 A2 6/2007
WO WO 2007/073737 Al 7/2007
WO WO 2007/090073 A2 8/2007
WO WO 2007/112754 A2 10/2007
WO WO 2008/016924 A2 2/2008
WO WO 2008/042231 A2 4/2008
(Continued)
OTHER PUBLICATIONS
Chang, “International Search Report,” 4 pages, from International
Patent Appl. No. PCT/US2008/071837, Korean Intellectual Property
Office, Daejon, Republic of Korea (mailed Nov. 27, 2009).
Chenget al., “MicroRNAsare Aberrantly Expressed in Hypertrophic
Heart,” Am.J. Pathol. 170(6):1831-1840 (2007).
Sayedet al., “MicroRNAs Play and Essential Role in the Develop-
ment of Cardiac Hypertrophy,” Cire. Res. 100(3):416-424 (2007).
Tatsuguchiet al., “Expression of MicroRNAsis Dynamically Regu-
lated During Cardiomyocyte Hypertrophy,” J. Mol. Cell. Cardiol.
42(6):1137-1141 (2007).
(Continued)
Primary Examiner — Richard Schnizer
(74) Attorney, Agent, or Firm — Cooley LLP
(57) ABSTRACT
The present invention relates to the identification of two
microRNAs, miR-499 and miR-208b, that repress fast skel-
etal muscle contractile protein genes. Expression ofmiR-499
and/or miR-208b can be usedto repress fast fiber genes and
activate slow fiber genes in the treatment of musculoskeletal
disorders. Inhibition of miR-499 and/or miR-208b is pro-
posed as a treatment for cardiac hypertrophy, myocardial
infarction, and/or heart failure. Pharmaceutical compositions
comprising antagonists and agonists of miR-499 and miR-
208b function are also disclosed.
41 Claims, 39 Drawing Sheets
US 8,962,588 B2
Page 2 
(56) References Cited
FOREIGN PATENT DOCUMENTS
WO WO 2008/043521 A2 4/2008
WO WO 2008/061537 A2 5/2008
WO WO 2008/074328 A2 6/2008
WO WO 2008/076324 A2 6/2008
WO WO 2008/147839 Al —12/2008
WO WO 2009/026576 Al 2/2009
WO WO 2009/043353 A2 4/2009
WO WO 2009/058818 A2 5/2009
WO WO 2009/062169 A2 5/2009
WO WO 2009/114681 A2 9/2009
WO WO 2009/149182 Al 12/2009
WO WO 2010/048585 A2 4/2010
OTHER PUBLICATIONS
Thum etal., “MicroRNAsin the human Heart. A Clue to Fetal Gene
Reprogramming in Heart Failure,’ Circulation 116(3):258-267
(2007).
Lagos-Quintanaet al., “New microRNAsfrom mouse and. human,”
RNA,vol. 9:175-179, 2003.
Lagos-Quintanaet al., “Identification of tissue-specific microRNAs
from mouse,” Current Biology, vol. 12:735-739, 2002.
Sempere et al., “Expression profiling of mammalian microRNAs
uncoversa subset ofbrain-expressed microRNAswith possible roles
in murine and human neuronal differentiation”’ Genome Biology,
vol. 5:R13, 2004.
Van Rooij et al. “A signature pattern of stress-responsive
microRNAsthat can evoke cardiac hypertrophy and heart failure,”
Proc. Natl. Acad. Sci. USA, vol. 103: 18255-18260, 2006.
Landgrafet al., “A mammalian microRNAexpressionatlas based on
small RNAlibrary sequencing,” Cell, vol. 129: 1401-1414, 2007.
Landgrafet al., “A mammalian microRNAexpressionatlas based on
small RNA library sequencing,” Cell, Supplementary Table S12,
2007.
Van Rooij et al., “Control of stress-dependent cardiac growth and
gene expression by a microRNA,”Science, vol. 316: 575-579, 2007.
Habedanck, Supplementary European Search Report for European
Application No. 08797004.2, 13 pages, European Patent Office,
Munich, mailed Sep. 16, 2011.
Lorell et al., “Left Ventricular Hypertrophy: Pathogenesis, Detection,
and Prognosis,” Circulation, vol. 102: 470-479, 2000.
Olson, “Transcriptional Control ofHeart Developmentand Disease,”
Symposium Presentation at Duke University, Sep. 26, 2006.
Olson, Genetic Pathways in Cardiovascular Development and Dis-
ease, Symposium Presentation at University of Cincinnati, Sep.
2006.
US 8,962,588 B2Sheet 1 of 39Feb. 24, 2015U.S. Patent
   
SPSjwISPAS 4
1
“Dig
©
ADANDOVYVVWOONDOWDTERY
ROS-HILGIMCW
(s
‘on
aI
Sas}
n
o
Ov
¥
Y¥
a
¥
O’DY
EAWOYY
3D
DD
Yyw¥HoOAnONA
OND
of
OU
U
U
TPGL
TERITERITTE
TLE
©
deomers(ce-onaroas)
mon
ovnwin
O2905
AnnnsewoeO
OWO
LS
a
)
a
9
38
@
oR
F
R
E
E
R
E
R
E
E
L
E
Y
R
E
E
R
E
S
E
R
E
R
E
R
E
A
D
E
E
R
E
D
B
E
E
B
E
M
E
S
R
E
E
R
E
KR
B
E
H
R
P
E
R
E
R
E
R
R
R
R
e
WUIODTEOLLOOVYVC
W
I
WOOOWESC
L
O
W
LOOLWOOOCULLOOOL
O
D
L
L
L
O
C
O
O
VOL,
Bog
PWOLDATLIOLLOOV
P
U
T
I
O
S
T
O
I
EPUELYLOOTOLILOVOLOOVEELLOODODODO
L
L
L
L
I
O
UOL
O
D
O
3ea
POLOOLOLLOOUUYYOUDVDTULLOOVNLOLOVOLOOULELIOODOODDSLLEIOOUILDDOOYOEL
«sSSRoH
UDLOOLEDLLIOVLUC
U
O
OUNDVOE
T
O
VOLOLA
L
O
U
L
O
D
O
I
I
OLELOOYOOOOOOVOE
«BRUM
  
OHMS
Sedaaees
ueluny
Q4 9°Bh  Q4 £9°Se
{%fe{z(it
‘ON
UI
OusS}
"ON
GI
O#S}
'ON
aI
Os)
'ON
UE
O85}
US 8,962,588 B2Sheet 2 of 39Feb. 24, 2015U.S. Patent
   
o oo 8¢ © N ft
1OUIODILS
Aynoesuog =
==
=
Aynoeuoes
yse4
S
S
S
MOIS
aut
|
auL-
oo 8 8on 0 WH
uoissaldxe OHIN aAne(ay
°a
 
    :loot ODUILUpesACSCLEO AVIVcto)= MLEeyUeema
US 8,962,588 B2Sheet 3 of 39Feb. 24, 2015U.S. Patent
  
 
     
[aQuoA
  
Ayinoesyuog
OOS
Aypoesu0E9
MOIS
}se4
El
v
y
ecenneerrnereveeemirninaecnesoenanematn
A
A
uisipioshyjodAHssa
STUTLEM
N
S
2tegWAVi\to)=
RETEsreyUES]78)
 
US 8,962,588 B2Sheet 4 of 39Feb. 24, 2015U.S. Patent
uolIssaidxe
S
H
Y
eaAeyay
 
SLIveyUBWINY
UlJuesaidA
 
UTEsLereyYasLE
 
US 8,962,588 B2Sheet 5 of 39Feb. 24, 2015U.S. Patent
 
y
“OL
  
 
a)5lIv
:
:
'
pexol-]
jeds
.
yeds
ucIsIax3
PSE]Poy-s1D
a
y
;
poaebie
4a
uoneuiquosey
snoBojowopy
JOLOBA
Sunebie;
aohy
odAy-PHM
 leds
dq ¢¢
jedg
Le
LelUbRLUISMtAmeLe
 
US 8,962,588 B2Sheet 6 of 39Feb. 24, 2015U.S. Patent
g
“OL
etpere
seaSahn
 Om
~/+
LM
yWeayjeyeucen
 
LIBOLHIVIBUOSAYul
teteh
e
Be)imere
ormle\BeeROvmtransLL
 
US 8,962,588 B2Sheet 7 of 39Feb. 24, 2015U.S. Patent
9
“SIg
 
  
  
  
 
 
 
SHA
OX
80
 
DEGLISAGBINSSSigBuimojyjos
Z-MiluUlSisolgi4
pue
AudosedAL
pousiuimmig
US 8,962,588 B2Sheet 8 of 39Feb. 24, 2015U.S. Patent
 
 
         
 
 
 
 
Oy
807-yIW
sueBsuelL
uunaulgje5
o1ueHsuel]
ULNeUlsje9
LSTULES
teTEs)fe)-s@MexMrieletcroysBey
oi
OdeirApe|LUEEventBeeitrlenieelseestee|
 
US 8,962,588 B2Sheet 9 of 39Feb. 24, 2015U.S. Patent
8
“DIE
 
|
1SPJ
 MoOjsOHIN-d«<——
SHI?
re).
LM
—]{_—_————
—
:Bj-u9
+
-
+
=
‘VL
2
3
2
02
e
s
or
a
a
09
3
3
a
g
8
3
a.
°
oO
=
=
 
 
 
 
OHI-9
totPFTSOTMSsL610to:beEeeEe|g
Och
 OHW-dUePet
ReeLe
Ral
Remirageise
 
US 8,962,588 B2Sheet 10 of 39Feb. 24, 2015U.S. Patent
6
“OTs
 
   
 
 Bisoz-yiw
=
edAy-pyin 
Toyictcreseb=Me)siiemayeleye)emer
IUSIDILING SIGOZ-MIwW 10UGISSIIAXA-1BAO
 
US 8,962,588 B2Sheet 11 of 39Feb. 24, 2015U.S. Patent
OL
“SIA
eydyje jo uONeAIIe
S}USABId pue e}Eq JO UOISSeldd/ SAADI}O1 L
d
 
  
 
 
 
SHINY
wisipiolAujodAu
 
Oo»
LM
a8
a
—_
+
=
:Ald
oeuoos
e
s
AyipoequogET
Se7-S
 AnaeUOD
OO£
oy
'
t
P009
§
aus
mom
ue
-006
g
~
~
-002)FZ
LE
a
00S}
=
0081>
s
u
e
t
be)ee
t
e
s
e
ReeaLe
l
RObcmsiTareto
 
U.S. Patent Feb. 24, 2015 Sheet 12 of 39 US 8,962,588 B2
 
 
 
1
 
FI
G.
=>i)=
&7mAaboio}>Lad
‘S)-s
Rendaie)i  ‘e:    
US 8,962,588 B2Sheet 13 of 39Feb. 24, 2015U.S. Patent
et
“Old
syjunoyoeaquoes
    
‘
sjeuBis
jequauidojaaegq
  
 
   
el nid
v
/
Buyeubis
L
L
L
$se83S
S0c-HIw
e
l
F
T
L
A
L
   
slebiel
souedejosniy
12}3/8NS
SerleoerBoseonlle
 
PSTLECATELengESLOhLS@Bemett
LoeMCATDeRyBatyAerLee)
U.S. Patent Feb. 24, 2015 Sheet 14 of 39 US 8,962,588 B2
 
 
mi
R-
21
mi
R-
19
5
 
  43
FI
G.  
sm=
= .
orn
Oe
od -2
ae
®.=oadee
oS
e..mneyndft
oaoi 
US 8,962,588 B2Sheet 15 of 39Feb. 24, 2015U.S. Patent
y     
MAAS
metel aleree
OL
“S14
HddvV9
q.yAw
66r-y!W
80e-uIW
TPO
STtowehCoM-yrooELLE
US 8,962,588 B2Sheet 16 of 39Feb. 24, 2015U.S. Patent
OVVLELOWVILVOYUDLYOLLE-LOLYWWWLLO
OVVLLLOYVOLYOVUDLYOVLLYLDLIVY--ALYOUELL
OVVOW WO
VO
LYOV VOLS
LVIO- LOLIO--LLYWELLID
DVVOOWO
VOLYOVVSLOSYDD-
LO10D--LOVVLLLS
DVVIOYTDWOLVOVYOLDOYDD-
LOLOD--LOVVLLLo
DVVOD
YO
VO
LYOVVOLS
LVYOO-LOLD09--LOSVLELD
DOVVONTOVO
LYOVVOLOLYOS-LO
LOD--LISVLLLOE
     
St
“Sid
aAnnSnavansvoonnowoWWoAnN
66P
Yiu
(oz-ONaIOSS)
on
ens
eB
bn
on
----
n
6o
nBeeoenoea
BoeeBnon
56a
BonSoon
Po
UVTETELEREPda
TEL
TL
PREREL
66PMIU-e1d(sz‘ONal038)
>
of8
ennnbnebnb
ofnnorbe
nb
s6eshS5
on
---
2
en
on
nDOH5
            WELLDYVODDWOODY  DOODDDOODDLODOWOOLLODD—WOODOOPDOODDOLLOIOLDLONDDOVODDNLODOLLD-—LOLODDL-—DYOOODLOPOLLOLILOLOD
-ainjoidSIU]88SO]pepsauaie
Josseiduiosep(passeidwiooun)sale
©PUe
wy.SULYOIND,
t
Gz
uleyo Aaeay
UIsoALy
S
T
S
c
o
n
e
k
a LISI—
sipeoido.yX(pz:onalO58)
USBYOIYD(ez‘ONCIOSS)
BYOBNSOPDODIOLNI|NLOOOO—-—s
wnsoddoizz:onaloas)
6oq(izonai03s)
ueBLUNH(0z‘ONalOFS)
FEY (6L(ON GiDAS)
BSNOW(8b‘ONdl03S)
US 8,962,588 B2Sheet 17 of 39Feb. 24, 2015U.S. Patent
 
gl
tiemeed
OM
B0e-uI
Bapyitu
alle Pi
Boz-HIM
adAy-PIIAA
e
s
r
2
a
&
a
o
x
m
a
2
4
o
Pe
os
&
   
G6PW
i 
 
‘Old
  
 
a0
   
   HodveS:qauknneerHie.&“(66mHI
G
gx
8gi
Vv
U.S. Patent Feb. 24, 2015 Sheet 18 of 39 US 8,962,588 B2
Daw+
fe&
ing
ca
rd
ia
c h
yp
er
t
FI
G.
17
 
=Sss)roLd
a=
oy)2SI=oS
a&aeSya= 
US 8,962,588 B2Sheet 19 of 39Feb. 24, 2015U.S. Patent
St
“DId
66r-y)u
VENNNONVSNDVOONNOVOVVNN
-.S(se
‘onaISas)
80c-uiw
NNNDNNIOVVVVVODYOOVOVYNY-G
(se
:ONar
das)
aJ9lWOo1eS
Aunaequog S+S—=+= Ayinoequoy
1sBLj
iS=o-=
MOIS      80¢-qlwsauaryoosniyIE}SSHSeeReceeLC roaLsme)slPeesaasom
 
US 8,962,588 B2Sheet 20 of 39Feb. 24, 2015U.S. Patent
 
6L
°DIa
soueb
JequyoAuw \se4
    SSIUISCIEISONSE
4.2...GGP-YILW
|
\
ZN
cJSiN
sjeuBbis ssayg
=
80Z-w!lu
cAAWN
syiw-oAi
Aq
uolssasdxe aueh
sjosnlu pajyelis jo joljuoD
 
US 8,962,588 B2Sheet 21 of 39Feb. 24, 2015U.S. Patent
by
2
66b-dTe
pue
“80g
“Aey
‘asnoy
 
“oO
440
49° 0
¥G"0
m
e
m
z
m
e
W
O
0%
“Sia
y
‘
se-utl
éz-uy
‘ueUNnH
UT
PeAsaSUOD
SBFTPFWes
YRYFH
JOY
SORTS
Pesussuoy
euay»+
4
t
L¥e-aye
zatvapt-ai
create
reerune
ZVHR-BIH
peure
Lovéeot-atw
E
u
see“
epb/vemnt
cute
e
a
t
erat
ape-aie
zara
o2G/eee/2Lb/Z06/G62/r6z/de~FEZ/RU S
U
T
gota
de-zpt-anl
a
u
ezz-ut
er-ard
pete/goT/mres/oz/de-ct-utd
ee-urd
¥
soz-utonan
£60/b2b/e5t/aT/cT-aIe
s6/oe/dereTrate
Torun
sor-urd
LorcoT-utW
seat
rotund
ar-at
uaATY]
PUE
<Bog
49ey
‘asnoy
‘uPUNY
UT
penJesunD
sOTT_TWeJYAMITU109
SOQTs
peruasuD]
 
 
ZTTaUISUST
AN
-E
SZZECOWN
OaNd
YEOH
 
ousy
°
%
*
8
»
z
.
ST-uF{
82t-a1”
eot-utd
oeT-an
szb/aoe-utl
eat-ure
cey-ard
S281a
ar-urd
sze-and
opreure
sz-ara
[
e
s
e
t
|
vree/ozsdg-ct-ure
get-uie
opts
dcet-aiater-ui
goz-uye
bebeacog-UTe
LBb/veb/oSt/OL/er-uTe
avenute
pendi
dg-zer-ure
tot-an!
ae-urd
sete
e
e
u
PSTY:su
erat
6ep/'o0g-ute
uayoFyy
pure‘Bog
2e%
<asnoy
“UGUNY
UT
pantesuod
SIFTTMCS
UNYTM
JDJ
SOqTS
passtosting  78
4
uvibtaL)elelleHesVOML
U
occemmycyoePLOUCoyPereyUOC)OlOro
COBESUIAUET
YEN
LE
T2TSOOWN
FdHUHL
WeUny
auag
a
>
t
84094Ln
ound
Hn
bdVYHLUn
 
US 8,962,588 B2Sheet 22 of 39Feb. 24, 2015U.S. Patent
quSewes.)
skep
TZ
 
 
 
quawes.
qUuSWed2}
JUSLUPS5]
qowesn
aulpeseqg
skep
¢t
shep
6
skep
9
skep
¢
791PN1duosheq
7®1PNiduosheq
TZ
St
GE
ZT
GG
9
€E
O
.
TZ
St
ST
2
6
9
€
O
0°0
I
B
a
i
a
cae00°0
,¥
LSz
LSZ'O
2
4
.
a
a
he
|
os
Aa
+OS°O
4
4
“
a
>
LSZ
LSLO
f
a
.
On
«
*
v
2
©
F
8
,
LO°OT
vy
|
oot
2
@
v
a
LGtr
LGz't
SHIN[PAD]
UOIsseidxssAQREIDY
ate
‘Ola
DHWD
[eAaq]UOISSesdxaDAILEIEY
W
T
“Ora
 
US 8,962,588 B2Sheet 23 of 39Feb. 24, 2015U.S. Patent
PIO}E°T
PjOS E°TT
PjOJ 8°9E
PIOJGEL
ce
OIA
ude
jeyajayseudiy
je}a/BxS yseJ‘OW
JeJajaHSyses‘ELumodosy
JPJ@BjOSYsey‘TuUlUodosyDeipueD
 
U.S. Patent
 
Feb. 24, 2015
 
 
 
 
g
a ==a °<<
ee
on om CO MH TF MO N
SUUP) GABON
©“
© 5zo g
| { ij I | | :$a&88s8 8 8¢ &- ee
SYUN BANESY
2
9 5=8 g
eee |anertrnqgaortagNrrr.rwr = 8 OG So Ga
SHUN eARB]EY
Sheet 24 of 39
TA
B
Ba
se
li
ne
TA
B
Ba
se
li
ne
TA
B
Ba
se
li
ne
23
FI
G,
US 8,962,588 B2
US 8,962,588 B2Sheet 25 of 39Feb. 24, 2015U.S. Patent
  é, Jossaiday
 
|
_
.
g07-yIW
 
1 OHING
 
 
 
soueb
Je]ajays Jsey
;  
 
  
\/
 
SHIN?
 
  
 
Ajiyjoesuoo jsey
|
 
veSls
  802-ulu
 a
 
aueb JH? I+
AIIIIIII
 
sjeubis peaiBojoyjed pue
jearBoyjoishyd‘jejuawidojeneq
 
US 8,962,588 B2Sheet 26 of 39Feb. 24, 2015U.S. Patent
S@
“pid
BR
P
E
R
R
Y
RENE
HR
e
e
E
E
R
E
K
E
RHEKREKRKER
HHH
DOWW
O
N
W
O
W
WOO
W
U
T
T
O
W
Nwoanonbony----vnpawnvawywaonopanrwoowWWANAoANooNAN(€t:ONGIbas)Ysyesqaz
WWUWOWOU WNW W
W
W
E
Y
noonppnvvnenvnpnvovayyyvonnoonnwwoo-wwnnndenoonn
§=6(zt:onarogs)
nbn4
DONNOSDOVAOWOSNNOOWWYVOOVWONSRON--
- -YOOOYAYONWYEOONDONNYWODYYWOOADOnADAN
$(TTION GI O3S) USHdIYD
DennoDOWnDWOSnnOo
V
T
YYhnoWWononeon-- - -wapnvwonwnrywwnonosnnywopyywnoandennonn
§=6(OT:ON al das)
60q
DOnNSSSwaDWoonnooW
a
n
ennonpony----vnpawavaywywnaonoonnwwopywywnonopnnonn
=
—
s
(6:ONdi63s)
ey
DENNSDSWNWooOnnooWY
W
WhnWwnnonpoav----vnoowawaAvwYwnonDDnnwwoSwyvanadenanonn
(8'ONGI03S)
s
u
n
DDANDSOWNOWOONNOOVWWNNWEnNONpoON----whonwawovywwnonoonnwwopyywnondennonn
=
(Z:onardas)
duuyD
DoOnnSSownoWwoaNnowWYYWnANYWhnOonpoaV----wopowawowwwwoonDonnwwooNvwnANDDNNINN
=
(9:oNa1das)
URWNH
PEAT
AW
d
o
e
(S°ON GI O3S) 80OzZ wI
«LS
~YaWWwOWOSW------pOWWWWwpOOnen
«=6¢
TdVUHLULE
(T 48quINUdVUHL) J251e3 aiqissodpeylpeid ov
142131d
(gJaquinudVyHL)326129aqissodpaypipeidST
SBPUueYIW
:uonoipeid yabuey
US 8,962,588 B2Sheet 27 of 39Feb. 24, 2015U.S. Patent
9¢@
“Old
B0Z
wit
O@T
wil
 
Bu0Sz
oot
os
6uasz
aot
os
BSEIOJON|-TAVUHLULILE
 
 
 
US 8,962,588 B2Sheet 28 of 39Feb. 24, 2015U.S. Patent
  
soueb
[B]BJOYSISeF
 
 80¢-yu
 
  
I[_feJE}OHS1se4
ureydyUbrqursoAy   £¢SlsSHUN @AHEIOY
OM
LAK
   JeeJEHSJSey*Luruodosy
SUUP) SAHEOY
 
   rO04r82h-OFL}PJS}eyHS jseq“|utuodosy
SLU SARE[AY
US 8,962,588 B2Sheet 29 of 39Feb. 24, 2015U.S. Patent
8¢
“DIa
NOONHASSYVVYOVVOOVOVTOY
2D
fe
ze
5
onB
n
Seenenee
o6e
seeeebSnnnnonbebb5
©(MITAMTLUUHILULIMIT
2
nnnénenn
bon
Snnnnnofee
SHeonono
no
&
2
6
o--
OVLLOLILSLLOOYYYLYO
BwDDWOVULYLO
LLYLIS LO.LLLL
DLS
LOLSLOLLLODUNYWOVWOOVOVWLY
L
U
D
LOLYOOLLIA
SDOVILOILOLLILSovuvwoue
DVOVWLWLYWO
YO
LVSLOLLL
DOPOD
LOLDLLLD
O
V
Y
V
WOUNDJWOVWLVLYVO
YOLYS
LOLLL
SdPoVOLOLOLLID
OWUYUOWYDOVOWWLYLYWD
OO
LVOLOLLL
PDD
VOLOLOL
L
L
OVEYWOTUS,OWDWWLWLYWO
VOLYOLILLE
qg0z-yiu
A
qn
SET
a807-ylw(22
‘ON
dI
Ogs)
G807-Ulwi-oad (9¢
‘on aI a5)
syecedog,
*x (Se
‘ON
dI
unssodo(re
‘ON
dI
Boa(ce
*ON
dr
Wa
(Ze
1ON
AI
@SNOW(TE
‘ON
CI
UEUNH
(OE
‘ON
AI
DHINGJOLEUosU!UII
pazedo]Siqgoz-yIW
Oas)
ous)
as)
ous)
oas)
ous)
AITS
A
Y
N
A
I
A
 
US 8,962,588 B2Sheet 30 of 39Feb. 24, 2015U.S. Patent
 
6%
‘OIA
(§(ONGTO85)NDNOSDDYVYWWOOYDPYOYUN
gOZ-uIW
eudje‘guéy
(21ONatdas)NPNNNPOSVYUVOVYODYOVWOW
qgoz7-Mw
BVaq‘JUAW
 
 
 
1U0Aiqua
‘eyAy
gq
BI ‘ZUAW
x11‘LUA
ail‘puAW
jeqeuad‘gud
sepnooesyxe‘¢LUA
qzudueye‘pLyA
auSb UISOA]
    
(@arhevor 
 
 
GEOET
j
ray
IOP)8Lb  
  
@sibr'st
 
a
varays
 
 
ooo
ANCIENT
M
I
T
TYY OY
-— PUBl}s Salata
ay eo°tz
 
  
sewUl
 
 
cut T
M
T
AS
T
E
um
PUBIS Selaray
 
  
 
wiaw
etttydarsLULAtyAgbsLL O01CS ZA
   
US 8,962,588 B2Sheet 31 of 39Feb. 24, 2015U.S. Patent
 
flid
 66P-uielg0cRNwe 0¢“Sls     agnz- erHilune
 
  
 
Qe
~
e
<
e
2
22
t22
fel
=
*
=
aa
Fes
EE
3
FE
3
g
a5
It
aL2
z
Sho¢
qi uaw
e
s
e
e
8
OHIN=
Abbewit
QRGE~HIS
BOT-HNE
“a3
WL
dD
snpjog
Heo
aooeoBe
 
US 8,962,588 B2Sheet 32 of 39Feb. 24, 2015U.S. Patent
66P-yluW
 ey
e
e
e
wa»
.
 qgot-alw
 
soc-ulu
      
€173
Nld
Nid
jeuuoU
Stelem
eR
AS Bods LetereyMercenmComollielere keyme
 
US 8,962,588 B2Sheet 33 of 39Feb. 24, 2015U.S. Patent
ee
‘Od
‘e
qgoz-alw
 e
e
a
L
he
   
 
soc-yiu
SAePTZ
sAepST
sAepe
skep 0
SCLRoyUVMPRM emtelil-](alel-emeyAwe]
 
US 8,962,588 B2Sheet 34 of 39Feb. 24, 2015U.S. Patent
e€€
“Old
BIBWIODIES
hy
F
e
s
«,
DL
euog
Sats
e11U0
sed
E
s
p
o
s
80z-uIW
LM
      
80¢-uiur
|
saueyaosniy
IEeIONS
 
RCeyUNIVLIEReyAt(RCL
T
MUMeyl=][telcoMts
y
ict10dpyAOeLEE
qsoz-ulw
_ qgoz-unu
66P-ylwW
V
 
US 8,962,588 B2Sheet 35 of 39Feb. 24, 2015U.S. Patent
 ve
“DIA
Buljapouies seipseo
W
K
_
jeaibojouzed
mr
|
qZOHW
OS1Y-667-ay!w
   
 
OS1u:807-wIul
M
V
osty“480c-ut
_
|
Sum
rf
  
e
e
e
  
sEoireta(@Beer)oyBLOVEC)UISTreyNTRvd
 
US 8,962,588 B2Sheet 36 of 39Feb. 24, 2015U.S. Patent
  
 
   
 
 
 
feces£
*
—
—
—
we
.
THES
THWweg
qx£°9
uoneuiquiosay
snoBbojowopH
dXO1
dX01
q4
6'b
i
Inujfed
*
[eae
“
dq
9z
|
IHweg
«
™
IHweg
 
qy
TOT
{q80e-ylwuLelyAeLemiVeLL-eiLomole]pt=)eel-aEl
BIPHV
pajaiuey
AOJIIA
Bunjebiel
SPly
odAq-PIEMFr}wo1yD
qeod-ulu
  
US 8,962,588 B2Sheet 37 of 39Feb. 24, 2015U.S. Patent
9€
“DIA
 
yoeoidde
,aBuods,
ajosnu
[233]394S
ez
ronatois)
NNNONWOSNOWOSNONOWOWTwToON
667-aTw
uz tox at 03) DDOANNDDWYWWOVWD OVDVVOV:98072
~aTul
issonarois)
N
O
N
N
O
D
W
V
W
V
V
V
O
D
T
O
O
W
O
T
v
n
V
*80c-aFul
SMIW-OAI
OU} S}ejndiuew Oo} sayseoudde OAJA uf
 
US 8,962,588 B2Sheet 38 of 39Feb. 24, 2015U.S. Patent
26 Old
       JURLAOUS
C45)
   
 
    
 
jurinw aysZN
dA,BIN
ad] HAA
peey INDY
BOAIGMIA SZ
LOS
-
Aareae
ogdennw
66p Ww
ON
LA
BL
LAA
q
C
e
eee
e
gesan
Bogor
Begg,
Bu ge
yee
 
 
    
eqnyeh
 
 
BRE +
U.S. Patent Feb. 24, 2015
 
 
 
Sheet 39 of 39 US 8,962,588 B2
       
 
 
 
 
    
A = 80 D ild-type MCK Tg miR-4993 ,5 miR-499 ‘ —€ 70
5 60
¢WT 3°? a: BS 40 imiR-499 g2
S530
oe
g 20
MCKTg = 40
miR-499 o
i 8 a oO = alBa 6 FGx= Gsw
C BMHC Tnni2 TnnT3 E PTU° _ “ miR-499 _ Tg
50 . 12 miR-208 WT KO wWTKO WT KO
40 1 1 :
“oy
0.8:
30: 0.836 8 miR-499
o4 04
10 oe 0.2
a 0 o
rpenk wg roh gal twa goga°rG ga°"R 30rd miR-208b=i 6 x=s rs
a ” “ 25002000] WT
F 15004 Ml KO
TnnT3 Tnnl2 1000+140 ml pMHC
120 7 regular chow PiU
PIU &miR-499 Tg
100 -
80 -
60 -
40 4
20 4
0
WT KO KO & WT KO KO &
miR-499 Tg miR-499 Tg
PIG. 39
US 8,962,588 B2
1
MICRO-RNAS THAT CONTROL MYOSIN
EXPRESSION AND MYOFIBER IDENTITY
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a continuation of U.S. application Ser.
No. 12/671,436,filed Jun. 25, 2010, whichis a national stage
application of International Application No. PCT/US2008/
071837, filed Jul. 31, 2008, which claims the benefit of U.S.
Provisional Application No. 60/952,911, filed Jul. 31, 2007;
US. Provisional Application No. 60/980,113, filed Oct. 15,
2007, and U.S.Provisional Application No. 60/980,3 14,filed
Oct. 16, 2007, all of which are herein incorporated by refer-
encein their entireties.
STATEMENT OF GOVERNMENT SUPPORT
This invention was made with grant support undergrantno.
HL53351-06 from the NationalInstitutes ofHealth. The gov-
ernmenthas certain rights in the invention.
DESCRIPTION OF THE TEXT FILE SUBMITTED
ELECTRONICALLY
The contents of the text file submitted electronically here-
with are incorporated herein by reference in their entirety: A
computer readable format copy ofthe Sequence Listing(file-
name: MIRG 004 03US SeqList ST25.txt, date recorded:
Mar. 12, 2013 file size 9 kilobytes).
FIELD OF THE INVENTION
The present invention relates generally to the fields of
developmental biology and molecular biology. More particu-
larly, it concerns gene regulation and cellular physiology in
cardiomyocytes and skeletal muscle cells. Specifically, the
invention relates to the inhibition of a MEF2-dependent
miRNAthatresults in reduced expression of }-myosin heavy
chain B-MHC) as well as a second miRNA that is co-ex-
pressed with B-MHCInhibiton of these miRNAsprovides a
treatmentfor cardiac hypertrophy and heart failure. Also con-
templated is up-regulation of these two miRNAsto treat
musculoskeletal diseases where fast-to-slow muscle fiber
switch is desired.
BACKGROUND OF THE INVENTION
Heart disease and its manifestations, including coronary
artery disease, myocardial infarction, congestive heart failure
and cardiac hypertrophy, clearly presents a major health risk
in the United States today. The cost to diagnose, treat and
support patients suffering from these diseases is well into the
billions of dollars. Two particularly severe manifestations of
heart disease are myocardial infarction and cardiac hypertro-
phy. With respect to myocardial infarction, typically an acute
thrombocytic coronary occlusion occurs in a coronary artery
as a result of atherosclerosis and causes myocardial cell
death. Because cardiomyocytes, the heart muscle cells, are
terminally differentiated and generally incapableofcell divi-
sion, they are generally replaced by scar tissue when they die
during the course of an acute myocardial infarction. Scar
tissue is not contractile, fails to contribute to cardiac function,
and often plays a detrimentalrole in heart functionby expand-
ing during cardiac contraction, or by increasing the size and
effective radius of the ventricle, for example, becoming
hypertrophic.
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With respect to cardiac hypertrophy, one theory regards
this as a disease that resembles aberrant developmentand,as
such,raises the question ofwhether developmentalsignals in
the heart can contribute to hypertrophic disease. Cardiac
hypertrophy is an adaptive response ofthe heart to virtually
all forms of cardiac disease, including those arising from
hypertension, mechanical load, myocardial infarction, car-
diac arrhythmias, endocrine disorders, and genetic mutations
in cardiac contractile protein genes. While the hypertrophic
response is initially a compensatory mechanism that aug-
ments cardiac output, sustained hypertrophy can lead to
dilated cardiomyopathy (DCM), heart failure, and sudden
death. In the United States, approximately half a million
individuals are diagnosed with heart failure each year, with a
mortality rate approaching 50%. The causes andeffects of
cardiac hypertrophy have been extensively documented, but
the underlying molecular mechanisms have not been eluci-
dated. Understanding these mechanismsis a major concern in
the prevention and treatment of cardiac disease and will be
crucialas a therapeutic modality in designing new drugsthat
specifically target cardiac hypertrophy andcardiac heart fail-
ure.
Treatment with pharmacological agents representsthepri-
mary mechanism for reducing or eliminating the manifesta-
tions of heart failure. Diuretics constitute the first line of
treatment for mild-to-moderate heart failure. If diuretics are
ineffective, vasodilatory agents, such as angiotensin convert-
ing enzyme (ACE) inhibitors(e.g., enalopril and lisinopril) or
inotropic agent therapy (i.e., a drug that improves cardiac
output by increasing the force ofmyocardial muscle contrac-
tion) may be used. Unfortunately, many of these standard
therapies have numerous adverse effects and are contraindi-
cated in some patients. Thus, the currently used pharmaco-
logical agents have severe shortcomingsin particular patient
populations. The availability ofnew,safe and effective agents
would undoubtedly benefit patients who either cannot use the
pharmacological modalities presently available, or who do
not receive adequate relief from those modalities.
The ratio of a- to B-MHCisoforms in the adult heart is a
major determinant ofcardiac contractility. }-MHC,the major
myosin isoform in the adult heart, displays relatively low
ATPase activity, whereas a-MHChas high ATPaseactivity.
In responseto a variety of pathological stimuli such as myo-
cardialinfarction, hypertension, and other disorders, }-MHC
expression increases, while a-MHC expression decreases
with a consequent reduction in myofibrillar ATPase activity
and reduced shortening velocity ofcardiac myofibers, leading
to eventual contractile dysfunction. Remarkably, minor
changes in a-MHCcontentofthe heart can have a profound
influence on cardiac performance.
Numerous signaling pathways, especially those involving
aberrant calcium signaling, drive cardiac hypertrophy and
pathological remodeling (Heineke & Molkentin, 2006).
Hypertrophic growth in responseto stress involves different
signaling pathways and gene expression patterns than physi-
ological hypertrophy as occurs in response to exercise.
Stress-mediated myocardial hypertrophy is a complex phe-
nomenon associated with numerous adverse consequences
with distinct molecular and histological characteristics caus-
ing the heart to fibrose, dilate and decompensate which,
through myocyte degeneration and death, often culminates in
heart failure. As such, there has been intense interest in deci-
phering the underlying molecular mechanismsand in discov-
ering novel therapeutic targets for suppressing adverse car-
diac growth.
Adult skeletal muscle fibers can be categorized into fast
and slow twitch subtypes based on specialized contractile and
US 8,962,588 B2
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metabolic properties. These properties reflect the expression
ofspecific sets offast and slow contractile protein isoforms of
myosin heavy andlight chains, tropomyosin, and troponins,
as well as myoglobin (Naya et al., 2000). Slow-twitch
muscles are primarily used in chronic activities such as pos-
ture maintenance and sustained locomotor activity. Fast-
twitchfibersare used primarily for high-force burst activities.
The adult skeletal muscle phenotypeis not static but instead
retains the ability to adjust to variations in load bearing and
contractile usage patterns, resulting in adaptations in mor-
phology, phenotype, and contractile properties. For example,
the removalofbody loading in the microgravity environment
of space flight results in a marked degree of muscle atrophy
and an altered protein phenotype that correlates with a slow-
to-fast change in contractile and metabolic properties for both
rodents and humans(Tsika et al., 2002; Baldwin and Haddad,
2001; Edgerton and Roy, (2000); Fitts et al., 2000).
Disuse atrophy, which is a muscular atrophy that results
from lack ofmuscle use, is typically seen in bedridden people,
people with limbsin casts, or those whoare inactive for other
reasons. Disruptions in myofiberelectrical activity, including
denervation, also lead to muscle atrophy. After short periods
of disuse, muscle atrophy is reversible. Extreme disuse of a
muscle, however, may result in a permanentloss of skeletal
muscle fibers and the replacementof those fibers by connec-
tive tissue. It is contemplated that by repressing fast fiber
genesin skeletal muscle and thereby activating the reciprocal
expression of slow fiber genes, the symptomsofmuscleatro-
phy may be reduced or prevented. There is also a positive
correlation of insulin resistance (a deficiency of insulin-
stimulated glucose uptake seen in patients with type I] diabe-
tes mellitus) with the percentage of slow-versus fast-twitch
muscle fibers.
MicroRNAshave recently been implicated in a numberof
biological processes including regulation of developmental
timing, apoptosis, fat metabolism, and hematopoietic cell
differentiation among others. MicroRNAs (miRs) are small,
non-protein coding RNAsofabout18 to about 25 nucleotides
in length thatare derived from individual miRNA genes, from
introns of protein coding genes, or from poly-cistronic tran-
scripts that often encode multiple, closely related miRNAs.
See review ofCarringtonet al. (2003). MiRsact as repressors
oftarget mRNAsby promoting their degradation, when their
sequences are perfectly complementary, or by inhibiting
translation, when their sequences contain mismatches.
miRNAsare transcribed by RNA polymeraseII (pol II) or
RNA polymeraseIII (polIIT; see Qi et al. (2006) Cellular &
Molecular ImmunologyVol. 3:411-419) andarise from initial
transcripts, termed primary miRNA transcripts (pri-miR-
NAs), that are generally several thousand bases long. Pri-
miRNAsare processed in the nucleus by the RNase Drosha
into about 70- to about 100-nucleotide hairpin-shaped pre-
cursors (pre-miRNAs). Following transport to the cytoplasm,
the hairpin pre-miRNAis further processed by Dicer to pro-
duce a double-stranded miRNA. The mature miRNAstrand is
then incorporated into the RNA-induced silencing complex
(RISC), where it associates with its target mRNAs by base-
pair complementarity. In the relatively rare cases in which a
miRNA base pairs perfectly with an mRNAtarget, it pro-
motes mRNA degradation. More commonly, miRNAs form
imperfect heteroduplexes with target mRNAs, affecting
either mRNAstability or inhibiting mRNAtranslation.
The 5' portion of a miRNAspanning bases 2-8, termed the
‘seed’ region, is especially important for target recognition
(Krenz and Robbins, 2004; Kiriazis and Kranias, 2000). The
sequence of the seed, together with phylogenetic conserva-
tion of the target sequence, forms the basis for many current
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target prediction models. Although increasingly sophisti-
cated computational approachesto predict miRNAsandtheir
targets are becoming available, target prediction remains a
major challenge and requires experimental validation.
Ascribing the functions of miRNAsto the regulation of spe-
cific mRNAtargets is further complicated by the ability of
individual miRNAsto base pair with hundreds of potential
high and low affinity mRNA targets and by the targeting of
multiple miRNAs to individual mRNAs. Enhanced under-
standing ofthe functions ofmiRNAswill undoubtedly reveal
regulatory networks that contribute to normal development,
differentiation, inter- and intra-cellular communication,cell
cycle, angiogenesis, apoptosis, and manyother cellular pro-
cesses. Recently, the inventors reported a cardiac-specific
microRNA, miR-208, which is encoded by an intron of the
a-myosin heavy chain (MHC) gene, andis required for up-
regulation of B-MHCexpression in responseto cardiac stress
and for repression of fast skeletal muscle genes in the heart
(see co-pending application WO2008/016924, which is
herein incorporated by reference in its entirety). The present
invention expands on the involvement of microRNAsin the
heart and skeletal muscle.
SUMMARY OF THE INVENTION
The inventors have discovered key roles ofmicroRNAsas
regulators of the growth, function and stress responsiveness
ofthe heart, revealing undiscovered regulatory mechanisms
and potential therapeutic targets for heart disease. Accord-
ingly, the present invention provides a method of treating
pathologic cardiac hypertrophy, heart failure, or myocardial
infarction in a subject in needthereof. In one embodiment, the
method comprises identifying a subject having cardiac hyper-
trophy, heart failure, or myocardial infarction; and inhibiting
expression or activity of miR-499 and/or miR-208b in heart
cells of said subject. In another embodiment, the method
further comprises administering to the subject a second
therapy. The second therapy may be, for example, a beta
blocker, an ionotrope, a diuretic, ACE inhibitor, AII antago-
nist, BNP, a Ca**-blocker, and ERA, or an HDACinhibitor.
In some embodiments of the invention, inhibiting the
expression or activity of miR-499 and/or miR-208b com-
prises administering an antagomir of miR-499 and/or miR-
208b. In one embodiment, the present invention provides a
miR-499 or miR-208b antagomir. In another embodiment,
miR-499 and/or miR-208b expression oractivity is inhibited
by administering an antisense oligonucleotide that targets the
mature miR499 and/or miR-208b sequence. In yet another
embodiment, miR-499 and/or miR-208b expressionor activ-
ity is inhibited by administering an inhibitory RNA molecule,
wherein the inhibitory RNA molecule comprises a sequence
having identity to the mature miR-499 and/or miR-208b
sequence. The inhibitory RNA molecule maybe a ribozyme,
siRNA or shRNA molecule.
The present invention also provides a methodofpreventing
pathologic hypertrophy or heart failure in a subject in need
thereof comprising identifying a subjectat risk ofdeveloping
pathologic cardiac hypertrophyor heart failure; and inhibit-
ing expression or activity of miR-499 or miR-208b in heart
cells of said subject. In one embodiment, inhibiting com-
prises delivering to the heart cells an inhibitor ofmiR-499 or
miR-208b. In another embodiment, the subject at risk may
exhibit one or more risk factors selected from the group
consisting of long standing uncontrolled hypertension,
uncorrected valvular disease, chronic angina, recent myocar-
dial infarction, congenital predisposition to heart disease, and
pathological hypertrophy.
US 8,962,588 B2
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Antagomirs, antisense oligonucleotides, inhibitory RNA
molecules, or other modulators of miR-499 or miR-208b
expression or activity may be administered by any method
knownto those in the art suitable for delivery to the targeted
organ, tissue, or cell type. For example, in certain embodi-
ments of the invention, the modulator of miR-499 or miR-
208b may be administered by parenteral administration, such
as intravenousinjection, intraarterial injection, intrapericar-
dial injection, or subcutaneous injection, or by direct injec-
tion into the tissue (e.g., cardiac tissue, skeletal muscle tis-
sue). In some embodiments, the modulator of miR-499 or
miR-208b may be administered by oral, transdermal, intrap-
eritoneal, subcutaneous, sustainedrelease, controlled release,
delayed release, suppository, or sublingual routes of admin-
istration. In other embodiments, the modulator ofmiR-499 or
miR-208b may be administered by a catheter system.
The present invention also contemplates a methodoftreat-
ing or preventing a musculoskeletal disorder in a subject in
need thereof. In one embodiment, the method comprises
identifying a subject having or at risk of a musculoskeletal
disorder; and increasing the expression and/or activity of
miR-499 and/or miR-208b in skeletal muscle cells of said
subject. The musculoskeletal disorder may include, for
example, disuse atrophy, muscle wasting in responseto anti-
gravity, and denervation. In some embodiments, increasing
the expression and/or activity of miR-499 and/or miR-208b
comprises administering to said subject a polynucleotide
comprising a mature miR-499 and/or mature miR-208b
sequence. In other embodiments, increasing the expression
and/or activity of miR-499 and/or miR-208b comprises
administering to said subject an expression vector that
encodes miR-499 and/or miR-208b. In another embodiment,
the method further comprises administering to the subject a
non-miR-499 or miR-208b therapy.
In one embodiment, the present invention provides a
methodofregulating cardiac or skeletal muscle contractility
comprising administering a modulator of miR-499 and/or
miR-208b expression or activity to heart or skeletal muscle
cells. In another embodiment, there is provided a method of
regulating cardiac contractile protein gene expression com-
prising administering a modulator of miR-499 and/or miR-
208b expressionoractivity to heart cells. In another embodi-
ment, there is provided a method ofregulating skeletal muscle
contractile protein gene expression comprising administering
a modulator of miR-499 and/or miR-208b expression or
activity to skeletal muscle cells. In still another embodiment,
the present invention provides a method of inducing a fiber
type switch of a skeletal muscle cell comprising administer-
ing a modulator of miR-499 and/or miR-208b expression or
activity to the skeletal muscle cell. The modulator may be an
agonist or an antagonist ofmiR-499 and/or miR-208b expres-
sion or activity. In some embodiments, the expression of
THRAP1, PURbeta, myostatin (a.k.a. GDF8), Sox 6 and fast
contractile proteins are increased in a cell by contacting the
cell with a miR-499 inhibitor. In other embodiments, expres-
sion of THRAP1, PURbeta, myostatin, Sox 6 and fast con-
tractile proteins are decreased in a cell by contacting the cell
with a miR-499 agonist. In another embodiment, the expres-
sion ofSp3, Myostatin, PURbeta, THRAP1, andfast contrac-
tile proteins are increasedin a cell by contacting the cell with
a miR-208b inhibitor. In still another embodiment, the
expression of Sp3, Myostatin, PURbeta, THRAP1, and fast
contractile proteins are decreased in a cell by contacting the
cell with a miR-208b agonist. Examples of fast skeletal
muscle contractile protein genes that may be increased or
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decreased according to the methods of the present invention
include: troponin 12; troponin T3, myosin light chain, or
alpha skeletal actin.
Thepresent invention also encompassesa transgenic, non-
human mammal, the cells ofwhichfail to express a functional
miR-499 and/or miR-208b. In another embodiment, the
invention provides a transgenic, non-human mammal, the
cells ofwhich comprise a miR-499 and/or miR-208b coding
region underthe control of a heterologous promoteractive in
the cells of said non-human mammal. In some embodiments,
the mammalis a mouse.
The present invention provides a methodfor identifying a
modulator ofmiR-499 and/ormiR-208b. In one embodiment,
the method comprises contacting a cell with a candidate sub-
stance; assessing miR-499 and/or miR-208b activity or
expression; and comparing the activity or expression in step
(b) with the activity or expression in the absence ofthe can-
didate substance, wherein a difference between the measured
activities or expression indicates that the candidate substance
is amodulator ofmiR-499 and/or miR-208b. The cell may be
contacted with the candidate substancein vitro or in vivo. The
candidate substance may bea protein, a peptide, a polypep-
tide, a polynucleotide, an oligonucleotide, or small molecule.
The modulator ofmiR-499 and/or miR-208b maybe an ago-
nist or antagonist of miR-499 and/or miR-208b. The modu-
lator of miR-499 and/or miR-208b may be an agonist or
antagonist of an upstream regulator ofmiR-499 and/or miR-
208b, such as miR-208.
The presentinvention also provides a pharmaceutical com-
position comprising an inhibitor of miR-499 and/or miR-
208b. The inhibitor may be an antagomir,an antisense oligo-
nucleotide, or an inhibitory RNA molecule. In another
embodiment, the present invention provides a pharmaceutical
composition comprising a polynucleotide containing a
mature sequence of miR-499 and/or miR-208b. The poly-
nucleotide may be contained within an expression vector.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention maybe better understood by reference to one
or more of these drawings in combination with the detailed
description of specific embodiments presented herein.
FIG. 1A-B. miR-208 is encoded by the a-MHCgeneandis
expressed specifically in the heart. (FIG. 1A) MiR-208 is
encoded within an intron ofthe a-MHCgene.Asterisks indi-
cate sequence conservation. (FIG. 1B) Detection ofmiR-208
transcripts by Northern analysis of adult mousetissues. U6
mRNAservesas a loading control.
FIG. 2A-B. Regulation ofa- and B-MHC.(FIG. 2A) Regu-
lation ofclass switchby thyroid hormone and TRE.(FIG. 2B)
Model for stress/hypothyroidism in fast-to-slow muscle fiber
contractility switch.
FIG. 3. Detection of miR-208 in humanheart. Transcripts
for a-MHC and miR-208 were detected by Northern blot of
cardiac tissue from six normalindividuals andsix individuals
with idiopathic cardiomyopathy. A close correlation exists
betweenthe level ofexpression ofa-MHCand pre-miR-208,
whereas mature miR-208 expression is maintained after the
latter has been down-regulated.
FIG. 4A-B. Generation of miR-208 mutant mice. (FIG.
4A) Strategy to generate miR-208 mutant mice by homolo-
gous recombination. The pre-miRNA sequence wasreplaced
with aneomycin resistance cassette flanked by loxP sites. The
neomycin cassette was removed in the mouse germline by
breeding heterozygous mice to transgenic mice harboring the
US 8,962,588 B2
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CAG-Cre transgene. (FIG. 4B) Detection of miR-208 tran-
scripts by Northern analysis of hearts from wild-type and
miR-208 mutant mice.
FIG. 5. Western analysis of a-MHC and B-MHCprotein
levels in hearts of neonatal mice of the indicated genotypes.
Two mice of each genotype were analyzed. GAPDH was
detected as a loading control.
FIG. 6. MiR-208~- mice show reduced cardiac hypertro-
phyin responseto pressure overload. Histological sections of
hearts of wild-type and miR-208-* mice stained for Masson
trichrome. The absence of miR-208 diminishes hypertrophy
and fibrosis seen in wild-type mice subjected to TAB for 21
days. Scale bar equals 2 mm in top panel and 20 um for
bottom panel.
FIG. 7. MiR-208-mice show reduced cardiac hypertro-
phy in response to calcineurin activation. Histological sec-
tions of hearts of 6 week-old mice expressing a calcineurin
transgene (CnA-Tg) and hearts of miR-208-"; CnA-Tg
stained for Masson trichrome. Absence of miR-208 dimin-
ishes hypertrophy and fibrosis seen in CnA-Tg mice. Scale
bar=2 mm for top panel, 20 um for bottom panel.
FIG. 8. Mir-208-" mice fail to up-regulate B-MHC in
response to Thoracic Aortic Banding (TAB)and calcineurin
activation.
FIG. 9. Western analysis ofa and B-MHCproteinlevels in
adult wild-type and miR-208 transgenic animals. GAPDH
wasdetected as a loading control.
FIG. 10. MiR-208-~ mice fail to up-regulate B-MHC in
response to hypothyroidism with propylthiouracil (PTU)
treatment.
FIG. 11. Schematic diagram of the role of miR-208 in the
control of B-MHCexpression.
FIG. 12. Schematic diagram of the role of miR-208 in the
regulation of B-MHCand fast skeletal muscle gene expres-
sion via Thrap1.
FIG. 13. Mechanismsofaction ofmicroRNAsduring car-
diac hypertrophy.
FIG. 14. Northern blot showing expression ofmiR-499 in
hearts of wild-type, miR-208-’~ and miR-208~’~ mice. There
is a direct correlation between the expression ofmiR-208 and
miR-499, as well as Myh7b in wild-type and mutant mice.
FIG. 15. Structure of the Myh7b locus andthe position of
the miR-499 coding region within it.
FIG. 16A-D. miR-208 regulates cardiac myh7b expres-
sion. (FIG. 16A) Myh7b, like miR-499, is specifically
expressed in the heart and slow skeletal muscle (soleus).
(FIG. 16B) Real-time PCRanalysis for miR-499 on heart and
4 skeletal muscle types (gastrocnemius/plantaris (GP), tibi-
alis anterior (TA) extensor digitorum longus (EDL), or
soleus) confirms that miR-499 is predominantly expressed in
the heart and soleus. Only minorlevels of miR-499 expres-
sion can be detected in TA and EDL. (FIG. 16C) In situ
hybridization indicates that during embryogenesis, myh7b is
specifically expressed in the heart and somites. (FIG. 16D)
Northern blot analysis for both wild-type and miR-208
mutant animals shows that in the absence of miR-208, the
expression of miR-499 is specifically absent in the heart,
while it is still expressed in soleus (lowerblot).
FIG. 17. Northern blot showing expression ofmiR-499 in
wild-type mice with heart disease. MI, myocardialinfarction.
CnA Tg, calcineurin transgenic mice.
FIG. 18. Schematic diagram of the regulation ofmiR-499
by miR-208 in cardiac muscle.
FIG. 19. Schematic diagram of the regulation ofmiR-499
by miR-208 in both cardiac and skeletal muscle.
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FIG. 20. miR-499 regulates myosin switching and fiber
type identity by targeting THRAP1, PURbeta and GDF8
(a.k.a myostatin).
FIG. 21A-C Inhibition of a-MHC expression leads to
decreased levels of miR-208. (FIG. 4A-B) Relative expres-
sion levels for a- and B-MHCtranscripts at 0, 3, 6, 9, 12, 15,
18 and 21 days of PTU exposure. (FIG. 4C) Northern blot
analysis ofmiR-208 in cardiac rat tissue at the indicated time
points during PTU treatment.
FIG. 22. Upregulation of fast skeletal genes in miR-208
knock-out.
FIG. 23. Dysregulation of cardiac stress response genes in
miR-208 knock-out mice.
FIG. 24. A modelfor the role of miR-208 in cardiac gene
regulation. The a-MHC gene encodes miR-208, which nega-
tively regulates expression of THRAP1 and skeletal muscle
genes amongadditionaltargets. The a- and B-MHC genesare
linked and miR-208is required for up-regulation of B-MHC
in response to stress signaling and blockade to T3 signaling
by PTU.a- and B-MHC promote fast and slow contractility,
respectively.
FIG. 25. THRAP1 as a predicted target of miR-208.
Sequence alignment of putative miR-208 binding site in 3'
UTR ofTHRAP!1showsa high level of complementarity and
sequence conservation (SEQ ID NOS:6-13).
FIG. 26. 3' UTR THRAP!1luciferase assay. Expression of
a luciferase gene containing the 3' UTR of THRAP!1is
decreasedin cells co-transfected with miR-208, but not miR-
126 (control).
FIG. 27. Up-regulation of fast skeletal muscle genes in
hearts of miR 208 mutant mice.
FIG. 28. Structure of the Myh7 locus 6-MHC) and the
position of the miR-208b coding region within it (SEQ ID
NO: 27 and SEQ ID NOS:30-36).
FIG. 29A-B. miR-208 and miR-208b developed due to a
genomic duplication ofthe myosin heavy chain genes (myh6
and myh7, aka a-MHC and 6-MHC). miR-208 and miR-
208b are co-expressed with a-MHC and B-MHC (FIG. 29A)
and share a homologousseed region althoughthetotal mature
miR5 differ by 3 bases in sequence (FIG. 29B) (SEQ ID NO:
27 and SEQ ID NO:5).
FIG. 30A-D. The myomiRsare co-expressed and co-regu-
lated with their myosin host-gene. (FIG. 30A) Northern
analysis showsthat mir-208b is expressed at very low levels
in the heart at baseline conditions and1s not expressedin fast
skeletal muscle fibers, such as gastrocnemius/plantaris (GP),
tibialis anterior (TA) or extensor digitorum longus (EDL).
MiR-208b is highly expressed in the slow skeletal muscle
soleus. (FIG. 30B) Realtime PCR analysis for the indicated
myosin genes showsthat blockade ofthyroid receptorsignal-
ing by feeding animals PTU-containing chow represses
a-MHCand induces B-MHCexpression in cardiac tissue of
rats. This effect can be reversed by subsequent supplementa-
tion of thyroid hormone(T3). The expression ofmyh7b mir-
rors the expression pattern of 8-MHCto a lesser extent. (FIG.
30C) Shortly after birth there is a shift from B-MHC towards
more a@-MHC. While miR-208 is responsible for miR-499
activation in adult heart, Northern blot analysis on cardiac
samples of pl, p6 and adult wild-type and miR-208 mutant
animals indicate the presence of miR-208b, generated from
the B-MHCgene,to besufficient to drive miR-499 expression
even in the absence of miR-208. (FIG. 30D) Northern blot
analysis for the myomiRsindicates that miR-208b mirrors the
reduced induction of 8-MHC in responseto stress signaling
in the absence ofmiR-208. MiR-208 knockout animals exert
a reduced increase in B-MHC in response to stress and
hypothyroidism. While northern analysis shows a severe
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induction of miR-208b in wild-type (WT) animals in
response to PTU,the induction ofmiR-208bin the absence of
miR-208 (knockout, KO) is only minor. Note that the pres-
ence of either 208a or 208b is sufficient to activate myh7b/
miR-499.
FIG. 31. Hypothyroidism with PTU treatment strongly
induces miR-208b expression. Although miR-208b, like
B-MHC,is hardly expressed in the heart under baseline con-
ditions, its expression is strongly induced in response to
hypothyrodism. This induction can be reversed by subse-
quent supplementation of thyroid hormone (T3).
FIG. 32. Time-dependent induction of miR-208b during
hypothyroidism with PTU treatment. Induction ofmiR-208b
by PTU treatmentis evident after 3 days. This PTU-induced
expression ofmiR-208b increases with duration ofPTUtreat-
ment.
FIG. 33A-C. miR-208 regulates the expression of miR-
208b and miR-499, (A) Northern blot showing that the
expression of miR-499 and miR-208b are dose-dependently
downregulated in miR-208 heterozygote (+/-) and homozy-
gote (KO) mutant animals. (B) MiR-208b is upregulated in
miR-208 trangenic animals which correlates with B-MHC
expression. (C) Schematic diagram of the regulation ofmiR-
499 by miR-208 in cardiac muscle.
FIG. 34. Schematic model of miR-208 regulation of car-
diac remodeling. miR-208 regulates cardiac remodeling
either directly or indirectly through the regulation ofmiR-499
and miR-208b expression.
FIG. 35. Schematic modeloftargeting strategy to design a
miR-208b knockout mouse model.
FIG. 36. Schematic of a transgenic mouse model overex-
pressing binding site regions for both miR-499 and miR-
208b. Skeletal muscle specific overexpression ofbinding site
regions for both miR-499 and miR-208b using a skeletal and
heart muscle specific promoter (muscle creatine kinase
(MCK)) should scavenge miR-208b and miR-499 in both
heart and skeletal muscle, thereby generating a knockdown
for both miRNAs (SEQ ID NOS:5, 26 and 27).
FIG. 37A-D. Myh7b/miR-499 expression is dependent on
MEF2.(FIG. 37A) A gel mobility shift assay was performed
using nuclear extracts from COS-1 cells transfected with
either empty pcDNA-Flag or Flag-MEF2C andthe radiola-
beled MEF2 site as probe. While pcDNA-Flag is unable to
bind the radiolabeled MEF2-site (lane 1), overexpression of
MEF2C induces binding (lane 2) which can be supershifted
with 1 wg of polyclonal Flag antibody (lane 3). Specific and
nonspecific competitors were used at 50-fold molar excess
(lane 4-6). (FIG. 37B) COScells (24-well plates, 5x10* cells/
well) were transfected with 100 ng of the myh7b-luciferase
reporters (wild-type and Mef2 mutant), 50 ng expression
vectors encoding Mef2c, a Mef2 co-activator, myocardin pro-
teins and 30 ng of pCMV-lacZ. Activation of the myh7b
reporter by Mef2c and myocardin required the Mef2-binding
site. (FIG. 37C) MEF2site is essential for cardiac expression
of myh7b/miR-499. LacZ transgenic mouse embryos were
generated, and stained for expression of B-galactosidase at
E12.5 and p1. While a region 0.8 Kb upstream of the myh7b
gene wassufficientto drive cardiac lacZ expression, mutation
of the MEF2 site abolished expression in the heart. (FIG.
37D) Northern blot analysis indicates that miR-499 expres-
sion is increased in hearts of cardiac specific MEF2D trans-
genic animals, while the level of miR-499 is decreased in
hearts where MEF2Cand-D are deleted.
FIG. 38A-F. miR-499 regulates the expression of B-MHC
and fast skeletal genes. (FIG. 38A) Northern blot analysis for
miR-499 indicates that transgenic overexpression of miR-
499, using a muscle specific promoter, efficiently induces the
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level of miR-499 in all muscle types. (FIG. 38B) Real-time
PCRanalysis showsthat transgenic overexpression results in
effective overexpression of miR-499 comparedto the base-
line cardiac expressionlevel, with the highest levels in the fast
skeletal muscle types (GP, TA and EDL). (FIG. 38C) Real-
time PCR analysis on muscle tissue of either wild-type or
transgenic animals showsthat overexpression of miR-499is
sufficient to drive B-MHCexpression in soleus, TA and EDL,
while it represses fast skeletal troponin 12 (TnnI2) and T3
(TnnT3) in heart, soleus and EDL. (FIG. 38D) Metachro-
matic ATPasestaining of snap-frozen histological sections of
myofibers ofboth wild-type and miR-499 transgenic animals
show a dramatic increase in slow myofibers in fast fibers
(EDL) of the transgenic mice. (FIG. 38E) The repressive
effect ofmiR-208 ablation on §}-MHCexpression in response
to PTU is absent when miR-499 is re-introduced. Transgeni-
cally reintroducing miR-499in heart ofmiR-208 mutantani-
mals results in a severe induction of $-MHCandits corre-
sponding miRNA, miR-208b. (FIG. 38F) While miR-208
removal induces an inappropriate induction of fast skeletal
genes, miR-499 very potently represses these genes when
transgenically expressed in the miR-208 mutant animals.
DETAILED DESCRIPTION OF ILLUSTRATIVE
EMBODIMENTS
Cardiac and skeletal muscles respondto a variety ofpatho-
physiological stimuli such as workload, thyroid hormonesig-
naling and injury by modulating the expression of myosin
isoforms, which regulate the efficiency of contraction.
Recently, the inventors reported a_ cardiac-specific
microRNA, miR-208, which is encoded by an intron of the
a-myosin heavy chain (MHC) gene, andis required for up-
regulation of B-MHCexpression in responseto cardiac stress
and for repression of fast skeletal muscle genes in the heart
(see co-pending application WO2008/016924, which is
herein incorporated by referencein its entirety).
Here, the inventors extend their earlier work and show that
miR-208 is also required for cardiac expression of closely
related microRNAs, miR-499 and miR-208b, which are
encodedby an intron ofthe Myh7b gene and the BMHCgene,
respectively. Expression ofMyh7b and miR-499 inthe heart,
as well as in slow skeletal muscle, is controlled by the MEF2
transcription factor, a signal-dependent regulator of striated
muscle gene expression. Forced expression of miR-499 or
miR-208 is sufficient to mediate a fast to slow myofiber
conversion in vivo. Mir-208 and miR-499 can negatively
regulate the expression ofThrap1, a thyroid hormonereceptor
coregulator, and members ofthe PUR family oftranscription
factors, which in turn negatively regulate B-MHCexpression
in cardiac and skeletal muscle. Sox6 functions as a repressor
of slow fiber type-specific genes. Knockdown of Sox6
expression in wild-type myotubes results in a significant
increase in B-MHCexpression. Analysis of the B-MHCpro-
moterrevealed a Sox consensus sequence which suggests that
Sox6 playsa critical role in thefiber type differentiation of
fetal skeletal muscle and $-MHC regulation in the heart.
These findings unveil a common regulatory mechanism in
which Myh genes regulate the gene expression patterns of
striated muscles by encoding regulatory microRNAsthat
govern contractility and signal responsiveness. Strategies to
manipulate skeletal and cardiac muscle gene expression by
modulating miR-499 expression in the settings of striated
muscle diseases are described in lightof these discoveries.
The inventors have also discovered the genometo contain
a second version of miR208, called miR-208b, which is
located within the B-MHC geneatintron 31, and like B-MHC,
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miRNA208bis expressed solely in the heart and slow skeletal
muscle (soleus). The sequence of this microRNA is largely
overlapping with miR-208 with a 100% homology in the so
called seed region, the region of the microRNAthat defines
mRNAtargets ofa certain miRNA.Thus, miR-208b can have
profound effects on cardiac contractility in humans, and
modulation of miR-208b to regulate cardiac contractility is
also contemplated by the invention.
Thus, the invention encompasses agonism ofmiR-499 and/
or miR-208b expressionoractivity, either by therapeutically
activating the endogenous miR-208b gene or miR-208 gene
(to upregulate miR-499) or introducing exogenous miR-499
Human pre-miR-208
aegggegage ttttggcecg ggttatacct
Mouse pre-miR-208
acegggtgage ttttggcecg ggttatacct
Rat pre-miR-208
acegggtgage ttttggcecg ggttatacct
Canine pre-miR-208
acgeatgage ttttggctcg ggttatacct
or miR-208b into the heart, either using the miRNAitself or
by the use of adenoviral vectors or other means of ectopic
expression to elevate B-MHC expression. The up-regulation
of several fast skeletal muscle contractile protein genesin the
hearts of miR-208 mutant mice suggests that miR-208 and
miR-208b typically repress the fast skeletal muscle gene pro-
gram, which implicates a similar role for miR-499 in skeletal
and cardiac muscle. Thus, activation of these genes in the
heart represents a potential approach to regulate cardiac con-
tractility.
In addition, the inventors present use of miR-499 and/or
miR-208b to repress fast fiber genes in skeletal muscle
thereby activating the reciprocal expression of slow fiber
genes. Expression of slow fiber genes are coupled to
enhancedinsulin sensitivity and skeletal muscle endurance.
Repression of slow fiber genes and activation of fast fiber
genesin skeletal muscle is associated with numerous muscu-
loskeletal disorders including disuse atrophy, muscle wasting
in responseto anti-gravity, and denervation.
Thus,the present inventors have discoveredthat, like miR-
208, miR-499 is a muscle-specific and essential regulator of
B-MHCgene expressionin the heart. In addition, miR-208b
was discovered to bea muscle-specific and essential regulator
ofmyosin gene expression in the heart that in addition regu-
lates cardiac fibrosis. Both of these discoveries are com-
pletely novel as is the use of these microRNAs to control
cardiac contractility and skeletal muscle function.
Analysis of the genomic location of the miR-499 gene
showedit to be contained within the 20” intron ofthe Myh7b
gene, a homolog of the a-MHC gene (FIG. 15; SEQ ID
NO:26 recites the mature miRNA sequence; SEQ ID NO:25
shows the stem-loop structure of the precursor sequence).
The pre-miRNA encoding sequences for miR-499 for mouse,
rat, human, canine, opposum, chicken and X. tropicalis are
provided in SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20,
SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 and SEQ ID
NO:24, respectively. (FIG. 15). The Myh7b gene is conserved
in vertebrates and is expressed solely in the heart and slow
skeletal muscle (e.g. soleus).
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MiR-208, which has been shown to regulate miR-499
expression, is an intronic miRNA that is located within an
intron of the a-MHC gene. Theprecise intron location is
dependent on the particular species and specific transcript.
For example,in humans, miR-208 is encoded within the 28”
intron ofthe a-MHCgene, while in mice, it is encoded within
the 29” intron. The pre-miRNAencoding sequences formiR-
208 for human, mouse,rat, and canine are provided in SEQ ID
NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17,
respectively. The mature miR-208 sequence is provided in
SEQ ID NO:5. Like a-MHC, miR-208is expressedsolely in
the heart. (FIG. 1).
(SEQ ID NO: 14)
gatgctcacg tataagacga gcaaaaaget tgttggtcag a
(SEQ ID NO: 15)
gactctcacg tataagacga gcaaaaaget tgttggtcag a
(SEQ ID NO: 16)
gactctcacg tataagacga gcaaaaaget tgttggtcag a
(SEQ ID NO: 17)
gatgctcacg tataagacga gcaaaaaget tgttggtcag a
Using the PicTar algorithm for the identification ofmiRNA
targets (Krek et al., 2005), the inventors identified thyroid
hormonereceptor associated protein 1 (THRAP1) as a pre-
dicted target for miR-208. THRAP1 3' UTR sequences from
human, chimp, mouse, rat, canine, chicken, fugu, and
zebrafish are provided in SEQ ID NO:6, SEQ ID NO:7, SEQ
ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11,
SEQ ID NO:12, and SEQ ID NO:13, respectively (FIG. 25).
Ina further search for microRNAsthat might be involved in
the regulation ofmuscle contractility, the inventors found the
BMHCgeneto contain miR208b, whichis closely related to
miR-208, in intron 31. Expression ofmiR-208b follows that
of BMHC,namely it is expressed solely in the heart and slow
skeletal muscle (soleus). The sequence of this microRNA is
largely overlapping with miR-208 with a 100% homology in
the so called seed region (indicated by underlining), the part
of the microRNA that helps to define mRNAtargets of a
certain miRNA:
(SEQ ID No:
AUAAGACGAGCAAAAAGCUUGU
5)
miR-208
(SEQ ID NO:
miR-208b AUAAGACGAACAAAAGGUUUGU
27)
The pre-miRNA encoding sequences for miR-208b for
human, mouse, rat, canine, opposum, and X. tropicalis are
provided in SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32,
SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35, respec-
tively. (FIG. 28). FIG. 28 also shows the stem-loop structure
of the miR-208b precursor sequence (SEQ ID NO:36).
Methods ofTreating Cardiac Hypertrophy, Heart Failure, and
Myocardial Infarction
The present invention provides a method for treating
pathologic cardiac hypertrophy, heart failure, or myocardial
infarction in a subject in needthereof. In one embodiment, the
method comprises identifying a subject having cardiac hyper-
trophy, heart failure, or myocardial infarction and inhibiting
expression or activity of miR-499 and/or miR-208b in heart
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cells ofthe subject. In another embodiment, the method com-
prises identifying a subject at risk of developing pathologic
cardiac hypertrophy, heart failure, or myocardial infarction
and inhibiting expressionoractivity ofmiR-499 and/or miR-
208b in heart cells of the subject. The subject at risk of
developing pathologic cardiac hypertrophy or heart failure
mayexhibit one or morerisk factors including, for example,
long standing uncontrolled hypertension, uncorrected valvu-
lar disease, chronic angina, recent myocardial infarction, con-
genital predisposition to heart disease or pathological hyper-
trophy. In certain embodiments, the subject at risk may be
diagnosed as having a genetic predisposition to cardiac
hypertrophy. In some embodimentsofthe invention, the sub-
ject at risk may have a familialhistory ofcardiac hypertrophy.
In another embodiment, the present invention provides a
methodofpreventing cardiac hypertrophy anddilated cardi-
omyopathyin a subject in need thereof comprising inhibiting
expression or activity of miR-499 and/or miR-208b in heart
cells of the subject. In yet a further embodiment, the present
invention provides a methodofinhibiting progression of car-
diac hypertrophy in a subject in need thereof comprising
inhibiting expression or activity of miR-499 and/or miR-
208bin heart cells ofthe subject. In certain embodiments, the
present invention provides a method of increasing exercise
tolerance, reducing hospitalization, improving quality oflife,
decreasing morbidity, and/or decreasing mortality in a sub-
ject with heart failure or cardiac hypertrophy comprising
inhibiting expression or activity of miR-499 and/or miR-
208b in heart cells of the subject.
Thus, the present invention provides methods for the treat-
ment of cardiac hypertrophy, heart failure, or myocardial
infarction utilizing inhibitors ofmiR-499 or miR-208b. Pref-
erably, administration of a miR-499 and/or miR-208b inhibi-
tor results in the improvement of one or more symptoms of
cardiac hypertrophy,heart failure, or myocardial infarction in
the subject, or in the delay in the transition from cardiac
hypertrophy to heart failure. The one or more improved
symptoms maybe, for example, increased exercise capacity,
increased cardiac ejection volume,decreased left ventricular
end diastolic pressure, decreased pulmonary capillary wedge
pressure, increased cardiac output, increased cardiac index,
lowered pulmonary artery pressures, decreased left ventricu-
lar end systolic and diastolic dimensions, decreased cardiac
fibrosis, decreased collagen deposition in cardiac muscle,
decreased left and right ventricular wall stress, decreased wall
tension, increased quality of life, and decreased disease
related morbidity or mortality. In addition, use ofinhibitors of
miR-499 and/or miR-208b mayprevent cardiac hypertrophy
and its associated symptomsfrom arising.
The function of miRNAs may beinhibited by the admin-
istration of antagomirs. Initially described by Kriitzfeldt and
colleagues (Kriitzfeldt et al., 2005), “antagomirs”are single-
stranded, chemically-modified ribonucleotides that are at
least partially complementary to the miRNA sequence.
Antagomirs may comprise one or more modified nucleotides,
such as 2'-O-methyl-sugar modifications. In some embodi-
ments, antagomirs comprise only modified nucleotides.
Antagomirs may also comprise one or more phosphorothio-
ate linkages resulting in a partial or full phosphorothioate
backbone. To facilitate in vivo delivery and stability, the
antagomir maybelinked to a cholesterol moiety at its 3' end.
Antagomirs suitable for inhibiting miRNAs may be about 15
to about 50 nucleotides in length, more preferably about 18 to
about 30 nucleotides in length, and most preferably about 20
to about 25 nucleotides in length.“Partially complementary”
refers to a sequence that is at least about 75%, 80%, 85%,
90%, 95%, 96%, 97%, 98%, or 99% complementary to a
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target polynucleotide sequence. The antagomirs may be at
least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or
99% complementary to a mature miRNA sequence. In some
embodiments, the antagomir may be substantially comple-
mentary to a mature miRNA sequence, that is at least about
95%, 96%, 97%, 98%, or 99% complementary to a target
polynucleotide sequence. In other embodiments, the antago-
mirs are 100% complementary to the mature miRNA
sequence.
Inhibition ofmicroRNA function may also be achieved by
administering antisense oligonucleotides targeting the
mature miR-499, miR-208, ormiR-208b sequences. Theanti-
sense oligonucleotides maybe ribonucleotides or deoxyribo-
nucleotides. Preferably, the antisense oligonucleotides have
at least one chemical modification. Antisense oligonucle-
otides may be comprised of one or more “locked nucleic
acids”. “Locked nucleic acids” (LNAs) are modified ribo-
nucleotides that contain an extra bridge between the 2' and 4'
carbons of the ribose sugar moiety resulting in a “locked”
conformation that confers enhanced thermalstability to oli-
gonucleotides containing the LNAs. Alternatively, the anti-
sense oligonucleotides may comprise peptide nucleic acids
(PNAs), which contain a peptide-based backbonerather than
a sugar-phosphate backbone. Other chemical modifications
that the antisense oligonucleotides may contain include, but
are not limited to, sugar modifications, such as 2'-O-alkyl
(e.g. 2'-O-methyl, 2'-O-methoxyethyl), 2'-fluoro, and 4' thio
modifications, and backbone modifications, such as one or
more phosphorothioate, morpholino, or phosphonocarboxy-
late linkages (see, for example, U.S. Pat. Nos. 6,693,187 and
7,067,641, which are herein incorporatedby reference in their
entireties). In some embodiments, suitable antisense oligo-
nucleotides are 2'-O-methoxyethy] “gapmers” which contain
2'-O-methoxyethyl-modified ribonucleotides on both 5' and
3' ends with at least ten deoxyribonucleotides in the center.
These “gapmers” are capable of triggering RNase H-depen-
dent degradation mechanisms of RNAtargets. Other modifi-
cationsofantisense oligonucleotides to enhancestability and
improve efficacy, such as those described in U.S. Pat. No.
6,838,283, which is herein incorporated by reference in its
entirety, are knownin the art and are suitable for use in the
methods of the invention. Preferable antisense oligonucle-
otides useful for inhibiting the activity of microRNAsare
about 19 to about 25 nucleotides in length. Antisense oligo-
nucleotides may comprise a sequencethatis at least partially
complementary to a mature miRNA sequence,e.g. at least
about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%
complementary to a mature miRNA sequence. In some
embodiments,the antisense oligonucleotide may be substan-
tially complementary to a mature miRNA sequence,thatis at
least about 95%, 96%, 97%, 98%, or 99% complementary to
a target polynucleotide sequence. In one embodiment, the
antisense oligonucleotide comprises a sequencethat is 100%
complementary to a mature miRNA sequence.
Another approach for inhibiting the function of miR-499,
miR-208, and miR-208b is administering an inhibitory RNA
molecule having at least partial sequence identity to the
mature miR-499, miR-208, and miR-208b sequences. The
inhibitory RNA molecule may be a double-stranded, small
interfering RNA (siRNA) or a short hairpin RNA molecule
(shRNA) comprising a stem-loop structure. The double-
stranded regions of the inhibitory RNA molecule may com-
prise a sequencethatis at least partially identical, e.g. about
75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% iden-
tical, to the mature miRNA sequence.In some embodiments,
the double-stranded regions of the inhibitory RNA comprise
a sequencethatis at least substantially identical to the mature
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miRNA sequence. “Substantially identical” refers to a
sequencethatis at least about 95%, 96%, 97%, 98%, or 99%
identical to a target polynucleotide sequence. In other
embodiments, the double-stranded regions of the inhibitory
RNA molecule may contain 100% identity to the target
miRNAsequence.
Theinhibitory nucleotide molecules described herein pref-
erably target the mature sequence of miR-499 (SEQ ID NO:
26), miR-208 (SEQ ID NO:5), or miR-208b (SEQ ID NO:
27). In some embodiments, inhibitors ofmiR-499, miR-208,
and miR-208b are antagomirs comprising a sequencethatis
perfectly complementary to the mature miR-499, mature
miR-208, ormature miR-208b sequence. In one embodiment,
an inhibitor of miR-499 is an antagomir having a sequence
that is partially or perfectly complementary to 5'-UUAA-
GACUUGCAGUGAUGUUU-3' (SEQ ID NO: 26). In
another embodiment, an inhibitor ofmiR-208is an antagomir
having a sequencethat is partially or perfectly complemen-
tary to 5'-AUAAGACGAGCAAAAAGCUUGU-3' (SEQ ID
NO:5). In another embodiment, an inhibitor of miR-208b is
an antagomir having a sequencethatis partially or perfectly
complementary to 5'-AUAAGACGAACAAAAGGUUUGU
(SEQ ID NO:27).
In some embodiments, inhibitors of miR-499, miR-208,
and miR-208b are chemically-modified antisense oligonucle-
otides. In one embodiment, an inhibitor of miR-499 is a
chemically-modified antisense oligonucleotide comprising a
sequence substantially complementary to 5'-UUAAGACU-
UGCAGUGAUGUUU-3' (SEQ ID NO: 26). In another
embodiment, an inhibitor ofmiR-208 is a chemically-modi-
fied antisense oligonucleotide comprising a sequence sub-
stantially complementary to 5'-AUAAGACGAG-
CAAAAAGCUUGU-3' (SEQ ID NO: 5). In another
embodiment, an inhibitor ofmiR-208b is a chemically-modi-
fied antisense oligonucleotide comprising a sequence sub-
stantially complementary to 5'-
AUAAGACGAACAAAAGGUUUGU(SEQ ID NO:27). As
used herein “substantially complementary” refers to a
sequencethatis at least about 95%, 96%, 97%, 98%, 99%, or
100% complementary to a target polynucleotide sequence
(e.g. mature or precursor miRNA sequence).
Antisense oligonucleotides may comprise a sequence that
is substantially complementary to a precursor miRNA
sequence(pre-miRNA)for miR-499, miR-208, or miR-208b.
In some embodiments, the antisense oligonucleotide com-
prises a sequencethat is substantially complementary to a
sequence located outside the stem-loop region of the pre-
miR-499, pre-miR-208, or pre-miR-208b sequence. In one
embodiment, an inhibitor ofmiR-499 function is an antisense
oligonucleotide having a sequence that is substantially
complementary to a pre-miR-499 sequence selected from the
group consisting of SEQ ID NO:18, SEQ ID NO:19, SEQ ID
NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 and
SEQ ID NO:24.In another embodiment, an inhibitor ofmiR-
208 function is an antisense oligonucleotide having a
sequencethat is substantially complementary to a pre-miR-
208 sequenceselected from the group consisting of SEQ ID
NO: 14, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17.
In still another embodiment, an inhibitor of miR-208b func-
tion is an antisense oligonucleotide having a sequencethatis
substantially complementary to a pre-miR-208b sequence
selected from the group consisting of SEQ ID NO:30, SEQ
ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34,
and SEQ ID NO:35.
In other embodiments of the invention, inhibitors ofmiR-
499, miR-208, and miR-208b may be inhibitory RNA mol-
ecules, such as ribozymes, siRNAs, or shRNAs. In one
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embodiment, an inhibitor of miR-499 is an inhibitory RNA
molecule comprising a double-stranded region, wherein the
double-stranded region comprises a sequence having 100%
identity to the mature miR-499 sequence (SEQ ID NO:26). In
another embodiment, an inhibitor ofmiR-208is an inhibitory
RNA molecule comprising a double-stranded region,
wherein the double-stranded region comprises a sequence
having 100% identity to the mature miR-208 sequence (SEQ
ID NO:5). In another embodiment, an inhibitor ofmiR-208b
is an inhibitory RNA molecule comprising a double-stranded
region, wherein the double-stranded region comprises a
sequence having 100% identity to the mature miR-208b
sequence (SEQ ID NO:27). In some embodiments, inhibitors
ofmiR-208, miR-208b, and miR-499 function are inhibitory
RNA molecules which comprise a double-stranded region,
wherein said double-stranded region comprises a sequence of
at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or
99% identity to the mature miR-208, miR-208b, or miR-499
sequence.
The presentinvention also contemplates methodsfor scav-
enging or clearing miR-499 and/or miR-208b antagonists
following treatment. The method may comprise overexpress-
ing binding sites for the miR-499 and/or miR-208b antago-
nists in cardiac tissue. In another embodiment, the present
invention provides a methodfor scavenging or clearing miR-
499 and/or miR-208b following treatment. In one embodi-
ment, the method comprises overexpression of binding site
regions for miR-499 and/or miR-208b in skeletal muscle
using a skeletal and heart muscle specific promoter (muscle
creatine kinase (MCK)). The bindingsite regions preferably
contain a sequence of the seed region for miR-499 and/or
miR-208b. In some embodiments, the binding site may con-
tain a sequence from the 3'UTR of one or moretargets of
miR-499 or miR-208b, such as THRAP1 or PURbeta. In
another embodiment, a miR-499 and/or miR-208b antagonist
may be administered after miR-499 and/or miR-208b to
attenuate or stop the function of the microRNA.
Combined Therapy
In another embodimentofthe invention,it is envisioned to
use an inhibitor ofmiR-499 or miR-208b in combination with
other therapeutic modalities. Current medical managementof
cardiac hypertrophyin the setting ofa cardiovascular disorder
includesthe useofat least two types ofdrugs inhibitors ofthe
renin-angiotensin system, and f-adrenergic blocking agents
(Bristow, 1999). Therapeutic agentsto treat pathologic hyper-
trophy in the setting of heart failure include angiotensin II
converting enzyme (ACE) inhibitors and B-adrenergic recep-
tor blocking agents (Eichhorn and Bristow, 1996). Other
pharmaceutical agents that have been disclosed for treatment
of cardiac hypertrophy include angiotensin II receptor
antagonists (U.S. Pat. No. 5,604,251) and neuropeptide Y
antagonists (WO 98/33791).
Non-pharmacological treatment is primarily used as an
adjunct to pharmacological treatment. One means of non-
pharmacological treatment involves reducing the sodium in
the diet. In addition, non-pharmacological treatment also
entails the elimination of certain precipitating drugs, includ-
ing negative inotropic agents (e.g., certain calcium channel
blockers and antiarrhythmic drugs like disopyramide), car-
diotoxins (e.g., amphetamines), and plasma volume expand-
ers (e.g., nonsteroidal anti-inflammatory agents and gluco-
corticoids).
Thus, in addition to the therapies described above, one may
also provide to the subject more “standard” pharmaceutical
cardiac therapies with the inhibitor of miR-499 and/or miR-
208b. Examples of other therapies include, without limita-
tion, so-called “beta blockers,” anti-hypertensives, cardioton-
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ics, anti-thrombotics, vasodilators, hormone antagonists,
iontropes, diuretics, endothelin receptor antagonists, calcium
channel blockers, phosphodiesterase inhibitors, ACE inhibi-
tors, angiotensin type 2 antagonists and cytokine blockers/
inhibitors, and HDAC inhibitors. The combination therapy
also may involve inhibiting the expression or activity of both
miR-499 and miR-208b,or inhibiting the expressionoractiv-
ity of miR-208, and/or additional miRNAs involvedin car-
diac remodeling such as miR-21 and miR-195. Combination
therapy may also include overexpression of particular
microRNAs, such as miR-29.
Combinations maybe achieved by contacting cardiac cells
with a single composition or pharmacological formulation
that includes an inhibitor of miR-499 or miR-208b and a
standard pharmaceutical agent, or by contacting the cell with
twodistinct compositions or formulations, at the same time,
wherein one composition includes an inhibitor ofmiR-499 or
miR-208b andthe other includes the standard pharmaceutical
agent. Alternatively, the therapy using an inhibitor of miR-
499 and/or miR-208b may precedeor follow administration
of the other agent(s) by intervals ranging from minutes to
weeks. In embodiments where the standard pharmaceutical
agent and miR-499 or miR-208b inhibitor are applied sepa-
rately to the cell, one would generally ensure that a significant
period of time did not expire between the time of each deliv-
ery, such that the pharmaceutical agent and miR-499 or miR-
208b inhibitor wouldstill be able to exert an advantageously
combined effect on the cell. In such instances, it is contem-
plated that one would typically contact the cell with both
modalities within about 12-24 hours of each other and, more
preferably, within about 6-12 hours ofeach other, with a delay
time of only about 12 hours being most preferred. In some
situations, it may be desirable to extend the time period for
treatmentsignificantly, however, where several days (2, 3, 4,
5, 6 or7) to several weeks(1, 2,3, 4, 5, 6, 7 or 8) lapse between
the respective administrations.
It also is conceivable that more than one administration of
either an inhibitor ofmiR-499 and/or miR-208b,or the other
pharmaceutical agent will be desired. In this regard, various
combinations may be employed. By way of illustration,
wherethe inhibitor of miR-499 or miR-208b is “A” and the
other agent is “B”’, the following permutations based on 3 and
4 total administrations are exemplary:
 
A/B/A B/A/B B/B/A A/A/B B/A/A A/B/B B/B/B/A B/B/A/B
A/A/B/B A/B/A/B A/B/B/A B/B/A/A B/A/B/A B/A/A/B B/B/B/A
A/A/A/B B/A/A/A A/B/A/A A/A/B/A A/B/B/B B/A/B/B B/B/A/B
Other combinationsare likewise contemplated.
Treatment regimens would vary depending ontheclinical
situation. However, long-term maintenance would appearto
be appropriate in most circumstances.It also may be desirable
to treat hypertrophy with inhibitors ofmiR-499 and/or miR-
208b intermittently, such as within a brief window during
disease progression.
Pharmacological therapeutic agents and methods of
administration, dosages, etc., are well knownto thoseof skill
in the art (see for example, the “Physicians Desk Reference”,
Klaassen’s “The Pharmacological Basis of Therapeutics”,
“Remington’s Pharmaceutical Sciences”, and “The Merck
Index, Eleventh Edition”, incorporated herein by reference in
relevant parts), and may be combined with the invention in
light of the disclosures herein. Somevariation in dosage will
necessarily occur depending on the condition of the subject
being treated. The person responsible for administration will,
in any event, determine the appropriate dose for the individual
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subject, and such individual determinations are within the
skill of those of ordinary skill in the art.
Non-limiting examples of a pharmacological therapeutic
agent that may be used in the present invention include an
antihyperlipoproteinemic agent, an antiarteriosclerotic agent,
an antithrombotic/fibrinolytic agent, a blood coagulant, an
antiarrhythmic agent, an antihypertensive agent, a vasopres-
sor, a treatment agent for congestive heart failure,an antiangi-
nal agent, an antibacterial agent or a combination thereof.
In addition, it shouldbe noted that any ofthe following may
be used to develop newsets of cardiac therapy target genes as
B-blockers were used in the present examples (see below).
While it is expected that many of these genes may overlap,
new genetargets likely can be developed.
In certain embodiments, administration of an agent that
lowers the concentration of one of more blood lipids and/or
lipoproteins, knownherein as an “antihyperlipoproteinemic,”
may be combined with a cardiovascular therapy according to
the present invention, particularly in treatment of atherscle-
rosis and thickenings or blockages of vascular tissues. In
certain embodiments, an antihyperlipoproteinemic agent
may comprise an aryloxyalkanoic/fibric acid derivative, a
resin/bile acid sequesterant, a HMG CoAreductase inhibitor,
a nicotinic acid derivative, a thyroid hormoneor thyroid hor-
moneanalog, a miscellaneous agent or a combination thereof.
Non-limiting examples of aryloxyalkanoic/fibric acid
derivatives include beclobrate, enzafibrate, binifibrate,
ciprofibrate, clinofibrate, clofibrate (atromide-S), clofibric
acid, etofibrate, fenofibrate, gemfibrozil (lobid), nicofibrate,
pirifibrate, ronifibrate, simfibrate and theofibrate.
Non-limiting examples of resins/bile acid sequesterants
include cholestyramine (cholybar, questran), colestipol
(colestid) and polidexide.
Non-limiting examples ofHMG CoAreductase inhibitors
include lovastatin (mevacor), pravastatin (pravochol) or sim-
vastatin (zocor).
Non-limiting examples of nicotinic acid derivatives
include nicotinate, acepimox, niceritrol, nicoclonate, nico-
mol and oxiniacic acid.
Non-limiting examples of thyroid hormonesand analogs
thereof include etoroxate, thyropropic acid and thyroxine.
Non-limiting examples of miscellaneous antihyperlipo-
proteinemicsinclude acifran, azacosterol, benfluorex, (f-ben-
zalbutyramide, carnitine, chondroitin sulfate, clomestrone,
detaxtran, dextran sulfate sodium, 5, 8, 11, 14, 17-eicosapen-
taenoic acid, eritadenine, furazabol, meglutol, melinamide,
mytatrienediol, ornithine, y-oryzanol, pantethine, pentaeryth-
ritol tetraacetate, a-phenylbutyramide, pirozadil, probucol
(lorelco), B-sitosterol, sultosilic acid-piperazine salt, tiad-
enol, triparanol and xenbucin.
Non-limiting examples of an antiarteriosclerotic include
pyridinol carbamate.
In certain embodiments, administration of an agent that
aids in the removal or prevention of blood clots may be
combined with administration of a modulator, particularly in
treatment of athersclerosis and vasculature (e.g., arterial)
blockages. Non-limiting examples of antithrombotic and/or
fibrinolytic agents include anticoagulants, anticoagulant
antagonists, antiplatelet agents, thrombolytic agents, throm-
bolytic agent antagonists or combinationsthereof.
In certain embodiments, antithrombotic agents that can be
administered orally, such as, for example, aspirin and wafarin
(coumadin), are preferred.
Non-limiting examples of anticoagulants include aceno-
coumarol, ancrod, anisindione, bromindione, clorindione,
coumetarol, cyclocumarol, dextran sulfate sodium, dicuma-
rol, diphenadione, ethyl biscoumacetate, ethylidene dicou-
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marol, fiuindione, heparin, hirudin, lyapolate sodium,
oxazidione, pentosan polysulfate, phenindione, phenprocou-
mon, phosvitin, picotamide, tioclomarol and warfarin.
Non-limiting examples of antiplatelet agents include aspi-
rin, a dextran, dipyridamole (persantin), heparin, sulfinpyra-
none(anturane) andticlopidine (ticlid).
Non-limiting examples ofthrombolytic agents includetis-
sue plaminogen activator (activase), plasmin, pro-urokinase,
urokinase (abbokinase) streptokinase (streptase), anistre-
plase/APSAC (eminase).
In certain embodiments wherein a subject is suffering from
a hemorrhageoran increased likelihood ofhemorrhaging, an
agent that may enhance blood coagulation may be used. Non-
limiting examples of a blood coagulation promoting agents
include thrombolytic agent antagonists and anticoagulant
antagonists.
Non-limiting examples of anticoagulant antagonists
include protamine and vitamine K1.
Non-limiting examples of thrombolytic agent antagonists
include amiocaproic acid (amicar) and tranexamic acid (am-
stat). Non-limiting examples of antithrombotics include
anagrelide, argatroban, cilstazol, daltroban, defibrotide,
enoxaparin, fraxiparine, indobufen, lamoparan, ozagrel,
picotamide, plafibride, tedelparin,ticlopidine andtriflusal.
Non-limiting examples of antiarrhythmic agents include
Class I antiarrhythmic agents (sodium channel blockers),
Class II antiarrhythmic agents (beta-adrenergic blockers),
Class III antiarrhythmic agents (repolarization prolonging
drugs), Class IV antiarrhythmic agents (calcium channel
blockers) and miscellaneous antiarrhythmic agents.
Non-limiting examples of sodium channel blockers
include Class IA, Class IB and Class IC antiarrhythmic
agents. Non-limiting examples of Class IA antiarrhythmic
agents include disppyramide (norpace), procainamide (pron-
estyl) and quinidine (quinidex). Non-limiting examples of
ClassIB antiarrhythmic agents include lidocaine (xylocalne),
tocamide (tonocard) and mexiletine (mexitil). Non-limiting
examples of Class IC antiarrhythmic agents include encam-
ide (enkaid) and flecamide (tambocor).
Non-limiting examplesofa beta blocker, otherwise known
asa B-adrenergic blocker, a B-adrenergic antagonist or a Class
II antiarrhythmic agent, include acebutolol (sectral), alpre-
nolol, amosulalol, arotinolol, atenolol, befunolol, betaxolol,
bevantolol, bisoprolol, bopindolol, bucumolol, bufetolol,
bufuralol, bunitrolol, bupranolol, butidrine hydrochloride,
butofilolol, carazolol, carteolol, carvedilol, celiprolol, ceta-
molol, cloranolol, dilevalol, epanolol, esmolol (brevibloc),
indenolol, labetalol, levobunolol, mepindolol, metipranolol,
metoprolol, moprolol, nadolol, nadoxolol, nifenalol,
nipradilol, oxprenolol, penbutolol, pindolol, practolol, prone-
thalol, propanolol (inderal), sotalol (betapace), sulfinalol,
talinolol, tertatolol, timolol, toliprolol and xibinolol. In cer-
tain embodiments, the beta blocker comprises an aryloxypro-
panolamine derivative. Non-limiting examples of arylox-
ypropanolamine derivatives include acebutolol, alprenolol,
arotinolol, atenolol, betaxolol, bevantolol, bisoprolol, bopin-
dolol, bunitrolol, butofilolol, carazolol, carteolol, carvedilol,
celiprolol, cetamolol, epanolol, indenolol, mepindolol,
metipranolol, metoprolol, moprolol, nadolol, nipradilol,
oxprenolol, penbutolol, pindolol, propanolol, talinolol, terta-
tolol, timolol and toliprolol.
Non-limiting examples of an agent that prolong repolar-
ization, also known as a Class III antiarrhythmic agent,
include amiodarone (cordarone) and sotalol (betapace).
Non-limiting examples of a calcium channel blocker, oth-
erwise knownas a Class IV antiarrhythmic agent, include an
arylalkylamine (e.g., bepridile, diltiazem, fendiline, gallo-
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pamil, prenylamine, terodiline, verapamil), a dihydropyri-
dine derivative (felodipine, isradipine, nicardipine, nife-
dipine, nimodipine, nisoldipine, nitrendipine) a piperazinde
derivative (e.g., cinnarizine, flunarizine, lidoflazine) or a
micellaneous calctum channel blocker such as bencyclane,
etafenone, magnesium, mibefradil or perhexyline. In certain
embodiments a calcium channel blocker comprises a long-
acting dihydropyridine (nifedipine-type) calcium antagonist.
Non-limiting examples of miscellaneous antiarrhythmic
agents include adenosine (adenocard), digoxin (lanoxin),
acecamide, ajmaline, amoproxan,aprindine, bretylium tosy-
late, bunaftine, butobendine, capobenic acid, cifenline, dis-
opyranide, hydroquinidine, indecamide, ipatropium bro-
mide, lidocaine, lorajmine, lorcamide, meobentine,
moricizine, pirmenol, prajmaline, propafenone, pyrinoline,
quinidine polygalacturonate, quinidine sulfate and viquidil.
Non-limiting examples of antihypertensive agents include
sympatholytic, alpha/beta blockers, alpha blockers, anti-an-
giotensin II agents, beta blockers, calctum channel blockers,
vasodilators and miscellaneous antihypertensives.
Non-limiting examples of an alpha blocker, also known as
an a-adrenergic blocker or an a-adrenergic antagonist,
include amosulalol, arotinolol, dapiprazole, doxazosin,
ergoloid mesylates, fenspiride, indoramin, labetalol, nicer-
goline, prazosin, terazosin,tolazoline, trimazosin and yohim-
bine. In certain embodiments, an alpha blocker may comprise
a quinazoline derivative. Non-limiting examples of quinazo-
line derivatives include alfuzosin, bunazosin, doxazosin,pra-
zosin, terazosin and trimazosin.
In certain embodiments, an antihypertensive agent is both
an alpha and beta adrenergic antagonist. Non-limiting
examples of an alpha/beta blocker comprise labetalol (nor-
modyne,trandate).
Non-limiting examples of anti-angiotensin I] agents
include angiotensin converting enzymeinhibitors and angio-
tensin II receptor antagonists. Non-limiting examples of
angiotensin converting enzyme inhibitors (ACE inhibitors)
include alacepril, enalapril (vasotec), captopril, cilazapril,
delapril, enalaprilat, fosinopril, listnopril, moveltopril, perin-
dopril, quinapril and ramipril. Non-limiting examples of an
angiotensin II receptor blocker, also knownas an angiotensin
II receptor antagonist, anANG receptorblocker or anANG-II
type-1 receptor blocker (ARBS), include angiocandesartan,
eprosartan, irbesartan, losartan and valsartan.
Non-limiting examples of a sympatholytic include a cen-
trally acting sympatholytic or a peripherially acting sym-
patholytic. Non-limiting examples of a centrally acting sym-
patholytic, also known as an central nervous system (CNS)
sympatholytic, include clonidine (catapres), guanabenz
(wytensin) guanfacine (tenex) and methyldopa (aldomet).
Non-limiting examples of a peripherally acting sym-
patholytic include a ganglion blocking agent, an adrenergic
neuron blocking agent, a B-adrenergic blocking agent or a
alpha] -adrenergic blocking agent. Non-limiting examples of
a ganglion blocking agent include mecamylamine(inversine)
and trimethaphan (arfonad). Non-limiting examples of an
adrenergic neuron blocking agent include guanethidine(is-
melin) and reserpine (serpasil). Non-limiting examples of a
B-adrenergic blocker include acenitolol (sectral), atenolol
(tenormin), betaxolol (kerlone), carteolol (cartrol), labetalol
(normodyne,trandate), metoprolol (lopressor), nadanol(cor-
gard), penbutolo] (levatol), pindolol (visken), propranolol
(inderal) and timolol (blocadren). Non-limiting examples of
alpha] -adrenergic blocker include prazosin (minipress), dox-
azocin (cardura) and terazosin (hytrin).
In certain embodiments a cardiovasculator therapeutic
agent may comprise avasodilator (e.g., a cerebral vasodilator,
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a coronary vasodilator or a peripheral vasodilator). In certain
preferred embodiments, a vasodilator comprises a coronary
vasodilator. Non-limiting examples of a coronary vasodilator
include amotriphene, bendazol, benfurodil hemisuccinate,
benziodarone, chloracizine, chromonar, clobenfurol, cloni-
trate, dilazep, dipyridamole, droprenilamine, efloxate, eryth-
rityl tetranitrane, etafenone, fendiline, floredil, ganglefene,
herestrol bis(B-diethylaminoethy! ether), hexobendine,itra-
min tosylate, khellin, lidoflanine, mannitol hexanitrane,
medibazine, nicorglycerin, pentaerythritol tetranitrate, pen-
trinitrol, perhexyline, pimethylline, trapidil, tricromyl, tri-
metazidine, trolnitrate phosphate and visnadine.
In certain embodiments, a vasodilator may comprise a
chronic therapy vasodilator or a hypertensive emergency
vasodilator. Non-limiting examples of a chronic therapy
vasodilator include hydralazine (apresoline) and minoxidil
(oniten). Non-limiting examples of a hypertensive emer-
gency vasodilator include nitroprusside (nipride), diazoxide
(hyperstat IV), hydralazine (apresoline), minoxidil (loniten)
and verapamil.
Non-limiting examples of miscellaneous antihyperten-
sives include ajmaline, y-aminobutyric acid, bufeniode, cicle-
tainine, ciclosidomine, a cryptenamine tannate, fenoldopam,
flosequinan, ketanserin, mebutamate, mecamylamine, meth-
yldopa, methyl 4-pyridyl ketone thiosemicarbazone,
muzolimine, pargyline, pempidine, pinacidil, piperoxan, pri-
maperone, a protoveratrine, raubasine, rescimetol, ril-
menidene, saralasin, sodium nitrorusside, ticrynafen, tri-
methaphan camsylate, tyrosinase and urapidil.
Incertain embodiments, an antihypertensive may comprise
an arylethanolamine derivative, a benzothiadiazine deriva-
tive, a N-carboxyalkyl(peptide/lactam) derivative, a dihydro-
pyridine derivative, a guanidine derivative, a hydrazines/ph-
thalazine, an imidazole derivative, a quanternary ammonium
compound,a reserpine derivative or a suflonamidederivative.
Non-limiting examples of arylethanolamine derivatives
include amosulalol, bufuralol, dilevalol, labetalol, proneth-
alol, sotalol and sulfinalol.
Non-limiting examples of benzothiadiazine derivatives
include althizide, bendroflumethiazide, benzthiazide, ben-
zylhydrochlorothiazide, buthiazide, chlorothiazide, chlortha-
lidone, cyclopenthiazide, cyclothiazide, diazoxide, epithiaz-
ide, ethiazide, fenquizone, hydrochlorothizide,
hydroflumethizide, methyclothiazide, meticrane, metola-
zone, paraflutizide, polythizide, tetrachlormethiazide and
trichlormethiazide.
Non-limiting examples of N-carboxyalkyl(peptide/lac-
tam) derivatives include alacepril, captopril, cilazapril, dela-
pril, enalapril, enalaprilat, fosinopril, lisinopril, moveltipril,
perindopril, quinapril and ramipril.
Non-limiting examples of dihydropyridine derivatives
include amlodipine, felodipine, isradipine, nicardipine, nife-
dipine, nilvadipine, nisoldipine and nitrendipine.
Non-limiting examples of guanidine derivatives include
bethanidine, debrisoquin, guanabenz, guanacline, guanadrel,
guanazodine, guanethidine, guanfacine, guanochlor, guan-
oxabenz and guanoxan.
Non-limiting examples ofhydrazines/phthalazines include
budralazine, cadralazine, dihydralazine, endralazine, hydra-
carbazine, hydralazine, pheniprazine, pildralazine and
todralazine.
Non-limiting examples of imidazole derivatives include
clonidine, lofexidine, phentolamine, tiamenidine andtoloni-
dine.
Non-limiting examples of quanternary ammonium com-
pounds include azamethonium bromide, chlorisondamine
chloride, hexamethonium, pentacynium bis(methylsulfate),
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pentamethonium bromide, pentolinium tartrate, phenactro-
pinium chloride and trimethidinium methosulfate.
Non-limiting examples of reserpine derivatives include
bietaserpine, deserpidine, rescinnamine, reserpine and syros-
ingopine.
Non-limiting examples of sulfonamide derivatives include
ambuside, clopamide, furosemide, indapamide, quineth-
azone,tripamide and xipamide.
Vasopressors generally are used to increase blood pressure
during shock, which may occur during a surgical procedure.
Non-limiting examples of a vasopressor, also known as an
antihypotensive, include amezinium methyl] sulfate, angio-
tensin amide, dimetofrine, dopamine, etifelmin, etilefrin,
gepefrine, metaraminol, midodrine, norepinephrine,
pholedrine and synephrine.
Non-limiting examples of agents for the treatment of con-
gestive heart failure include anti-angiotensin II agents, after-
load-preload reduction treatment, diuretics and inotropic
agents.
In certain embodiments, an animal subject that can not
tolerate an angiotensin antagonist may be treated with a com-
bination therapy. Such therapy may combine administration
of hydralazine (apresoline) and isosorbide dinitrate (isordil,
sorbitrate).
Non-limiting examples of a diuretic include a thiazide or
benzothiadiazine derivative (e.g., althiazide, bendroflumet-
hazide, benzthiazide, benzylhydrochlorothiazide, buthiazide,
chlorothiazide, chlorothiazide, chlorthalidone, cyclopenthi-
azide, epithiazide, ethiazide, ethiazide, fenquizone, hydro-
chlorothiazide, hydroflumethiazide, methyclothiazide, meti-
crane, metolazone, paraflutizide, polythizide,
tetrachloromethiazide, trichlormethiazide), an organomercu-
rial (e.g., chlormerodrin, meralluride, mercamphamide, mer-
captomerin sodium, mercumallylic acid, mercumatilin
dodium, mercurouschloride, mersaly]), a pteridine(e.g., fur-
therene, triamterene), purines (e.g., acefylline, 7-morpholi-
nomethyltheophylline, pamobrom, protheobromine, theo-
bromine), steroids including aldosterone antagonists (e.g.,
canrenone,oleandrin, spironolactone), a sulfonamide deriva-
tive (e.g., acetazolamide, ambuside, azosemide, bumetanide,
butazolamide, chloraminophenamide, clofenamide, clopam-
ide, clorexolone, diphenylmethane-4,4'-disulfonamide, dis-
ulfamide, ethoxzolamide, furosemide, indapamide, mefru-
side, methazolamide, piretanide, quinethazone, torasemide,
tripamide, xipamide), a uracil (e.g., aminometradine, ami-
sometradine), a potassium sparing antagonist (e.g.,
amiloride, triamterene) or a miscellaneous diuretic such as
aminozine, arbutin, chlorazanil, ethacrynic acid, etozolin,
hydracarbazine, isosorbide, mannitol, metochalcone,
muzolimine, perhexyline, ticrnafen and urea.
Non-limiting examples of a positive inotropic agent, also
known as a cardiotonic, include acefylline, an acetyldigi-
toxin, 2-amino-4-picoline, aminone, benfurodil hemisucci-
nate, bucladesine, cerberosine, camphotamide, convalla-
toxin, cymarin, denopamine,deslanoside, digitalin, digitalis,
digitoxin, digoxin, dobutamine, dopamine, dopexamine,
enoximone, erythrophleine, fenalcomine, gitalin, gitoxin,
glycocyamine, heptaminol, hydrastinine, ibopamine,a lana-
toside, metamivam, milrinone, nerifolin, oleandrin, ouabain,
oxyfedrine, prenalterol, proscillaridine, resibufogenin, scil-
laren, scillarenin, strphanthin, sulmazole, theobromine and
xamoterol.
In particular embodiments, an intropic agent is a cardiac
glycoside, a beta-adrenergic agonist or a phosphodiesterase
inhibitor. Non-limiting examples of a cardiac glycoside
includes digoxin (lanoxin) and digitoxin (crystodigin). Non-
limiting examples ofa B-adrenergic agonistinclude albuterol,
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bambuterol, bitolterol, carbuterol, clenbuterol, clorprenaline,
denopamine,dioxethedrine, dobutamine (dobutrex), dopam-
ine (intropin), dopexamine, ephedrine, etafedrine, ethylnore-
pinephrine, fenoterol, formoterol, hexoprenaline, ibopamine,
isoetharine, isoproterenol, mabuterol, metaproterenol, meth-
oxyphenamine, oxyfedrine, pirbuterol, procaterol, protoky-
lol, reproterol, rimiterol, ritodrine, soterenol, terbutaline, tre-
toquinol, tulobuterol and xamoterol. Non-limiting examples
of a phosphodiesterase inhibitor include aminone(inocor).
Antianginal agents may comprise organonitrates, calcium
channel blockers, beta blockers and combinations thereof.
Non-limiting examples of organonitrates, also known as
nitrovasodilators, include nitroglycerin (nitro-bid,nitrostat),
isosorbide dinitrate (isordil, sorbitrate) and amy]nitrate (as-
pirol, vaporole).
Endothelin (ET) is a 21-aminoacid peptide that has potent
physiologic and pathophysiologic effects that appear to be
involved in the developmentofheart failure. The effects ofET
are mediated through interaction with two classes of cell
surface receptors. The type A receptor (ET-A)is associated
with vasoconstriction and cell growth while the type B recep-
tor (ET-B) is associated with endothelial-cell mediated
vasodilation and with the release of other neurohormones,
such as aldosterone. Pharmacologic agents that can inhibit
either the production of ET orits ability to stimulate relevant
cells are known in the art. Inhibiting the production of ET
involvesthe use ofagents that block an enzyme termed endot-
helin-converting enzymethat is involved in the processing of
the active peptide from its precursor. Inhibiting the ability of
ETto stimulate cells involves the use of agents that block the
interaction ofET withits receptors. Non-limiting examples of
endothelin receptor antagonists (ERA) include Bosentan,
Enrasentan, Ambrisentan, Darusentan, Tezosentan, Atrasen-
tan, Avosentan, Clazosentan, Edonentan, sitaxsentan, TBC
3711, BQ 123, and BQ 788.
In certain embodiments, the secondary therapeutic agent
may comprise a surgery of some type, which includes, for
example, preventative, diagnostic or staging, curative and
palliative surgery. Surgery, and in particular a curative sur-
gery, may be used in conjunction with other therapies, such as
the present invention and one or more other agents.
Such surgical therapeutic agents for vascular and cardio-
vascular diseases and disorders are well known to those of
skill in the art, and may comprise, but are not limited to,
performing surgery on an organism, providing a cardiovas-
cular mechanical prostheses, angioplasty, coronary artery
reperfusion, catheter ablation, providing an implantable car-
dioverter defibrillator to the subject, mechanical circulatory
support or a combination thereof. Non-limiting examples ofa
mechanical circulatory support that may be used in the
present invention comprise an intra-aortic balloon counter-
pulsation, left ventricular assist device or combination
thereof.
MethodsofTreating Musculoskeletal Diseases
Thepresent invention also provides a methodofdecreasing
the expressionoractivity of a fast skeletal muscle contractile
protein genein skeletal muscle cells. In one embodiment, the
method comprises administering miR-499 and/or miR-208b
to the skeletal musclecells.
The up-regulation of several fast skeletal muscle contrac-
tile protein genes wasobservedin the hearts of mice lacking
both miR-208 alleles. This up-regulation of fast skeletal
muscle contractile protein genes in the hearts of miR-208
knockout mice indicates that miR-208 normally functions to
repress the fast skeletal muscle gene program. A concomitant
reduction of miR-499 expression was observed in miR-208
mutant mice, suggesting that miR-499 mayalso negatively
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regulate the expression of fast skeletal muscle contractile
protein genes. MiR-208b, which is encoded by an intron of
the B-MHCgene,differs from miR-208 by only three bases
and is expressed solely in heart and slow skeletal muscle.
Thus, miR-208b mayalso regulate the fast skeletal muscle
gene program and determinefiberidentity.
In skeletal muscle, the repression of slow fiber genes and
activation of fast fiber genes is associated with numerous
musculoskeletal disorders, including, but not limitedto, dis-
use atrophy, muscle wasting in response to anti-gravity, and
denervation. Thus, expression of miR-208, miR-208b, or
miR-499 in skeletal muscle cells may be useful in repressing
fast fiber genes and thereby activating the reciprocal expres-
sion of slow fiber genes. Accordingly, the present invention
also encompasses a methodfortreating or preventing a mus-
culoskeletal disorder in a subject in need thereof. In one
embodiment, the method comprises identifying a subject hav-
ing or at risk of a musculoskeletal disorder and increasing the
expression and/or activity of miR-499 and/or miR-208b in
skeletal muscle cells of said subject. In some embodiments,
increasing the expression and/or activity of miR-499 and/or
miR-208b may comprise administering an agonist of miR-
499 and/or miR-208bto the skeletal muscle of a subject who
has,oris at risk for developing, a musculoskeletal disorder. In
another embodiment, the present invention provides methods
of treating or preventing muscle wasting in response to a
reduced gravity environment by administering an agonist of
miR-499 and/or miR-208b to the skeletal muscle. In another
embodiment, the present invention provides methodsoftreat-
ing or preventing muscle atrophy by administering miR-499
or miR-208b to the skeletal muscle.
In addition, the results shown herein suggestthat strategies
to enhance slow fiber gene expression by elevating miR-499
or miR-208b expression can be used to augmentinsulin sen-
sitivity. Skeletal muscle accounts for the majority of insulin-
stimulated glucose uptake in humans. Insulin resistance is a
deficiency of insulin-stimulated glucose uptake seen in
patients with type II diabetes mellitus. There is a positive
correlation of insulin resistance and the percentage of slow-
versus fast-twitch muscle fibers. Thus, in another embodi-
ment, the present invention contemplates a method of aug-
menting insulin sensitivity in skeletal muscle comprising
increasing the expression and/or activity of miR-499 and/or
miR-208b in skeletal muscle cells.
In some embodiments of the invention, increasing the
expression oractivity ofmiR-499 or miR-208b in a cell may
comprise administering an agonist ofmiR-499 or miR-208b.
Tn one embodiment, an agonist ofmiR-499 or miR-208b may
bea polynucleotide comprising the mature miR-499 or miR-
208b sequence. In another embodiment, the polynucleotide
comprises the sequence ofSEQ ID NO: 26 or SEQ ID NO:27.
In another embodiment, the agonist ofmiR-499 or miR-208b
maybe a polynucleotide comprising the pri-miRNA orpre-
miRNA sequence for miR-499 or miR-208b. The polynucle-
otide comprising the mature miR-499 or miR-208b sequence
may be single stranded or double stranded. The polynucle-
otides may contain one or more chemical modifications, such
as locked nucleic acids, peptide nucleic acids, sugar modifi-
cations, such as 2'-O-alky] (e.g. 2'-O-methyl, 2'-O-methoxy-
ethyl), 2'-fluoro, and 4' thio modifications, and backbone
modifications, such as one or more phosphorothioate, mor-
pholino, or phosphonocarboxylate linkages. In one embodi-
ment, the polynucleotide comprising a miR-499 ormiR-208b
sequence is conjugated to cholesterol. In another embodi-
ment, the agonist of miR-499 or miR-208b may be an agent
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distinct from miR-499 or miR-208b that acts to increase,
supplement, or replace the function ofmiR-499 and/or miR-
208b.
In another embodiment, the agonist of miR-499 or miR-
208b maybe expressed in vivo from a vector. A “vector” is a
composition of matter which can be usedto deliver a nucleic
acid ofinterestto the interior of a cell. Numerous vectors are
known in the art including, but not limited to, linear poly-
nucleotides, polynucleotides associated with ionic or
amphiphilic compounds, plasmids, and viruses. Thus, the
term “vector” includes an autonomously replicating plasmid
or a virus. Examples of viral vectors include, but are not
limited to, adenoviral vectors, adeno-associated virus vec-
tors, retroviral vectors, and the like. An expression construct
can be replicated in a living cell, or it can be made syntheti-
cally. For purposesofthis application, the terms “expression
construct,” “expression vector,” and “vector,” are used inter-
changeably to demonstrate the application ofthe invention in
a general, illustrative sense, and are not intendedto limit the
invention.
In one embodiment, an expression vector for expressing
miR-499 or miR-208b comprises a promoter “operably
linked”to a polynucleotide encoding miR-499 or miR-208b.
The phrase “operably linked” or “under transcriptional con-
trol” as used herein meansthat the promoter is in the correct
location and orientation in relation to a polynucleotide to
control the initiation oftranscription by RNA polymerase and
expression of the polynucleotide. The polynucleotide encod-
ing miR-499 may encode the primary-microRNA-499
sequence (pri-miR-499), the precursor-microRNA-499
sequence (pre-miR-499) or the mature miR-499 sequence.
The polynucleotide encoding miR-208b may encodethepri-
mary-microRNA-208b sequence(pri-miR-208b), the precur-
sor-microRNA-208b sequence (pre-miR-208b)or the mature
miR-208b sequence. In some embodiments, the expression
vector comprises a polynucleotide operably linked to a pro-
moter, wherein said polynucleotide comprises the sequence
of SEQ ID NO: 26 or SEQ ID NO:27. The polynucleotide
comprising the sequence of SEQ ID NO: 26 or SEQ ID NO:
27 may be about 18 to about 2000 nucleotides in length, about
70 to about 200 nucleotides in length, about 20 to about 50
nucleotides in length, or about 18 to about 25 nucleotides in
length. In other embodiments, the polynucleotide encoding
miR-499 ormiR-208b is located in a nucleic acid encoding an
intron or in a nucleic acid encoding an untranslated region of
an mRNAor in a non-coding RNA.In one embodiment, the
expression construct may contain sequences from the 20”
intron from the Myh7b gene. In another embodiment, the
expression construct may contain sequences from the 31°
intron from the Myh7 (B-MHC)gene.
In another embodiment, an expression vector may be used
to deliver an inhibitor of miR-499 and/or miR-208bto a cell
or subject. An expression vectorfor expressing an inhibitor of
miR-499 or miR-208b comprises a promoter operably linked
to a polynucleotide encoding an antisense oligonucleotide,
wherein the sequence of the expressed antisense oligonucle-
otide is partially or perfectly complementary to the mature
miR-499 or miR-208b sequence.In yet another embodiment,
an expression vector for expressing an inhibitor of miR-499
or miR-208b comprises one or more promoters operably
linked to a polynucleotide encoding a shRNA or siRNA,
wherein the expressed shRNA or siRNA comprises a
sequencethatis identical or partially identical to the mature
miR-499 or miR-208b sequence.“Partially identical” refers
to a sequencethat is at least about 75%, 80%, 85%, 90%,
95%, 96%, 97%, 98%, or 99% identical to a target polynucle-
otide sequence.
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Throughout this application, the term “expression con-
struct” is meant to include any type of genetic construct
containing a nucleic acid coding for a gene product in which
part or all ofthe nucleic acid encoding sequenceis capable of
being transcribed. The transcript may be translated into a
protein, but it need notbe. In some embodiments, expression
only includes transcription of the nucleic acid encoding a
geneofinterest.
In certain embodiments, the nucleic acid encoding a the
polynucleotide ofinterest is under transcriptional control of a
promoter.A “promoter”refers toa DNA sequence recognized
by the synthetic machinery ofthecell, or introduced synthetic
machinery, required to initiate the specific transcription of a
gene. The term promoterwill be used hereto refer to a group
of transcriptional control modules that are clustered around
the initiation site fora RNApolymerase. Muchofthe thinking
about how promoters are organized derives from analyses of
several viral promoters, including those for the HSV thymi-
dine kinase (tk) and SV40early transcription units. These
studies, augmented by more recent work, have shown that
promoters are composedofdiscrete functional modules, each
consisting of approximately 7-20 bp ofDNA,and containing
one or more recognition sites for transcriptional activator or
repressorproteins.
Atleast one module in each promoter functionsto position
the start site for RNA synthesis. The best known example of
this is the TATA box,but in some promoters lacking a TATA
box, such as the promoter for the mammalianterminal deoxy-
nucleotidyl transferase gene and the promoter for the SV40
late genes, a discrete element overlying the start site itself
helpsto fix the place of initiation.
Additional promoter elements regulate the frequency of
transcriptional initiation. Typically, these are located in the
region 30-110 bp upstream ofthestart site, although a number
ofpromoters have recently been shownto contain functional
elements downstream of the start site as well. The spacing
between promoter elements frequently is flexible, so that
promoterfunction is preserved when elements are inverted or
movedrelative to one another. In the tk promoter,the spacing
between promoter elements can be increased to 50 bp apart
before activity begins to decline. Depending on the promoter,
it appears that individual elements can function either co-
operatively or independently to activate transcription.
In other embodiments, the human cytomegalovirus (CMV)
immediate early gene promoter, the SV40 early promoter, the
Rous sarcomavirus long terminal repeat, rat insulin pro-
moter, RNA pol II promoter, and glyceraldehyde-3-phos-
phate dehydrogenase promoter can be used to obtain high-
level expression of the polynucleotide of interest. The use of
other viral or mammalian cellular or bacterial phage promot-
ers which are well-knownin the art to achieve expression of
a polynucleotide ofinterest is contemplated as well, provided
that the levels ofexpression aresufficient for a given purpose.
By employing a promoter with well-known properties, the
level and pattern of expression ofthe polynucleotideofinter-
est following transfection or transformation can be opti-
mized. Further, selection of a promoter that is regulated in
responseto specific physiologic signals can permit inducible
expression of the gene product. Tables 1 and 2 list several
regulatory elements that may be employed,in the context of
the present invention, to regulate the expressionofthe gene of
interest. This list is not intended to be exhaustiveofall the
possible elements involved in the promotion of gene expres-
sion but, merely, to be exemplary thereof.
Enhancers are genetic elements that increase transcription
from a promoter located at a distant position on the same
molecule of DNA. Enhancers are organized muchlike pro-
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moters. That is, they are composed of many individualele-
ments, each of which binds to one or more transcriptional
proteins.
The basic distinction between enhancers and promotersis
operational. An enhancer region as a whole mustbe able to
stimulate transcription at a distance; this need notbe true ofa
promoter region or its component elements. On the other
hand, a promoter must have one or more elements that direct
initiation of RNA synthesis at a particular site and in a par-
ticular orientation, whereas enhancerslackthese specificities.
Promoters and enhancers are often overlapping and contigu-
ous, often seeming to have a very similar modular organiza-
tion.
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Below is a list of viral promoters, cellular promoters/en-
hancers and inducible promoters/enhancers that could be
used in combination with the nucleic acid encoding a gene of
interest in an expression construct (Table 1 and Table 2).
Additionally, any promoter/enhancer combination (as per the
Eukaryotic Promoter Data Base EPDB) could also be used to
drive expression of the gene. Eukaryotic cells can support
cytoplasmictranscription from certain bacterial promoters if
the appropriate bacterial polymerase is provided, either as
part of the delivery complex or as an additional genetic
expression construct.
TABLE1
 
Promoter/Enhancer
Promoter and/or Enhancer
References
Immunoglobulin Heavy Chain
Immunoglobulin Light Chain
T-Cell Receptor
HLA DQ aand/orDQ B
f-Interferon
Interleukin-2
Interleukin-2 Receptor
MHCClass II 5
MHCClass IIT HLA-DRa
f-Actin
Muscle Creatine Kinase (MCK)
Prealbumin (Transthyretin)
Elastase I
Metallothionein (MTID
Collagenase
Albumin
a-Fetoprotein
t-Globin
6-Globin
c-fos
c-HA-ras
Insulin
Neural Cell Adhesion Molecule (NCAM)
a,-Antitrypain
H2B (TH2B) Histone
Mouse and/or Type I Collagen
Glucose-Regulated Proteins
(GRP94 and GRP78)
Rat Growth Hormone
Human Serum Amyloid A (SAA)
Troponin I (TN I)
Platelet-Derived Growth Factor(PDGF)
Duchenne Muscular Dystrophy
SV40
Polyoma
Retroviruses
Papilloma Virus
Hepatitis B Virus
Banerji et al., 1983; Gilles et al., 1983; Grossched]etal.,
1985; Atchinsonetal., 1986, 1987; Imler etal., 1987;
Weinberger et al., 1984; Kiledjian et al., 1988; Porton et
al; 1990
Queenetal., 1983; Picard et al., 1984
Luria et al., 1987; Winoto et al., 1989; Redondoetal;
1990
Sullivan etal., 1987
Goodbourn et al., 1986; Fujita et al., 1987; Goodbournet
al., 1988
Greeneetal., 1989
Greeneetal., 1989; Lin etal., 1990
Kochet al., 1989
Sherman et al., 1989
Kawamotoet al., 1988; Ng et al.; 1989
Jaynes et al., 1988; Horlick et al., 1989; Johnsonet al.,
1989
Costa et al., 1988
Ornitz et al., 1987
Karin et al., 1987; Culotta et al., 1989
Pinkert et al., 1987; Angelet al., 1987
Pinkert et al., 1987; Troncheet al., 1989, 1990
Godboutet al., 1988; Campereet al., 1989
Bodineetal., 1987; Perez-Stable et al., 1990
Trudel et al., 1987
Cohenetal., 1987
Triesman, 1986; Deschampsetal., 1985
Edlundetal., 1985
Hirshet al., 1990
Latimeret al., 1990
Hwanget al., 1990
Ripeet al., 1989
Changet al., 1989
Larsen et al., 1986
Edbrooket al., 1989
Yutzey et al., 1989
Pechet al., 1989
Klamutet al., 1990
Banerji et al., 1981; Moreauet al., 1981; Sleigh et al.,
1985; Firak et al., 1986; Herr et al., 1986; Imbraetal.,
1986; Kadeschet al., 1986; Wanget al., 1986; Ondek et
al., 1987; Kuhlet al., 1987; Schaffner etal., 1988
Swartzendruberetal., 1975; Vasseuret al., 1980; Katinka
et al., 1980, 1981; Tyndell et al., 1981; Dandoloet al.,
1983; de Villiers et al., 1984; Henet al., 1986; Satake et
al., 1988; Campbell and/or Villareal, 1988
Kriegler et al., 1982, 1983; Levinsonet al., 1982; Kriegler
et al., 1983, 1984a, b, 1988; Bosze et al., 1986; Miksicek
et al., 1986; Celanderet al., 1987; Thiesenet al., 1988;
Celanderet al., 1988; Choiet al., 1988; Reisman etal.,
1989
Campoet al., 1983; Lusky et al., 1983; Spandidos and/or
Wilkie, 1983; Spalholz et al., 1985; Lusky et al., 1986;
Cripe etal., 1987; Gloss et al., 1987; Hirochikaetal.,
1987; Stephenset al., 1987.
Bulla et al., 1986; Jameel etal., 1986; Shaul et al., 1987;
Spandauet al., 1988; Vanniceet al., 1988
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Promotetr/Enhancer
Promoter and/or Enhancer
References
Human Immunodeficiency Virus
Cytomegalovirus (CMV)
Gibbon Ape Leukemia Virus
Muesinget al., 1987; Hauberet al., 1988; Jakobovits et
al., 1988; Fenget al., 1988; Takebeetal., 1988; Rosen et
al., 1988; Berkhoutet al., 1989; Laspiaet al., 1989; Sharp
et al., 1989; Braddocket al., 1989
Weberet al., 1984; Boshart et al., 1985; Foecking etal.,
1986
Holbrooket al., 1987; Quinnet al., 1989
TABLE 2
 
Inducible Elements
Element Inducer References
MT II Phorbol Ester (TFA) Palmiter et al., 1982;
Heavy metals Haslinger et al., 1985;
Searle et al., 1985; Stuart
et al., 1985; Imagawaet
al., 1987, Karin et al.,
1987; Angelet al., 1987b;
McNeall et al., 1989
MMTV (mouse Glucocorticoids Huanget al., 1981; Lee et
mammary tumor al., 1981; Majorset al.,
virus) 1983; Chandleret al.,
1983; Ponta et al., 1985;
Sakaiet al.,1988
§-Interferon poly(@)x Tavernieret al., 1983
poly(re)
Adenovirus 5 E2 EIA Imperiale et al., 1984
Collagenase Phorbol Ester (TPA) Angelet al., 1987a
Stromelysin Phorbol Ester (TPA) Angelet al., 1987b
SV40 Phorbol Ester (TPA) Angelet al., 1987b
Murine MX Gene Interferon, Hug et al., 1988
Newcastle
Disease Virus
GRP78 Gene A23187 Resendezet al., 1988
a-2-Macroglobulin IL-6 Kunzet al., 1989
Vimentin Serum Rittling et al., 1989
MHCClass I Gene Interferon Blanar et al., 1989
H-2kb
HSP70 EIA, SV40 Large T Tayloret al., 1989, 1990a,
Antigen 1990b
Proliferin Phorbol Ester-TPA Mordacq et al., 1989
Tumor Necrosis Factor PMA Henselet al., 1989
Thyroid Stimulating Thyroid Hormone Chatterjee et al., 1989
Hormone a@ Gene
 
Ofparticular interest are muscle specific promoters (e.g.
muscle creatine kinase), and moreparticularly, cardiac spe-
cific promoters. These include the myosin light chain-2 pro-
moter (Franz et al., 1994; Kelly et al., 1995), the alpha actin
promoter (Moss et al., 1996), the troponin 1 promoter
(Bhavsar et al., 1996); the Na*/Ca?* exchanger promoter
(Barneset al., 1997), the dystrophin promoter (Kimuraetal.,
1997), the alpha7 integrin promoter (Ziober and Kramer,
1996), the brain natriuretic peptide promoter (LaPointeetal.,
1996) and the alpha B-crystallin/small heat shock protein
promoter (Gopal-Srivastava, 1995), alpha myosin heavy
chain promoter (Yamauchi-Takihara et al., 1989) and the
ANFpromoter (LaPointeet al., 1988).
WhereacDNaAinsert is employed, one will typically desire
to include a polyadenylation signal to effect proper polyade-
nylation of the gene transcript. The nature of the polyadeny-
lation signal is not believed to be crucial to the successful
practice of the invention, and any such sequence may be
employed such as human growth hormone and SV40 poly-
adenylation signals. Also contemplated as an elementof the
expression cassette is a terminator. These elements can serve
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to enhance message levels and to minimize read through from
the cassette into other sequences.
In certain embodimentsofthe invention, the cells contain-
ing nucleic acid constructs of the present invention may be
identified in vitro or in vivo by including a marker in the
expression construct. Such markers would confer an identi-
fiable changeto the cell permitting easy identificationofcells
containing the expression construct. Usually the inclusion of
a drug selection markeraids in cloning andin the selection of
transformants, for example, genes that confer resistance to
neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and
histidinol are useful selectable markers. Alternatively,
enzymes such as herpes simplex virus thymidine kinase (tk)
or chloramphenicol acetyltransferase (CAT) may be
employed. Immunologic markers also can be employed. The
selectable marker employedis not believed to be important,
so long as it is capable of being expressed simultaneously
with the nucleic acid encoding a gene product. Further
examples of selectable markers are well known to one of skill
in the art.
There are a numberof ways in which expression vectors
may introduced into cells. In certain embodiments of the
invention, the expression construct comprises a virus or engi-
neered construct derived from a viral genome. Theability of
certain viruses to enter cells via receptor-mediated endocyto-
sis, to integrate into host cell genomeandexpressviral genes
stably andefficiently have made them attractive candidates
for the transfer offoreign genes into mammaliancells (Ridge-
way, 1988; Nicolas and Rubenstein, 1988; Baichwal and
Sugden, 1986; Temin, 1986).
Oneofthe preferred methodsfor in vivo delivery involves
the use of an adenovirus expression vector. “Adenovirus
expression vector” is meant to include those constructs con-
taining adenovirus sequencessufficient to (a) support pack-
aging ofthe construct and(b) to express a polynucleotide that
has been cloned therein. The expression vector comprises a
genetically engineered form ofadenovirus. Knowledge ofthe
genetic organization of adenovirus, a 36 kB, linear, double-
stranded DNA virus, allows substitution of large pieces of
adenoviral DNA with foreign sequences up to 7 kB (Grun-
haus and Horwitz, 1992). In contrast to retrovirus, the aden-
oviral infection of host cells does not result in chromosomal
integration because adenoviral DNAcan replicate in an epi-
somal manner without potential genotoxicity. Also, adenovi-
ruses are structurally stable, and no genomerearrangement
has been detected after extensive amplification. Adenovirus
can infect virtually all epithelial cells regardless of their cell
cycle stage.
Adenovirusis particularly suitable for use as a genetrans-
fer vector because of its mid-sized genome, ease ofmanipu-
lation, high titer, wide target cell range and high infectivity.
Both ends of the viral genome contain 100-200 base pair
inverted repeats (ITRs), which are cis elements necessary for
viral DNA replication and packaging.
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Other than the requirement that the adenovirus vector be
replication defective, or at least conditionally defective, the
nature ofthe adenovirus vector1s not believed to be crucial to
the successful practice of the invention. The adenovirus may
be of any of the 42 different known serotypes or subgroups
A-F. Adenovirus type 5 ofsubgroup C is the preferred starting
material in order to obtain the conditional replication-defec-
tive adenovirus vector for usein the present invention. Thisis
because Adenovirus type 5 is a human adenovirus about
which a great deal of biochemical and genetic information is
known, andit has historically been used for most construc-
tions employing adenovirus as a vector.
Asstated above,the typical vector according to the present
invention is replication defective and will not have an aden-
ovirus E1 region. Thus, it will be most convenient to intro-
duce the polynucleotide encoding the geneofinterest at the
position from which the El-coding sequences have been
removed. However, the position of insertion of the construct
within the adenovirus sequencesis not critical to the inven-
tion. The polynucleotide encoding the gene of interest may
also beinserted in lieu ofthe deleted E3 region in E3 replace-
mentvectors, as described by Karlsson et al. (1986), or in the
E4 region where a helper cell line or helper virus comple-
ments the E4 defect.
Adenovirus vectors have been used in eukaryotic gene
expression (Levrero et al., 1991; Gomez-Foix et al., 1992)
and vaccine development (Grunhausand Horwitz, 1992; Gra-
ham and Prevec, 1991). Recently, animal studies suggested
that recombinant adenovirus could be used for gene therapy
(Stratford-Perricaudet and Perricaudet, 1991; Stratford-Per-
ricaudetet al., 1990; Rich et al., 1993). Studies in adminis-
tering recombinant adenovirus to different tissues include
trachea instillation (Rosenfeld et al., 1991; Rosenfeld et al.,
1992), muscle injection (Ragotet al., 1993), peripheral intra-
venous injections (Herz and Gerard, 1993) and stereotactic
inoculation into the brain (Le Gal La Salle et al., 1993).
Retroviral vectors are also suitable for expressing the poly-
nucleotides of the invention in cells. The retroviruses are a
group of single-stranded RNA viruses characterized by an
ability to convert their RNA to double-stranded DNA in
infected cells by a process of reverse-transcription (Coffin,
1990). The resulting DNAthenstably integrates into cellular
chromosomes as a provirus and directs synthesis of viral
proteins. The integration results in the retention of the viral
gene sequencesin the recipient cell and its descendants. The
retroviral genomecontainsthree genes, gag, pol, and env that
code for capsid proteins, polymerase enzyme, and envelope
components, respectively. A sequence found upstream from
the gag gene contains a signal for packaging of the genome
into virions. Two long terminal repeat (LTR) sequences are
presentat the 5' and 3' ends ofthe viral genome. These contain
strong promoter and enhancer sequences and are also
required for integration in the host cell genome (Coffin,
1990).
In order to construct a retroviral vector, a nucleic acid
encoding a geneofinterest is insertedinto the viral genome in
the place of certain viral sequences to produce a virus that is
replication-defective. In order to produce virions, a packag-
ing cell line containing the gag,pol, and env genes but without
the LTR and packaging components is constructed (Mann et
al., 1983). When a recombinant plasmid containing a cDNA,
together with the retroviral LTR and packaging sequencesis
introduced into this cell line (by calctum phosphate precipi-
tation for example), the packaging sequence allows the RNA
transcript of the recombinant plasmid to be packaged into
viral particles, which are then secreted into the culture media
(Nicolas and Rubenstein, 1988; Temin, 1986; Mann etal.,
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1983). The media containing the recombinantretrovirusesis
then collected, optionally concentrated, and used for gene
transfer. Retroviral vectors are able to infect a broad variety of
cell types. However, integration and stable expression require
the division of host cells (Paskindet al., 1975).
Other viral vectors may be employed as expression con-
structs in the present invention. Vectors derived from viruses
such as vaccinia virus (Ridgeway, 1988; Baichwal and Sug-
den, 1986; Coupar et al., 1988) adeno-associated virus (AAV)
(Ridgeway, 1988; Baichwal and Sugden, 1986; Hermonat
and Muzycska, 1984) and herpesviruses may be employed.
They offer several attractive features for various mammalian
cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sug-
den, 1986; Couparet al., 1988; Horwichetal., 1990).
In order to effect expression of sense or antisense gene
constructs, the expression construct must be delivered into a
cell. This delivery may be accomplishedin vitro, as in labo-
ratory procedures for transformingcells lines, or in vivo or ex
vivo, as in the treatment ofcertain disease states. One mecha-
nism for delivery is via viral infection where the expression
construct is encapsidated in an infectious viral particle.
Several non-viral methods for the transfer of expression
constructs into cultured mammalian cells also are contem-
plated by the present invention. These include calcium phos-
phate precipitation (Graham andVan Der Eb, 1973; Chen and
Okayama, 1987; Rippeet al., 1990) DEAE-dextran (Gopal,
1985), electroporation (Tur-Kaspaet al., 1986; Potteret al.,
1984), direct microinjection (Harland and Weintraub, 1985),
DNA-loaded liposomes (Nicolau and Sene, 1982; Fraley et
al., 1979) and lipofectamine-DNA complexes,cell sonication
(Fechheimer et al., 1987), gene bombardment using high
velocity microprojectiles (Yang et al., 1990), and receptor-
mediated transfection (Wu and Wu, 1987; Wu and Wu,1988).
Someofthese techniques may be successfully adapted for in
Vivo or ex Vivo use.
Once the expression construct has been delivered into the
cell the nucleic acid encoding the gene of interest may be
positioned and expressedatdifferent sites. In certain embodi-
ments, the nucleic acid encoding the gene may be stably
integrated into the genomeofthe cell. This integrationmay be
in the cognate location and orientation via homologous
recombination (gene replacement)or it may be integrated in
a random, non-specific location (gene augmentation). In yet
further embodiments, the nucleic acid may be stably main-
tained in the cell as a separate, episomal segment of DNA.
Such nucleic acid segments or “episomes” encode sequences
sufficient to permit maintenance andreplication independent
of or in synchronization with the host cell cycle. How the
expression construct is delivered to acell andwhere in the cell
the nucleic acid remains is dependent on the type of expres-
sion construct employed.
In yet another embodimentofthe invention, the expression
construct may simply consist of naked recombinant DNA or
plasmids. Transfer of the construct may be performed by any
of the methods mentioned above which physically or chemi-
cally permeabilize the cell membrane. This is particularly
applicable for transfer in vitro but it may be applied to in vivo
use as well. Dubensky et al. (1984) successfully injected
polyomavirus DNAinthe form ofcalcium phosphateprecipi-
tates into liver and spleen of adult and newborn mice demon-
strating active viral replication and acute infection. Ben-
venisty and Neshif (1986) also demonstrated that direct
intraperitoneal injection of calctum phosphate-precipitated
plasmids results in expression of the transfected genes. It is
envisioned that DNA encoding a gene of interest may also be
transferred in a similar manner in vivo and express the gene
product.
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In still another embodimentof the invention for transfer-
ring anakedDNA expression construct into cells may involve
particle bombardment. This method depends onthe ability to
accelerate DNA-coated microprojectiles to a high velocity
allowing them to pierce cell membranesandenter cells with-
out killing them (Klein et al., 1987). Several devices for
accelerating small particles have been developed. One such
device relies on a high voltage discharge to generate an elec-
trical current, which in turn provides the motive force (Yang
et al., 1990). The microprojectiles used have consisted of
biologically inert substances such as tungsten or gold beads.
Selected organs includingthe liver, skin, and muscle tissue
of rats and mice have been bombarded in vivo (Yanget al.,
1990; Zelenin et al., 1991). This may require surgical expo-
sure of the tissueor cells, to eliminate any intervening tissue
between the gun andthe target organ, i.e., ex vivo treatment.
Again, DNA encodinga particular gene maybe delivered via
this methodandstill be incorporatedby the present invention.
In a further embodiment of the invention, the expression
construct may be entrapped in a liposome. Liposomes are
vesicular structures characterized by a phospholipid bilayer
membraneand an inner aqueous medium. Multilamellarlipo-
somes have multiple lipid layers separated by aqueous
medium. They form spontaneously when phospholipids are
suspended in an excess of aqueous solution. The lipid com-
ponents undergo self-rearrangement before the formation of
closed structures and entrap water and dissolved solutes
between the lipid bilayers (Ghosh and Bachhawat, 1991).
Also contemplated are lipofectamine-DNA complexes.
Liposome-mediated nucleic acid delivery and expression
offoreign DNAinvitro has been very successful. Wongetal.,
(1980) demonstrated the feasibility of liposome-mediated
delivery and expression of foreign DNA in cultured chick
embryo, HeLa and hepatoma cells. Nicolau et al., (1987)
accomplished successful liposome-mediated gene transfer in
rats after intravenous injection.
In certain embodimentsofthe invention,the liposome may
be complexed with a hemagglutinating virus (HVJ). This has
been shownto facilitate fusion with the cell membrane and
promote cell entry of liposome-encapsulated DNA (Kaneda
et al., 1989). In other embodiments, the liposome may be
complexed or employed in conjunction with nuclear non-
histone chromosomalproteins (HMG-1) (Kato et al., 1991).
In yet further embodiments, the liposome may be complexed
or employed in conjunction with both HVJ and HMG-1. In
that such expression constructs have been successfully
employed in transfer and expression of nucleic acid in vitro
and in vivo, then they are applicable for the present invention.
Where a bacterial promoter is employed in the DNA con-
struct, it also will be desirable to include within the liposome
an appropriate bacterial polymerase.
Other expression constructs which can be employed to
deliver a nucleic acid encoding a particular geneinto cells are
receptor-mediated delivery vehicles. These take advantage of
the selective uptake ofmacromolecules by receptor-mediated
endocytosis in almostall eukaryotic cells. Because ofthe cell
type-specific distribution of various receptors, the delivery
can be highly specific (Wu and Wu, 1993).
Receptor-mediated gene targeting vehicles generally con-
sist of two components: a cell receptor-specific ligand and a
DNA-binding agent. Several ligands have been used for
receptor-mediated gene transfer. The most extensively char-
acterized ligands are asialoorosomucoid (ASOR) (Wu and
Wu, 1987) and transferrin (Wagner et al., 1990). Recently, a
synthetic neoglycoprotein, which recognizes the same recep-
tor as ASOR,has been usedas a gene delivery vehicle (Ferkol
et al., 1993; Perales et al., 1994) and epidermal growth factor
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(EGF)hasalso been used to deliver genes to squamous car-
cinoma cells (Myers, EPO 0273085).
In other embodiments, the delivery vehicle may comprise a
ligand and a liposome. For example, Nicolau et al. (1987)
employed lactosyl-ceramide, a galactose-terminal asialgan-
glioside, incorporated into liposomes and observed an
increase in the uptake of the insulin gene by hepatocytes.
Thus, it is feasible that a nucleic acid encoding a particular
gene also maybespecifically delivered into a cell type by any
number of receptor-ligand systems with or without lipo-
somes. For example, epidermal growth factor (EGF) may be
used as the receptor for mediated delivery of a nucleic acid
into cells that exhibit upregulation ofEGF receptor. Mannose
can be usedto target the mannosereceptoron liver cells. Also,
antibodies to CD5 (CLL), CD22 dymphoma), CD25 (T-cell
leukemia) and MAA (melanoma) can similarly be used as
targeting moieties.
In aparticularexample, the polynucleotide may be admin-
istered in combination with a cationic lipid. Examples of
cationic lipids include, but are not limited to, lipofectin,
DOTMA, DOPE, and DOTAP. The publication of
WO/0071096, which is specifically incorporated by refer-
ence, describes different formulations, such as a DOTAP:
cholesterol or cholesterol derivative formulation that can
effectively be used for gene therapy. Other disclosures also
discuss different lipid or liposomal formulations including
nanoparticles and methods of administration; these include,
butare not limited to, U.S. Patent Publication 20030203865,
20020150626, 20030032615, and 20040048787, which are
specifically incorporated by reference to the extent they dis-
close formulations and other related aspects ofadministration
and delivery of nucleic acids. Methods used for forming
particles are also disclosed in U.S. Pat. Nos. 5,844,107, 5,877,
302, 6,008,336, 6,077,835, 5,972,901, 6,200,801, and 5,972,
900, which are incorporated by reference for those aspects.
In certain embodiments, gene transfer may more easily be
performed under ex vivo conditions. Ex vivo gene therapy
refers to the isolation of cells from an animal, the delivery of
a nucleic acid into the cells in vitro, and then the return ofthe
modified cells back into an animal. This may involve the
surgical removalof tissue/organs from an animalorthe pri-
mary culture of cells andtissues.
Drug Formulations and Routes forAdministration to Subjects
The present invention also encompasses a pharmaceutical
composition comprising an inhibitor or agonist of miR-499
and/or miR-208b. Where clinical applications are contem-
plated, pharmaceutical compositions will be prepared in a
form appropriate for the intended application. Generally, this
will entail preparing compositions that are essentially free of
pyrogens, as well as other impurities that could be harmful to
humansor animals.
Colloidal dispersion systems, such as macromolecule
complexes, nanocapsules, microspheres, beads, and lipid-
based systems including oil-in-water emulsions, micelles,
mixed micelles, and liposomes, may be used as delivery
vehicles for the oligonucleotide inhibitors of microRNA
function or constructs expressing particular microRNAs.
Commercially available fat emulsions that are suitable for
delivering the nucleic acids of the invention to cardiac and
skeletal muscle tissues include Intralipid®, Liposyn®, Lipo-
syn® II, Liposyn® III, Nutrilipid, and other similar lipid
emulsions. A preferred colloidal system for use as a delivery
vehicle in vivo is a liposome(i.e., an artificial membrane
vesicle). The preparation and use of such systems is well
knownin the art. Exemplary formulations are also disclosed
in U.S. Pat. Nos. 5,981,505; 6,217,900; 6,383,512; 5,783,
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565; 7,202,227; 6,379,965; 6,127,170; 5,837,533; 6,747,014;
and WO03/093449, which are herein incorporated byrefer-
ence in their entireties.
One will generally desire to employ appropriate salts and
buffers to render delivery vehicles stable and allow for uptake
by target cells. Buffers also will be employed when recom-
binant cells are introduced into a subject. Aqueous composi-
tions ofthe present invention comprise an effective amount of
the delivery vehicle comprising the inhibitor polynucleotides
or miRNApolynucleotide sequences(e.g. liposomesor other
complexes or expression vectors) or cells, dissolved or dis-
persed in a pharmaceutically acceptable carrier or aqueous
medium. The phrases “pharmaceutically acceptable” or
“pharmacologically acceptable” refers to molecular entities
and compositions that do not produce adverse, allergic, or
other untoward reactions when administered to an animal or
a human.Asused herein, “pharmaceutically acceptable car-
rier” includes solvents, buffers, solutions, dispersion media,
coatings, antibacterial and antifungal agents, isotonic and
absorption delaying agents and the like acceptable for use in
formulating pharmaceuticals, such as pharmaceuticals suit-
able for administration to humans. The use ofsuch media and
agents for pharmaceutically active substances is well known
in the art. Except insofar as any conventional media or agent
is incompatible with the active ingredients of the present
invention, its use in therapeutic compositions is contem-
plated. Supplementary active ingredients also can be incor-
poratedinto the compositions, providedthey do not inactivate
the vectors or cells of the compositions.
The active compositions of the present invention may
include classic pharmaceutical preparations. Administration
ofthese compositions accordingto the present invention may
be via any common route so long as the target tissue is
available via that route. This includes oral, nasal, or buccal.
Alternatively, administration may be by intradermal, subcu-
taneous, intramuscular, intraperitoneal or intravenousinjec-
tion, or by direct injection into cardiac tissue. Pharmaceutical
compositions comprising miRNA inhibitors or expression
constructs comprising miRNA sequences mayalso be admin-
istered by catheter systems or systems that isolate coronary
circulation for delivering therapeutic agents to the heart. Vari-
ous catheter systems for delivering therapeutic agents to the
heart and coronary vasculature are known in the art. Some
non-limiting examples of catheter-based delivery methods or
coronary isolation methods suitable for use in the present
invention are disclosed in U.S. Pat. Nos. 6,416,510; 6,716,
196; 6,953,466, WO 2005/082440, WO 2006/089340, U.S.
Patent Publication No. 2007/0203445, U.S. Patent Publica-
tion No. 2006/0148742, and U.S. Patent Publication No.
2007/0060907, which are all herein incorporated by refer-
ence in their entireties. Such compositions would normally be
administered as pharmaceutically acceptable compositions,
as described supra.
The active compounds mayalso be administered parenter-
ally or intraperitoneally. By way ofillustration, solutions of
the active compounds as free base or pharmacologically
acceptable salts can be prepared in water suitably mixed with
a surfactant, such as hydroxypropylcellulose. Dispersions
can also be preparedin glycerol, liquid polyethylene glycols,
and mixtures thereofandin oils. Under ordinary conditions of
storage and use, these preparations generally contain a pre-
servative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use or
catheter delivery include, for example, sterile aqueous solu-
tionsor dispersions andsterile powders for the extemporane-
ous preparation ofsterile injectable solutions or dispersions.
Generally, these preparationsare sterile and fluid to the extent
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that easy injectability exists. Preparations should be stable
under the conditions of manufacture and storage and should
be preserved against the contaminating action ofmicroorgan-
isms, such as bacteria and fungi. Appropriate solvents or
dispersion media may contain, for example, water, ethanol,
polyol (for example, glycerol, propylene glycol, and liquid
polyethylene glycol, and thelike), suitable mixtures thereof,
and vegetable oils. The proper fluidity can be maintained, for
example, by the use of a coating, such as lecithin, by the
maintenance of the required particle size in the case of dis-
persion and by the use of surfactants. The prevention of the
action of microorganisms can be brought about by various
antibacterial an antifungal agents, for example, parabens,
chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
In manycases,it will be preferable to include isotonic agents,
for example, sugars or sodium chloride. Prolonged absorp-
tion of the injectable compositions can be brought about by
the use in the compositions ofagents delaying absorption, for
example, aluminum monostearate and gelatin.
Sterile injectable solutions maybe prepared by incorporat-
ing the active compounds in an appropriate amount into a
solvent along with any other ingredients (for example as
enumerated above) as desired, followedbyfiltered steriliza-
tion. Generally, dispersions are prepared by incorporating the
various sterilized active ingredients into a sterile vehicle
which contains the basic dispersion medium andthe desired
other ingredients, e.g., as enumerated above. In the case of
sterile powders for the preparation ofsterile injectable solu-
tions, the preferred methods of preparation include vacuum-
drying and freeze-drying techniques which yield a powder of
the active ingredient(s) plus any additional desired ingredient
from a previously sterile-filtered solution thereof.
The compositions of the present invention generally may
be formulated in a neutral or salt form. Pharmaceutically-
acceptable salts include, for example, acid addition salts
(formed with the free amino groupsofthe protein) derived
from inorganic acids (e.g., hydrochloric or phosphoric acids,
or from organic acids (e.g., acetic, oxalic, tartaric, mandelic,
and thelike. Salts formed with the free carboxyl groups ofthe
protein can also be derived from inorganic bases (e.g.,
sodium, potassium, ammonium,calcium, or ferric hydrox-
ides) or from organic bases(e.g., isopropylamine, trimethy-
lamine,histidine, procaine andthe like.
Upon formulation, solutionsare preferably administered in
a manner compatible with the dosage formulation and in such
amountas is therapeutically effective. The formulations may
easily be administered in a variety of dosage forms such as
injectable solutions, drug release capsules and the like. For
parenteral administration in an aqueous solution, for
example, the solution generally is suitably buffered and the
liquid diluentfirst rendered isotonic for example with suffi-
cient saline or glucose. Such aqueoussolutions may be used,
for example, for intravenous, intramuscular, subcutaneous
and intraperitoneal administration. Preferably, sterile aque-
ous media are employedas is knownto those ofskill in theart,
particularly in light of the present disclosure. By way of
illustration, a single dose may be dissolved in 1 ml of isotonic
NaC]solution and either added to 1000 ml ofhypodermocly-
sis fluid or injected at the proposedsite of infusion, (see for
example, “Remington’s Pharmaceutical Sciences” 15th Edi-
tion, pages 1035-1038 and 1570-1580). Some variation in
dosage will necessarily occur depending on the condition of
the subject being treated. The person responsible for admin-
istration will, in any event, determine the appropriate dose for
the individual subject. Moreover, for human administration,
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preparations should meetsterility, pyrogenicity, general
safety and purity standards as required by FDA Office of
Biologics standards.
Any of the compositions described herein may be com-
prised in a kit. In a non-limiting example, an individual
miRNAis includedin a kit. The kit may further include water
and hybridization bufferto facilitate hybridization ofthe two
strands of the miRNAs. In some embodiments, the kit may
include one or more oligonucleotides for inhibiting the func-
tion of a target miRNA.The kit may also include one or more
transfection reagent(s) to facilitate delivery of the miRNA or
miRNA inhibitors to cells.
The components of the kits may be packaged either in
aqueous media or in lyophilized form. The container means
of the kits will generally include at least one vial, test tube,
flask, bottle, syringe or other container means, into which a
component maybeplaced, and preferably, suitably aliquoted.
Wherethere is more than one componentin the kit (labeling
reagent and label may be packagedtogether), the kit also will
generally contain a second, third or other additional container
into which the additional components may be separately
placed. However, various combinations of components may
be comprisedin a vial. The kits of the present invention also
will typically include a means for containing the nucleic
acids, and any other reagent containers in close confinement
for commercial sale. Such containers may include injection or
blow-moldedplastic containers into which the desired vials
are retained.
Whenthe componentsofthe kit are provided in one and/or
moreliquid solutions, the liquid solution is an aqueous solu-
tion, with a sterile aqueous solution being particularly pre-
ferred.
However, the components of the kit may be provided as
dried powder(s). When reagents and/or componentsare pro-
vided as a dry powder, the powder can be reconstituted by the
addition ofa suitable solvent. It is envisioned that the solvent
mayalso be provided in another container means.
The container means will generally include at least one
vial, test tube, flask, bottle, syringe and/or other container
means, into which the nucleic acid formulations are placed,
preferably, suitably allocated. The kits may also comprise a
second container meansfor containing a sterile, pharmaceu-
tically acceptable buffer and/or other diluent.
Thekits ofthe present invention will also typically include
a means for containing the vials in close confinement for
commercial sale, such as, e.g., injection and/or blow-molded
plastic containers into which the desired vials are retained.
Such kits may also include components that preserve or
maintain the miRNA or miRNAinhibitory oligonucleotides
or that protect against their degradation. Such components
may be RNAse-free or protect against RNAses. Such kits
generally will comprise, in suitable means, distinct containers
for each individual reagentor solution.
A kit will also include instructions for employing the kit
components as well the use ofany other reagent not included
in the kit. Instructions may include variations that can be
implemented. A kit may also include utensils or devices for
administering the miRNA agonist or antagonist by various
administration routes, such as parenteral or catheter admin-
istration.
Tt is contemplated that such reagents are embodiments of
kits ofthe invention. Such kits, however, are not limited to the
particular items identified above and may include any reagent
used for the manipulation or characterization of miRNA.
Methodsfor Identifying Modulators
The present invention further comprises methodsfor iden-
tifying a modulator of miR-499 and/or miR-208b.Identified
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inhibitors of miR-499 and/or miR-208b are useful in the
prevention or treatment or reversal of cardiac hypertrophy,
heart failure, or myocardial infarction. Identified agonists of
miR-499 and/or miR-208b are useful in the treatment or
prevention of musculoskeletal disorders. Modulators of miR
499 and/or miR-208b may be included in pharmaceutical
compositions for the treatment of cardiac disorders and/or
musculoskeletal disorders according to the methods of the
present invention.
These assays may comprise random screening of large
libraries of candidate substances; alternatively, the assays
may be used to focus on particular classes of compounds
selected with an eye towards structural attributes that are
believed to make them morelikely to inhibit or enhance the
expression and/or function ofmiR-499 and/or miR-208b. To
identify a modulator ofmiR-499 or miR-208b, one generally
will determine the function ofa miR-499 and/or miR-208b in
the presence and absence of the candidate substance. For
example, a method generally comprises:
(a) providing a candidate substance;
(b) admixing the candidate substance with a miR-499 and/
or miR-208b;
(c) measuring miR-499 and/or miR-208b activity; and
(d) comparingthe activity in step (c) with the activity in the
absenceofthe candidate substance,
wherein a difference between the measuredactivities indi-
cates that the candidate substanceis, indeed, a modula-
tor of miR-499 and/or miR-208b.
Assays also may be conductedin isolated cells, organs, or in
living organisms.
Assessing the miR-499 or miR-208bactivity or expression
may comprise assessing the expression level of miR-499 or
miR-208b. Thosein the art will be familiar with a variety of
methods for assessing RNA expression levels including, for
example, northern blotting or RT-PCR. Assessing the miR-
499 or miR-208b activity or expression may comprise assess-
ing the activity of miR-499 or miR-208b. In some embodi-
ments, assessing the activity of miR-499 or miR-208b
comprises assessing expressionor activity ofa gene regulated
by miR-499 or miR-208b. Genes regulated by miR-499
include, for example, B-myosin heavy chain andfast skeletal
muscle protein genes, such as troponin 12, troponin T3, myo-
sin light chain, and « skeletal actin. Genes regulated by miR-
208b include, for example, Sp3, Myostatin, PURbeta,
THRAPI,and fast skeletal muscle protein genes. In certain
embodiments ofthe invention, assessing the activity ofmiR-
499 or miR-208b comprises assessing the ratio of a-myosin
heavy chain expression level to B-myosinheavy chain expres-
sion level in the heart. In other embodiments, assessing the
activity of miR-499 or miR-208b comprises assessing the
expression level of the different B-myosin heavy chain iso-
forms in skeletal muscles. Those in the art will be familiar
with a variety ofmethods for assessing the activity or expres-
sion ofgenes regulated by miR-499 or miR-208b. Such meth-
ods include, for example, northern blotting, RT-PCR, ELISA,
or western blotting.
It will, of course, be understood that all the screening
methods of the present invention are useful in themselves
notwithstanding the fact that effective candidates may not be
found. The invention provides methodsfor screening for such
candidates, not solely methodsoffinding them.
As used herein the term “candidate substance”refers to any
molecule that may potentially modulate the B-MHC-regulat-
ing aspects of miR-499 and/or miR-208b. One will typically
acquire, from various commercial sources, molecular librar-
ies that are believed to meet the basiccriteria for useful drugs
in an effort to “brute force”the identification of useful com-
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pounds. Screening of such libraries, including combinatori-
ally-generated libraries (e.g., antagomirlibraries), is a rapid
and efficient way to screen a large numberofrelated (and
unrelated) compounds for activity. Combinatorial
approachesalso lend themselves to rapid evolution of poten-
tial drugs by the creation of second, third, and fourth genera-
tion compounds modeled on active, but otherwise undesir-
able compounds. Non-limiting examples of candidate
substances that may be screened according to the methods of
the present invention are proteins, peptides, polypeptides,
polynucleotides, oligonucleotides or small molecules. Modu-
lators of miR-499 and/or miR-208b may also be agonists or
antagonists of an upstream regulators of miR-499 and/or
miR-208b, such as miR-208.
A quick, inexpensive and easy assay to run is an in vitro
assay. Such assays generally use isolated molecules, can be
run quickly and in large numbers, thereby increasing the
amountofinformation obtainable in a short period oftime. A
variety ofvessels may be usedto run the assays, including test
tubes, plates, dishes and other surfaces such as dipsticks or
beads.
A technique for high throughput screening of compounds
is described inWO 84/03564, which1s herein incorporated by
reference in its entirety. Large numbers of small antogomir
compounds may be synthesized on a solid substrate, such as
plastic pins or some other surface. Such molecules can be
rapidly screening fortheir ability to hybridize to miR-499 or
miR-208b.
The present invention also contemplates the screening of
compounds for their ability to modulate miR-499 or miR-
208b activity and expression in cells. Various cell lines,
including those derived from skeletal muscle cells, can be
utilized for such screening assays, including cells specifically
engineered for this purpose. Primary cardiac cells also may be
used, as can the H9C2cellline.
In vivo assays involve the use of various animal models of
heart disease or musculoskeletal disease, including trans-
genic animals, that have been engineered to have specific
defects, or carry markers that can be used to measure the
ability of a candidate substance to reach and effect different
cells within the organism. Due totheir size, ease ofhandling,
and information on their physiology and genetic make-up,
mice are a preferred embodiment, especially for transgenics.
However, other animals are suitable as well, includingrats,
rabbits, hamsters, guinea pigs, gerbils, woodchucks, cats,
dogs, sheep, goats, pigs, cows, horses and monkeys (includ-
ing chimps, gibbons and baboons). Assaysfor inhibitors may
be conducted using an animal model derived from any of
these species.
Treatmentofanimals with test compoundswill involve the
administration of the compound, in an appropriate form, to
the animal. Administration will be by any route that could be
utilized for clinical purposes. Determining the effectiveness
of a compound in vivo may involve a variety of different
criteria, including but notlimited to alteration ofhypertrophic
signaling pathways and physical symptoms of hypertrophy.
Also, measuring toxicity and dose responses can be per-
formed in animals in a more meaningful fashion than in in
vitro or in cyto assays.
In one embodiment, the present invention provides a
methodofregulating cardiac and/or skeletal muscle contrac-
tility comprising administering a modulator ofmiR 499 and/
or miR-208b expression or activity to heart and/or skeletal
muscle cells. In another embodiment, there is provided a
methodofregulating cardiac contractile protein gene expres-
sion comprising administering a modulator of miR 499 and/
or miR-208b expression or activity to heart cells. In another
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embodiment, there is provided a method ofregulating skel-
etal muscle contractile protein gene expression comprising
administering a modulator of miR 499 and/or miR-208b
expression or activity to skeletal muscle cells. In still another
embodiment, the present invention provides a method of
inducing a fiber type switch of a skeletal muscle cell com-
prising administering a modulator of miR 499 and/or miR-
208b expression or activity to the skeletal muscle cell. The
modulator may be an agonist or an antagonist of miR 499
and/or miR-208b expression or activity. In some embodi-
ments, the expression ofTHRAP1, PURbeta, myostatin, and
Sox 6 are increased in a cell by contacting the cell with a
miR-499 inhibitor. In other embodiments, expression of
THRAP1, PURbeta, myostatin, and Sox 6 are decreased in a
cell by contacting the cell with a miR-499 agonist. In another
embodiment, the expression of Sp3, Myostatin, PURbeta,
and THRAP!1are increased in a cell by contacting the cell
with a miR-208b inhibitor. In still another embodiment, the
expression of Sp3, Myostatin, PURbeta, and THRAP1 are
decreased in a cell by contacting the cell with a miR-208b
agonist.
In certain embodimentsofthe invention, there is provided
a method of reducing B-MHCexpression in heart cells com-
prising administering an inhibitor of miR 499 and/or miR-
208b expression oractivity to the heart cells. In other embodi-
ments of the invention, there is provided a method of
elevating B-MHC expression in heart cells comprising
increasing endogenous miR 499 and/or miR-208b expression
or activity or administering exogenous miR-499 and/or miR-
208b to heart cells. In one embodimentofthe invention, there
is provided a method of increasing the expression of a fast
skeletal muscle contractile protein gene in heart cells com-
prising administering to the heart cells an inhibitor of miR-
499 and/or miR-208b expression or activity. In another
embodimentofthe invention, there is provided a method of
decreasing the expression of afast skeletal muscle contractile
protein gene in heart cells comprising increasing endogenous
miR 499 and/or miR-208b expression or activity or adminis-
tering exogenous miR-499 and/or miR-208b to the heart
cells. Examples of fast skeletal muscle contractile protein
genes that may be increased or decreased according to the
methods of the present invention include, but are not limited
to, troponin 12; troponin T3, myosin light chain, or alpha
skeletal actin.
In one embodiment, the present invention provides a
method for treating pathologic cardiac hypertrophy, heart
failure, or myocardial infarction in a subject in need thereof
comprising: identifying a subject having cardiac hypertrophy,
heart failure, or myocardial infarction; and administering an
miR-499 and/or miR-208b inhibitor to the subject. In certain
embodimentsofthe invention the miR-499 and/or miR-208b
inhibitor may be identified by a method comprising: (a) con-
tacting a cell with a candidate substance; (b) assessing miR-
499 and/or miR-208b activity or expression; and (c) compar-
ing the activity or expression in step (b) with the activity or
expression in the absence ofthe candidate substance, wherein
a reduction in the activity or expression of miR-499 and/or
miR-208b in the cell contacted with the candidate substance
compared to the activity or expression in the cell in the
absence of the candidate substance indicates that the candi-
date substanceis an inhibitor of miR-499 and/or miR-208b.
In another embodiment, the present invention provides a
methodfor treating a musculoskeletal disorder in a subject in
need thereof comprising: identifying a subject having a mus-
culoskeletal disorder or at risk for developing a musculosk-
eletal disorder; and administering an miR 499 and/or miR-
208b agonist to the subject. In certain embodiments of the
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invention, the miR 499 and/or miR-208b agonist may be
identified by a method comprising: (a) contacting a cell with
a candidate substance; (b) assessing miR 499 and/or miR-
208b activity or expression; and (c) comparing the activity or
expression in step (b) with the activity or expression in the
absence ofthe candidate substance, wherein an increase in the
activity or expression ofmiR 499 and/or miR-208b inthe cell
contacted with the candidate substance comparedto the activ-
ity or expression in the cell in the absence of the candidate
substance indicates that the candidate substance is an agonist
of miR-499 and/or miR-208b.
Transgenic Animals
A particular embodimentofthe present invention provides
transgenic animals that lack one or both functional miR-499
and/or miR-208b alleles. Also, transgenic animals that
express miR-499 and/or miR-208b under the control of an
inducible, tissue selective or a constitutive promoter, recom-
binant cell lines derived from such animals, and transgenic
embryos may be useful in determining the exact role that
miR-499 or miR-208b plays in the development and differ-
entiation ofcardiomyocytes and in the developmentofpatho-
logic cardiac hypertrophy and heart failure. Furthermore,
these transgenic animals may provide an insight into heart
development. The use ofan inducible or repressable miR-499
and/or miR-208b encoding nucleic acid provides a model for
over- or unregulated expression. Also, transgenic animals that
are “knocked out” for miR-499 and/or miR-208b, in one or
both alleles, are contemplated.
In a general embodiment, a transgenic animal is produced
by the integration of a given transgene into the genome in a
mannerthat permits the expression ofthe transgene. Methods
for producing transgenic animals are generally described by
Wagner and Hoppe (U.S. Pat. No. 4,873,191; incorporated
herein by reference), and Brinsteret al. (1985; incorporated
herein by reference).
Typically, a gene flanked by genomic sequencesis trans-
ferred by microinjection into a fertilized egg. The microin-
jected eggs are implantedinto a host female, and the progeny
are screened for the expression of the transgene. Transgenic
animals may be produced from the fertilized eggs from a
number of animals including, but not limited to reptiles,
amphibians, birds, mammals, andfish.
DNA clones for microinjection can be prepared by any
meansknowninthe art. For example, DNA clones for micro-
injection can be cleaved with enzymesappropriate for remov-
ing the bacterial plasmid sequences, and the DNA fragments
electrophoresed on 1% agarose gels in TBE buffer, using
standard techniques. The DNA bandsare visualized by stain-
ing with ethidium bromide, and the band containing the
expression sequences is excised. The excised band is then
placed in dialysis bags containing 0.3 M sodium acetate, pH
7.0. DNA is electroeluted into the dialysis bags, extracted
with a 1:1 phenol:chloroform solution and precipitated by
two volumesof ethanol. The DNAis redissolved in 1 ml of
low salt buffer (0.2 M NaCl, 20 mM Tris, pH 7.4, and 1 mM
EDTA)andpurified on an Elutip-D™column. The column is
first primed with 3 ml ofhigh salt buffer (1 M NaCl, 20 mM
Tris, pH 7.4, and 1 mM EDTA) followed by washing with 5
mlof low salt buffer. The DNA solutions are passed through
the column three times to bind DNAto the column matrix.
After one wash with 3 mloflow salt buffer, the DNA is eluted
with 0.4 ml high salt buffer and precipitated by two volumes
of ethanol. DNA concentrations are measured by absorption
at 260 nm in a UV spectrophotometer. For microinjection,
DNA concentrations are adjusted to 3 ug/ml in 5 mM Tris, pH
7.4 and 0.1 mM EDTA. Other methods for purification of
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DNA for microinjection are described in Palmiter et al.
(1982); and in Sambrooket al. (2001).
In an exemplary microinjection procedure, female mice six
weeksofage are inducedto superovulate with a 5 IU injection
(0.1 cc, ip) of pregnant mare serum gonadotropin (PMSG;
Sigma) followed 48 hourslater by a 5 IU injection (0.1 cc, ip)
ofhuman chorionic gonadotropin (hCG;Sigma). Females are
placed with males immediately after hCG injection. Twenty-
one hours after hCG injection, the mated females are sacri-
ficed by C02 asphyxiation or cervical dislocation and
embryosare recovered from excised oviducts and placed in
Dulbecco’s phosphate buffered saline with 0.5% bovine
serum albumin (BSA; Sigma). Surrounding cumuluscells are
removed with hyaluronidase (1 mg/ml). Pronuclear embryos
are then washed and placed in Earle’s balancedsalt solution
containing 0.5% BSA (EBSS)in a 37.5° C. incubator with a
humidified atmosphere at 5% CO,, 95% air until the time of
injection. Embryos can be implanted at the two-cell stage.
Randomly cycling adult female miceare paired with vasec-
tomized males. C57BL/6 or Swiss mice or other comparable
strains can be used for this purpose. Recipient females are
mated at the same time as donor females. At the time of
embryotransfer, the recipient females are anesthetized with
an intraperitoneal injection of 0.015 ml of 2.5% avertin per
gram of body weight. The oviducts are exposed bya single
midline dorsal incision. An incision is then made through the
body wall directly over the oviduct. The ovarian bursa is then
torn with watchmakers forceps. Embryosto be transferred are
placed in DPBS (Dulbecco’s phosphate buffered saline) and
in the tip of a transfer pipet (about 10 to 12 embryos). The
pipet tip is inserted into the infundibulum and the embryos
transferred. After the transfer, the incision is closed by two
sutures.
Definitions
As used herein, the term “heart failure” is broadly used to
mean any condition that reduces the ability of the heart to
pumpblood. Asa result, congestion and edema develop in the
tissues. Most frequently, heart failure is caused by decreased
contractility ofthe myocardium,resulting from reduced coro-
nary blood flow; however, many other factors may result in
heart failure, including damage to the heart valves, vitamin
deficiency, and primary cardiac muscle disease. Though the
precise physiological mechanisms of heart failure are not
entirely understood, heart failure is generally believed to
involve disorders in several cardiac autonomic properties,
including sympathetic, parasympathetic, and baroreceptor
responses. The phrase “manifestations of heart failure” is
used broadly to encompassall ofthe sequelae associated with
heart failure, such as shortness of breath, pitting edema, an
enlarged tender liver, engorged neck veins, pulmonary rales
and the like including laboratory findings associated with
heart failure.
The term “treatment” or grammatical equivalents encom-
passes the improvementand/or reversal of the symptoms of
heart failure (i.e., the ability of the heart to pump blood).
“Improvementin the physiologic function” of the heart may
be assessed using any of the measurements described herein
(e.g., measurementofejectionfraction, fractional shortening,
left ventricular internal dimension, heart rate, etc.), as well as
any effect upon the animal’s survival. In use of animal mod-
els, the response of treated transgenic animals and untreated
transgenic animals is compared using any of the assays
described herein (in addition, treated and untreated non-
transgenic animals may be included as controls). A com-
pound which causes an improvement in any parameter asso-
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ciated with heart failure used in the screening methodsofthe
instant invention may thereby be identified as a therapeutic
compound.
Theterm “dilated cardiomyopathy”refers to a type ofheart
failure characterized by the presence of a symmetrically
dilated left ventricle with poor systolic contractile function
and, in addition, frequently involves the right ventricle.
The term “compound”refers to any chemicalentity, phar-
maceutical, drug, and the like that can be used to treat or
prevent a disease, illness, sickness, or disorder of bodily
function. Compounds comprise both known and potential
therapeutic compounds.A compound can be determined to be
therapeutic by screening using the screening methodsof the
present invention.A “known therapeutic compound”refers to
a therapeutic compoundthat has been shown(e.g., through
animal trials or prior experience with administration to
humans)to be effective in such treatment. In other words, a
known therapeutic compoundis not limited to a compound
efficacious in the treatmentofheart failure.
Asused herein, the term “cardiac hypertrophy”refers to
the process in which adult cardiac myocytes respondto stress
through hypertrophic growth. Such growth is characterized
by cell size increases without cell division, assembling of
additional sarcomeres within the cell to maximize force gen-
eration, and an activation of a fetal cardiac gene program.
Cardiac hypertrophyis often associated with increased risk of
morbidity and mortality, and thus studies aimed at under-
standing the molecular mechanismsof cardiac hypertrophy
could have a significant impact on humanhealth.
As used herein, the term “modulate”refers to a change or
an alteration in a biological activity. Modulation may be an
increase or a decrease in protein activity, a change in kinase
activity, a change in binding characteristics, or any other
changein the biological, functional, or immunological prop-
erties associated with the activity of a protein or other struc-
ture of interest. The term “modulator” refers to any molecule
or compound which is capable of changing oraltering bio-
logical activity as described above.
The term “B-adrenergic receptor antagonist” refers to a
chemical compound or entity that is capable of blocking,
either partially or completely, the beta (B) type of adrenore-
ceptors (1.e., receptors of the adrenergic system that respond
to catecholamines, especially norepinephrine). Some (-adr-
energic receptor antagonists exhibit a degree of specificity for
one receptor subtype (generally 6,); such antagonists are
termed “B,-specific adrenergic receptor antagonists” and
“B,-specific adrenergic receptor antagonists.” The term
B-adrenergic receptor antagonist” refers to chemical com-
pounds that are selective and non-selective antagonists.
Examples of f-adrenergic receptor antagonists include, but
are not limited to, acebutolol, atenolol, butoxamine,carteolol,
esmolol, labetolol, metoprolol, nadolol, penbutolol, pro-
panolol, and timolol. The use of derivatives of known (-adr-
energic receptor antagonists is encompassed by the methods
ofthe present invention. Indeed any compound, which func-
tionally behaves as a B-adrenergic receptor antagonist is
encompassed by the methods ofthe present invention.
The terms “angiotensin-converting enzyme inhibitor” or
“ACEinhibitor”refer to a chemical compoundorentity that
is capable of inhibiting, either partially or completely, the
enzyme involved in the conversion ofthe relatively inactive
angiotensin I to the active angiotensin IJ in the renin-angio-
tensin system. In addition, the ACE inhibitors concomitantly
inhibit the degradation of bradykinin, which likely signifi-
cantly enhances the antihypertensive effect oftheACE inhibi-
tors. Examples ofACE inhibitors include, but are not limited
to, benazepril, captopril, enalopril, fosinopril, lisinopril, qui-
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april and ramipril. The use of derivatives of known ACE
inhibitors is encompassed by the methods of the present
invention. Indeed any compound, which functionally behaves
as an ACE inhibitor, is encompassed by the methods of the
present invention.
As used herein, the term “genotypes”refers to the actual
genetic make-up ofan organism, while “phenotype”refers to
physical traits displayed by an individual. In addition, the
“phenotype” is the result of selective expression of the
genome(1.e., it is an expression of the cell history and its
response to the extracellular environment). Indeed, the
human genomecontains an estimated 30,000-35,000 genes.
In eachcell type, only a small (1.e., 10-15%)fraction ofthese
genes are expressed.
The use of the word “a”or “an” when used in conjunction
with the term “comprising” in the claims and/or the specifi-
cation may mean “one,” but it is also consistent with the
meaning of “one or more,” “at least one,” and “one or more
than one.”It is contemplated that any embodimentdiscussed
herein can be implemented with respect to any method or
composition of the invention, and vice versa. Furthermore,
compositions and kits ofthe invention can be used to achieve
methods of the invention. Throughout this application, the
term “about” is used to indicate that a value includes the
standard deviation of error for the device or method being
employedto determinethe value. The use of the term “or” in
the claimsis used to mean “and/or” unless explicitly indicated
to refer to alternatives only or the alternatives are mutually
exclusive, although the disclosure supports a definition that
refers to only alternatives and “and/or.”
Asused in this specification and claim(s), the words “com-
prising” (and any form ofcomprising, suchas “comprise” and
“comprises”), “having” (and any form of having, such as
“have” and “has”’), “including” (and any form of including,
such as “includes” and “include”) or “containing” (and any
form of containing, such as “contains” and “contain’’) are
inclusive or open-ended and do not exclude additional, unre-
cited elements or methodsteps.
Although section headers have been inserted into this
application to facilitate review, such headers should not be
construed as a division of embodiments.
The following examples are included to further illustrate
various aspects of the invention. It should be appreciated by
those of skill in the art that the techniques disclosed in the
examples which follow represent techniques and/or compo-
sitions discovered by the inventor to function well in the
practice of the invention, and thus can be considered to con-
stitute preferred modes for its practice. However, those of
skill in the art should, in light of the present disclosure,
appreciate that many changes can be made in the specific
embodiments which are disclosed andstill obtain a like or
similar result without departing from the spirit and scope of
the invention.
EXAMPLES
Encoded within an intron of the a-MHCgene is miR-208
(FIG. 1A). Like a-MHC, miR-208 is expressed specifically in
the heart with trace expression in the lung (FIG. 1B). miR-208
is processed out of the a-MHC pre-mRNArather than being
transcribed as a separate transcript. Intriguingly, however,
miR-208 displays a remarkably long half-life of at least 14
days, and can thereby exert functions even when a-MHC
mRNA expression has been down-regulated. Although
genetic deletion ofmiR-208 in micefailed to induce an overt
phenotype, microarray analysis on hearts from wild-type and
miR-208-~ animals at 2 months of age revealed removal of
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miR-208to result in pronounced expression ofnumerousfast
skeletal muscle contractile protein genes, which are normally
not expressed in the heart. Thus, these results suggest that
under normal conditions miR-208 is co-expressed with the
sole cardiac-specific MHC gene to maintain cardiomyocyte
identity by repressing the expression ofskeletal muscle genes
in the heart.
The most remarkable function ofmiR-208 wasrevealed by
the aberrant response of miR-208 null mice to cardiac stress
(van Rooij, Science 2007). In response to pressure overload
by thoracic aortic constriction or signaling by calcineurin, a
calcium/calmodulin-dependent phosphatase that drives
pathological remodeling of the heart, miR-208 null mice
showedvirtually no hypertrophy of cardiomyocytes or fibro-
sis and were unable to up-regulate 8-MHCexpression (FIGS.
6-8). In contrast, other stress responsive genes, such as those
encoding ANF and BNP, werestrongly induced in miR-208
mutant animals, demonstrating that miR-208 is dedicated
specifically to the control of B-MHC expression, which can
be uncoupled from other facets ofthe cardiac stress response.
B-MHCexpression is repressed by thyroid hormonesig-
naling and is up-regulated in the hypothyroid state (Leung et
al., 2006). miR-208-" animals were also resistant to up-
regulation of}-MHCexpression following treatment with the
T3 inhibitor propylthiouracil (PTU), which induces hypothy-
roidism.Intriguingly, however, expression of B-MHCbefore
birth was normal in miR-208 mutant mice, indicating that
miR-208is dedicated specifically to the post-natal regulation
of B-MHCexpression, which coincides with the acquisition
ofthyroid hormone responsiveness ofthe B-MHCgene(FIG.
5).
A clue to the mechanism of action ofmiR-208 comes from
the resemblance ofmiR-208~~ hearts to hyperthyroid hearts,
both of which display a block to B-MHC expression, up-
regulation of stress-response genes and protection against
pathological hypertrophy andfibrosis (FIGS. 6-10). The up-
regulation offast skeletal muscle genes in miR-208-” hearts
(FIGS. 22 and 27) also mimics the induction of fast skeletal
muscle fibers in the hyperthyroid state (Wei et al., 2005).
These findings suggest that miR-208acts, at least in part,
by repressing expression of a common componentofstress-
response and thyroid hormone signaling pathways in the
heart. Amongthe strongest predicted targets of miR-208 is
the thyroid hormone receptor (TR) co-regulator THRAP1,
which can exert positive and negative effects on transcription
(Pantoset al., 2006; Yao and Eghbali, 1992; FIG. 12). The TR
acts through a negative thyroid hormoneresponse element
(TRE)to repress B-MHCexpression in the adult heart (Zhao
etal., 2005). Thus, the increase in THRAP1 expression in the
absence of miR-208 would be predicted to enhance the
repressive activity ofthe TR toward B}-MHCexpression, con-
sistent with the blockade to B-MHCexpression inmiR-208~-
hearts. However, although THRAP1 appearsto be a bonefide
target for miR-208 (FIGS. 25 and 26), these data do not
exclude the potential involvementof additional targets in the
regulation of }-MHCexpression.
Since even a subtle shift towards B-MHCreduces mechani-
cal performance andefficiency ofthe adult heart, it would be
oftherapeutic value to exploit miR-208 regulation to prevent
an increase in B-MHCexpression during cardiac disease. The
cardiac specificity and dedication of miR-208 to the cardiac
stress response, but not to normalcardiac development, make
miR-208 (and its down-stream effectors) an attractive thera-
peutic target for manipulating B-MHClevels (FIG. 13).
Materials & Methods
Northern blot analysis. Cardiac tissue samples of left ven-
tricles of anonymous humansdiagnosed as having non-fail-
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ing or failing hearts were obtained from Gilead Colorado
(Westminster, Colo.). Total RNA wasisolated from mouse,
rat and humancardiac tissue samples using Trizol reagent
(Gibco/BRL). Northern blots to detect microRNAs were per-
formed as described previously (1). A U6 probe served as a
loading control (U6 forward: 5-GTGCTCGCTTCG-
GCAGC-3, (SEQ ID NO:28); U6 reverse: 5-AAAATATG-
GAACGCTTCACGAATTTGCG-3 (SEQ ID NO: 29)). To
detect a-MHCexpression, a Northern blot containing 10 ug
ofRNA from cardiac tissue ofboth adult wild-type and miR-
208 mutant animals was probed with a cDNA fragment of
a-MHCcovering a part of the 5'UTRregion andfirst exon.
PTUtreatment. Thyroid hormonedeficiency was induced
by feeding animals for the indicated durations with iodine-
free chow supplemented with 0.15% PTU purchased from
Harlan Teklad Co. (TD 97061) (Madison, Wis.).
Microarray and realtime PCR analysis. Total RNA from
cardiac tissue wasisolated using Trizol (Invitrogen). Microar-
ray analysis was performed using Mouse Genome 430 2.0
array (Affymetrix). RT-PCR with random hexamer primers
(Invitrogen) was performed on RNA samples, after which the
expression of a subset of genes was analyzed by quantitative
real time PCR using Taqman probes purchased from ABI.
Generation ofmiR-208 mutant mice. To generate the miR-
208 targeting vector, a 0.4 kb fragment (5' arm) extending
upstream of the miR-208 coding region was digested with
SacII and NotI andligated into the pGKneoF2L2dta targeting
plasmid upstream of the loxP sites and the Frt-flanked neo-
mycin cassette. A 3.3 kb fragment (3' arm) was digested with
SalI and HindIII and ligated into the vector between the
neomycin resistance and Dta negative selection cassettes.
Targeted ES-cells carrying the disruptedallele were identified
by Southern blot analysis with 5' and 3' probes. Three miR-
208 targeted ES clones wereidentified and used for blastocyst
injection. The resulting chimeric mice were bred to CS7BL/6
to obtain germline transmission of the mutantallele.
Western blotting. Myosin was extracted from cardiactis-
sue as described (Morkin, 2000). MHC isoforms were sepa-
rated by SDS PAGEandWestern blotting was performed with
mouse monoclonal a-MHC (BA-G5) (ATCC, Rockville,
Md.) and mouse monoclonal antimyosin (slow, skeletal
M8421) (Sigma, Mo.), which is highly specific for B-MHC.
To detect all striated myosin a pan specific antibody (mouse
monoclonal 3-48; Accurate Chemical & Scientific Corpora-
tion, NY) was used. THRAP1 was detected by immunopre-
cipitation from 400 ug of cardiac protein lysate. After pre-
clearing the samples for 1 hour at 4° C., the supernatant was
incubated overnight at 4° C. with 1 wl rabbit polyclonal anti-
THRAP!I(a kind gift of R. Roeder, Rockefeller University)
and 15 ul of protein A beads. The beads were washedthree
times with lysis buffer and boiled in SDS sample buffer.
Immunoprecipitated THRAP!1protein was resolved by SDS-
PAGEand analyzed using rabbit polyclonal anti-THRAP1at
a dilution of 1:3000 andanti-rabbit IgG conjugated to horse-
radish peroxidase at a dilution of 1:5000 with detection by
Luminol Reagent (Santa Cruz).
Histological analysis and RNA In situ hybridization. Tis-
sues used for histology were incubated in Krebs-Henselheit
solution, fixed in 4% paraformaldehyde, sectioned, and pro-
cessed for hematoxylin and eosin (H&E) and Masson’s
Trichromestaining or in situ hybridization by standard tech-
niques (Krenz and Robbins, 2004). *°S-labeled RNA probes
were generated using Maxiscript kit (Amersham). Signals
were pseudocolored in red using Adobe Photoshop.
Transthoracic echocardiography. Cardiac function and
heart dimensions were evaluated by two-dimensional
echocardiography in conscious mice using a Vingmed Sys-
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tem (GE Vingmed Ultrasound, Horten, Norway) and a 11.5-
MHzlinear array transducer. M-modetracings were used to
measure anterior and posterior wall thicknesses at end dias-
tole and end systole. Left ventricular (LV) internal diameter
(LVID) was measuredasthe largest anteroposterior diameter
in either diastole (LVIDd) or systole (LVIDs). The data were
analyzed by a single observer blinded to mouse genotype. LV
fractional shortening (FS) was calculated according to the
following formula: FS (%)=[(LVIDd-LVIDs)/LVIDd]x100.
Generation oftransgenic mice.Amouse genomic fragment
flanking the miRNA ofinterest was subclonedinto a cardiac-
specific expression plasmid containing the a-MHC and
human GH poly(A)+ signal (Kiriazis and Kranias, 2000).
Genomic DNA was isolated from mouse tail biopsies and
analyzed by PCR using primers specific for the human GH
poly(A)+ signal.
Generation of LacZ and MCKtransgenic mice. To search
for cis-regulatory elements responsible for cardiac and skel-
etal muscle expression of myh7b/miR-499, 0.8 Kb genomic
fragments ofthe mouse myh7b gene were fused to the hsp68
basal promoterupstream ofa lacZ reporter gene and tested for
expression in FO transgenic mouse embryos.For the genera-
tion oftransgenic mice, constructs were digested with Sall to
remove vector sequences. DNA fragments were purified
using a QiaQuick spin column (Qiagen, MD), injected into
fertilized eggs from B6C3F 1 female mice, and implanted into
pseudopregnant ICR mice as previously described (Lien et
al., 1999). Embryos were collected and stained for B-galac-
tosidase activity. Transgenic mice that express constitutively
active forms of miR-499 underthe control of a muscle-spe-
cific enhancer from the muscle creatine kinase (MCK) gene
are described elsewhere (Nagaet al. (2000) J. Biol. Chem.,
Vol. 275: 4545-4548). Genomic DNA wasisolated from
mousetail biopsies and analyzed by PCRusing primers spe-
cific for the human GH poly(A)+ signal.
Plasmids andtransfection assays. A 305 bp genomicfrag-
ment encompassing the miR-208 coding region was ampli-
fied by PCR and ligated into pCMV6. A 1 kb fragment
encompassing the entire murine THRAP1-UTR was PCR-
amplified and ligated into an HA-tagged pCMV6expression
construct and the firefly luciferase (flue) reporter construct
(pMIR-REPORT™, Ambion). A mutation of the UCGU-
CUUA miR-208 seed binding sequence was constructed
through PCR-based mutagenesis.
Example 1
miR-208 is Required for Expression of miR-499
To further explore the mechanism ofaction ofmiR-208 in
the heart, the inventors defined the microRNA expression
patterns in hearts from wild type and miR-208 null mice by
microarray analysis. Among several microRNAsthat were
up- and down-regulated in mutant hearts, the inventors dis-
covered that miR-499 was highly abundantin normalhearts,
but was not expressed above background levels in miR-208
mutants. These findings were confirmed by Northern blot
(FIG. 14). Analysis of the genomic location of the miR-499
gene showedit to be contained within the 20intron of the
Myh7b gene, a homolog of the a-MHC gene (FIG. 15).
miR-208 appears to regulate Myh7b and thereby miR-499
expression at the level of transcription since RT-PCR for
myh7b indicates that the mRNA of the host gene is dose-
dependently abrogated in the absence ofmiR-208 (FIG.14).
The Myh7b geneis conservedin vertebrates and is expressed
solely in the heart and slow skeletal muscle(e.g. soleus) (FIG.
16A). This expression pattern for miR-499 was confirmed by
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real-time PCR analysis for miR-499 (FIG. 16B). In situ
hybridization using a probe directed against the 3' end of the
Myh7b gene, indicated that this myosin was expressed in
heart and somites as early as E10.5 (FIG. 16C). Genetic
deletion of miR-208 specifically inhibits cardiac expression
of miR-499 while leaving skeletal muscle expression intact
(FIG. 16D). These data indicate that miR-208 is required to
drive an additional myosin, Myh7b, which gives rise to
related miR-499. In addition, miR-499 is down-regulated
during cardiac hypertrophy (FIG. 17).
Example 2
MEF2 Regulates miR-499 Expression in Cardiac and
Skeletal Muscle
Within the 5' flanking region of the Myh7 gene,the inven-
tors identified a potential MEF2 consensus sequencethat was
conservedacross species. This sequence bound MEF?avidly
in gel mobility shift assays (FIG. 37A), and mutation ofthis
sequence abolished both binding (FIG. 37A)and transcrip-
tionalactivation ofa luciferase reporter by MEF2 (FIG. 37B).
The promoter region of the Myh7 gene wasfused to a lacZ
reporter and transgenic mice were generated. As shown in
FIG. 37C,this genomic region was sufficient to direct lacZ,
expression specifically in the heart at E12.5. In the postnatal
heart, lacZ staining was observed only in the ventricles, con-
sistent with in situ hybridization (data not shown). Mutation
of the MEF2 site completely eliminated expression of the
lacZ transgene (FIG. 37C). Northern blot analysis on in vivo
mouse models also showed the expression of miR-499 to be
sensitive to MEF2. Cardiac-specific over-expression of
MEF2D resulted in an increase in miR-499 expression,
whereas cardiac deletion of both MEF2C and D caused a
decrease in miR-499 expression (FIG. 37D). Direct binding
ofMEF2to the promoter ofMyh7bis required for the expres-
sion of Myh7b and miR-499 in vivo.
The MEF2 site is juxtaposed to a conserved E-box
sequence (CANNTG), which serves as a binding site for
members of the MyoD family of bHLH proteins that drive
skeletal muscle gene expression with MEF2.Indeed, MyoD
together with the ubiquitous bHLH protein E12 bound the
E-box from the promoter. Mutation of this sequence pre-
vented expression of the lacZ transgene in skeletal muscle,
but did not affect expression in the heart.
Example 3
Identification of Targets for miR-499
Given the sequence homology between miR-208 and miR-
499 and the inventors’ previous data demonstrating that
genetic disruption of miR-208 lead to a strong induction of
specifically fast skeletal muscle genes and repression of
B-MHCin the heart, it is likely that miR-499 has a compa-
rable function in skeletal muscle and could act as a dominant
regulator of fiber type. Expression of miR-499 andits host
transcript are regulated by the myogenic transcription factor
MEF2,a positive regulator of slow fiber gene expression and
muscle endurance. The inventors suggest that the fiber type
regulation of miR-499 is likely to be dependent on target
genes of miR-499 involvedin fiber type regulation.
MiR-208 is highly homologous to miR-499 and, the
remarkable fact that both microRNAsare encodedby introns
of Mhe genes, suggests that they share common regulatory
mechanisms. Since miRNAs negatively influence gene
expression in a sequence specific manner, the high degree of
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homologypredisposes miR-208 and miR-499 to exert com-
parable functions due to overlap in target genes. The inventors
have identified transcriptional regulators ofMHC expression
that appear to serve as targets of miR-499. They have also
shown that miR-499 expression is controlled by miR-208 in
the heart, such that knockdown of miR-208 eliminates miR-
499 expression.
Since the inventors’ previous data demonstrated that
genetic disruption of miR-208 leads to strong induction of
specifically fast skeletal muscle genesin the heart, it is likely
that miR-499 has a comparable function in skeletal muscle
and could act as a dominant regulator offiber type. In line
with this hypothesis, promoter analysisofthis transcript indi-
cates that the expression ofmiR-499 andits host transcript are
regulated by the myogenic transcription factor MEF2, a cen-
tral regulator of skeletal muscle fiber type and slow fiber gene
expression. The inventors have shown that MEF2 activity
promotes muscle endurance and prevents muscle fatigue fol-
lowing prolonged exercise, and suggest that these actions of
MEF2are dependent, at least in part, on the direct activation
of miR-499 expression (FIG. 18)
These data indicate that the MEF2-regulated expression of
the Myh7b geneadditionally induces the expression ofa slow
muscle and cardiac specific miRNA, miR-499, which down-
regulates the expression ofthe fast skeletal muscle gene pro-
gram. Further, these data provide evidence for miR-499 as a
central regulator of skeletal muscle fiber type (FIG. 19).
mRNA-499 is predicted to target THRAP1, PURbeta and
GDF8 (aka myostatin), genes that are known to be crucial
regulators of myosin expression and muscle fiber type, and
are likely to be the effectors of miR-499 functionality in
myofiber identity (FIG. 20). THRAP1 waspreviously iden-
tified to be targeted by miR-208 and regulates thyroid recep-
tor signaling (van Roojj et al., 2007). Adult skeletal muscle
retains the capability of transcriptional reprogramming. This
attribute is readily observable in the non-weight-bearing
(NWB)soleus muscle, which undergoes a slow-to-fast fiber
type transition concurrent with decreased beta-myosin heavy
chain (BMyHC) gene expression. This decrease in MyHC
gene expression under NWBconditions is mediated by inter-
actions between Sp3, Pura, and Pur proteins. These data
demonstrate that Pur proteins collaborate with Sp3 to regulate
a transcriptional program that enables muscle cells to
remodel their phenotype (Ji et al., 2007). Since miR-499
directly targets PUR, the fiber type regulation might be
mediated by targeting ofPURB. An additional target involved
in muscle regulation is myostatin. Myostatin is a transform-
ing growth factor-6 family member that acts as a negative
regulator of skeletal muscle growth. In mice, genetic disrup-
tion ofthe myostatin gene leads to a marked increase in body
weight and muscle mass. Similarly, pharmacological inter-
ference with myostatin in vivo in mdx knockout miceresults
in a functional improvement of the dystrophic phenotype
(Tanget al., 2007). Consequently, myostatin is an important
therapeutic target for treatment of diseases associated with
muscle wasting. Manipulating the functionality of miR-499
to regulate muscle specific fiber types could have far reaching
implications for clinical pathologies, like muscular dystro-
phy. In addition, these results suggest that strategies to
enhance slow fiber gene expression by elevating miR-499
expression will augmentinsulin sensitivity, endurance and
other salutary aspects of the slow fiber gene program.
Example 4
MiR-208 is Counterbalanced by miR-208b
Located within the B-MHC (a.k.a. myh7) gene is miR-
208b, which is co-expressed with its host-gene (FIG. 28). The
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mature miR-208b sequencediffers by 3 bases as compared to
miR-208, but has an identical seed region. The homology
between the two miRNAsandtheir host genes may have been
the result of a genomic duplication that gave rise to a-MHC
(myh6) and B-MHC (FIG. 29). Northern blot analysis was
conducted to examine the expression pattern ofmiR-208b. At
baseline, miR-208b shows a comparable expression pattern
as its host gene (8-MHC), namely expression is predomi-
nantly observed in the soleus, a slow skeletal muscle, while
little expression is observed in the heart andthe fast skeletal
muscle types (FIG. 30A).
Post-natally, T3 signaling induces a-MHCtranscription
via a positive T3 response element (TRE), whereas a negative
TREin the promoterofthe B-MHC gene mediates transcrip-
tional repression (Ojamaaet al. (2000) Endocrinology, Vol.
141: 2139-2144). To test the expression of miR-208, miR-
208b, and miR-499 (i.e. myomiRs) in response to myosin
regulation, rats were fed PTU-containing chow for 2 weeks to
block T3 signaling, and subsequently supplemented PTU-
treated rats with T3 to reverse the PTU effect. PTU, as
expected, induced a decline in a-MHCand an increase in
B-MHCin response to PTU, which could be reversed by T3
(FIG. 30B). Although to a lesser extent, the expression of
myh7b followed the expression pattern of B-MHC; induced
expression in response to PTU,and diminished expression in
response to PTU together with T3 (FIG. 30B). Northern blot
analysis indicates that miR-208b and miR-499 precisely fol-
lowedthe expression pattern of B-MHC and myh7b,respec-
tively (FIG. 31). This increase appeared to be dose-dependent
since longer exposure to PTU increased miR-208b expres-
sion over time (FIG.32).
As a- and B-MHCare counterbalanced in the heart, the
expression ofmiR-208/miR-208bis likely maintainedatrela-
tively constant levels. While B-MHC in mice is the dominant
MHCgene expressed during embryogenesis andshortly after
birth, a-MHCtakes over during adulthood. Since the inven-
tors’ previous data indicated that miR-208 in the adult heart
was required for miR-499 expression, the inventors tested
whether miR-208b can substitute for miR-208. Northern
analysis for the myomiRsat pl, p6 and in adult heart indi-
cated that in the absence of miR-208, miR-499 remains
expressed while miR-208b is present (FIG. 30C). To test
whether miR-208b also responds to myosin switching in a
comparable way as B-MHC, both wild-type and miR-208
mutant animals were treated with PTU.In response to PTU,
a-MHCexpression was severely repressed, which resulted in
aloss ofpre-miRNA-208 (indicated by asterisks) in wild-type
animals. As expected, miR-499 was completely absentin the
miR-208 mutant animals and only slightly induced in
response to PTU in wild-type animals. However, miR-208b,
like B-MHC, wasstrongly induced by PTU, while in the
absence of miR-208, this induction was only minor (FIG.
30D). Together, these results suggest that the myomiRs
located within the myosin genes regulate the expression lev-
els of the myosin genes and therefore the miRNAsthey har-
bor.
Previously the inventors showedthat cardiac specific dele-
tion ofmiR-208 inhibited the induction of B-MHCexpression
by stress stimuli (FIG. 8). Although 6-MHC expression is
very low at baseline, Northern blotting for miR-208b showed
a dose-dependent decrease in miR-208b expression corre-
sponding to the removalofone or both miR-208alleles (FIG.
33A). However, transgenic overexpression of miR-208,
which has been shownto induce B-MHCexpression (FIG. 9),
induced miR-208b expression (FIG. 33B). These data imply
that althoughmiR-208 appears to be the upstream regulator of
the effect on cardiac B-MHCexpression, pathological cardiac
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remodeling mayalso be due to the regulation ofmiR-499 and
miR-208b (FIGS. 33C and 34).
Example 5
MiR-208 and miR-499 Repress the Fast Skeletal
Muscle Phenotype
The up-regulation of fast skeletal muscle genes in hearts of
miR-208 null mice, combined with the slow fiber-specific
expression of miR-499 suggested that these miRNAs may
function to repress the expression of fast skeletal muscle
genes. To address this issue, transgenic mice were generated
that expressed miR-499 in fast skeletal muscle under control
of the MCK promoter and enhancer. Multiple stable trans-
genic lines were obtained that expressed miR-499 in fast
fibers (FIG. 38A). Compared to cardiac expression, these
transgenic animals efficiently overexpressed miR-499 in
soleus andfast skeletal muscle types (FIG. 38B). Analysis of
fiber type-specific gene expression showed that fast fibers
were transformed toward a slow myofiber phenotype by the
forced expression of miR-499, Gene expression analysis in
all five muscle types in both wild-type and miR-499 trans-
genic animals indicated that miR-499 is sufficient to drive
B-MHCexpression in soleus, TA and EDL, while miR-499
repressesthefast skeletal troponin I and T in heart, soleus and
EDL (FIG. 38C). Fast muscle fibers of these transgenic ani-
mals werereadily identifiable by their deep red color, indica-
tive of high levels ofmyoglobin expression and vasculariza-
tion. Similarly, metachromatic ATPase staining of
histological sections showed a dramatic increase in slow
myofiber gene expression in fast fibers (EDL) ofthe trans-
genic mice (FIG. 38D).
To determine whetherthe loss ofmiR-499 in the miR-208
knockout animals was in series or in parallel with the regula-
tion of B-MHCand the fast skeletal genes, miR-499 was
transgenically overexpressed in the miR-208 null back-
ground. Northern blot analysis and realtime PCR for B-MHC
indicates that PTU potently induces }-MHC andmiR-208b in
wild-type (WT) animals but not in miR-208 mutant animals
(KO). However, re-introduction of miR-499 by transgenic
overexpression abolishes this repressive effect on B-MHC in
the absence ofmiR-208 (FIG. 38E). Also, the induced expres-
sion of fast skeletal troponins in the absence of miR-208 is
repressed in the presence of the miR-499 transgene (FIG.
38F). These data indicate that miR-499 is sufficient to drive a
slow skeletal fiber phenotype andis responsibleforthe effects
on B-MHCandfast skeletal genes in the miR-208 mutant
animals.
Since miR-208b is expressed in slow skeletal muscle,it is
very likely that it regulates fiber type identity in skeletal
muscles either directly or through regulation of miR-499.
Previous data showed that cardiac removal of miR-208 (a
cardiac family member of miR-208b) resulted in a cardiac
inhibition of miR-499 and an upregulation of fast skeletal
muscle genes (FIGS. 22 and 27). Removal ofmiR-208b from
skeletal muscle will likely inhibit miR-499 expression and
produce an expression of fast skeletal muscle genes, thereby
inducing a fiber type shift from slow towards fast. To inves-
tigate the functional implications ofmiR-208b in moredetail,
a targeting strategy was designed to very precisely remove
miR-208b from the mouse genome (FIG.35). An additional
approach to scavenge both miR-499 and miR-208b mayalso
be undertaken. Skeletal muscle specific overexpression of
binding site regions for both miR-499 and miR-208b using a
skeletal and heart muscle specific promoter (muscle creatine
kinase (MCK)) should scavenge miR-208b and miR-499 in
40
45
55
52
both heart and skeletal muscle, thereby generating a knock-
down for both miRNAs(FIG.36).
Example 6
Control of Myh7b/miR-499 by miR-208
In the heart, miR-208is the upstream regulator ofa system
responsible for maintaining cardiomyocyte identity by
repressing fast skeletal gene expression and, in addition, con-
tributes to pathological remodeling in response to stress.
miR-208 doesso, at least in part, by regulating the expression
of an additional miRNA, miR-499, which is located within
the myosin gene myh7b. Although miR-208is absent in skel-
etal muscle, a closely related miR, miR-208b, is expressed in
slow skeletal muscle from the S-MHCtranscript.
Based on the restricted expression of miR-499 to slow
skeletal muscle fibers, miR-208b may induce miR-499 to
repress the fast fiber gene program in slow skeletal muscles.
However, our data indicate that miR-499 is required for
B-MHC expression, which would generate a feed-forward
loop in which B-MHC,through activation of miR-208b and
miR-499, stimulates its own expression.
It is remarkable that a 50% reduction in miR-208 expres-
sion in hearts ofmiR-208+/- miceresults in a corresponding
decrease in Myh7b/miR-499 expression and the absence of
miR-208 completely eliminates expression of Myh7b/miR-
499. The sensitivity of Myh7b/miR-499to the level of miR-
208 expression suggests that the target(s) of miR-208 are
precisely regulated, which is exceptional since miRNAsusu-
ally are thought of as fine-tuners of gene expression rather
than on-off switches.
The inventors previously determined THRAP1, a thyroid
hormonereceptor co-regulator, to be a target ofmiR-208. Due
to the significant overlap in seed sequence between miR-208
and miR-499, these miRNAs may have overlappingtargets.
Thus, miR-499 may regulate THRAP1 and thereby control
B-MHC and fast skeletal gene expression. In addition to
THRAP!1, Sox6, a memberofthe Sox family oftranscription
factors, might also contribute to the phenotype. Sox6, which
is highly expressed in skeletal muscle and known to nega-
tively regulate 6-MHC expression in cardiac and skeletal
muscle, contains multiple conserved miR-499 bindingsites
in its 3' UTR andrepresentsa likely mediatorofthe effects of
miR-499 on muscle gene expression.
Example 7
Regulation of Cardiac Remodeling by miR-208 and
miR-499
The most remarkable function ofmiR-208 wasrevealed by
the aberrant response ofmiR-208 null mice to cardiac stress
(von Rooij et al. (2007) Science, Vol. 316: 575-579). In
response to pressure overload by thoracic aortic constriction
or signaling by calcineurin, miR-208 null mice showed vir-
tually no hypertrophy or fibrosis and were unable to up-
regulate BMHCexpression. In contrast, other stress respon-
sive genes, such as those encoding ANF and BNP, were
strongly induced in miR-208 mutant animals, demonstrating
that miR-208 is dedicated specifically to the control of
B-MHCexpression, which can be uncoupled from otherfac-
ets of the cardiac stress response. Since the inventors’ data
indicate that miR-499 is responsible for some of the gene
regulatory effects seen in the miR-208 mutant animals, miR-
499 mutant animals may also be resistant to pathological
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remodeling ofthe heart, like miR-208 mutant animals. The
absence of both miR-208 and miR-499 may be induce the
protective effect.
Asalpha- and beta-MHCare counterbalancedin the heart,
the expression of miR-208/miR-208b is likely maintained at
relatively constant levels. However, while alpha-MHCis the
dominant MHCisoform in mice and beta-MHC dominates in
humans,the relative expression ofmiR-208 versus miR-208b
differs accordingly in mice versus humans. Since miR-208is
required for cardiac beta-MHC expression in response to
stress and hypothyroidism in mice, miR-208b may play an
importantrole in the human shift towards beta-MHC during
heart disease. Nonetheless, these data indicate that there must
exist an intimate form of cross-talk between these miRNAs
and the myosin genes. Manipulating the functionality ofmiR-
208b to regulate muscle specific fiber types can have far
reaching implicationsfor clinical pathologies, like muscular
dystrophy. In addition, these results suggest that strategies to
enhance slow fiber gene expression by elevating miR-208b
expression will augmentinsulin sensitivity, endurance and
other salutary aspects of the slow fiber gene program.
Sie se ae
All publications, patents and patent applications discussed
and cited herein are incorporated herein by reference in their
entireties. All ofthe compositions and methodsdisclosed and
claimed herein can be made and executed without undue
experimentation in light of the present disclosure. While the
compositions and methods of this invention have been
described in terms ofpreferred embodiments,it will be appar-
ent to those of skill in the art that variations maybe applied to
the compositions and methods, and in the steps or in the
sequence of steps of the methods described herein without
departing from the concept, spirit and scope ofthe invention.
Morespecifically, it will be apparentthat certain agents which
are both chemically and physiologically related may be sub-
stituted for the agents described herein while the same or
similar results would be achieved.All such similar substitutes
and modifications apparent to those skilled in the art are
deemed to be within the spirit, scope and concept of the
invention as defined by the appended claims.
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SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 39
<210> SEQ ID NO 1
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<211>
<212>
<213>
<400>
LENGTH: 71
TYPE: DNA
ORGANISM: Homo sapiens
SEQUENCE: 1
tgacgggega gettttggcee cgggttatac ctgatgetca cgtataagac gagcaaaaag
ettgttggte a
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 2
LENGTH: 71
TYPE: DNA
ORGANISM: Mus sp.
SEQUENCE: 2
tgacgggtga gettttggce cgggttatac ctgactctca cgtataagac gagcaaaaag
ettgttggte a
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 3
LENGTH: 71
TYPE: DNA
ORGANISM: Rattus sp.
SEQUENCE: 3
tgacgggtga gettttggce cgggttatac ctgactctca cgtataagac gagcaaaaag
ettgttggte a
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 4
LENGTH: 71
TYPE: DNA
ORGANISM: Canis sp.
SEQUENCE: 4
tgacgeatga gcettttggct cgggttatac ctgatgetca cgtataagac gagcaaaaag
ettgttggte a
<210>
<211>
<212>
<213>
<220>
<223>
<400>
SEQ ID NO 5
LENGTH: 22
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Mature miR-208 sequence
SEQUENCE: 5
auaagacgag caaaaagecuu gu
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 6
LENGTH: 69
TYPE: RNA
ORGANISM: Homo sapiens
SEQUENCE: 6
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuuaauuaa aaaguugcag
uaggguuge
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 7
LENGTH: 69
TYPE: RNA
ORGANISM: Pan sp.
SEQUENCE: 7
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuuaauuaa aacguugcag
60
71
60
71
60
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60
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60
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uaggguuge
<210> SEQ ID NO 8
<211> LENGTH: 69
<212> TYPE: RNA
<213> ORGANISM: Mus sp.
<400> SEQUENCE: 8
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuuaauuaa aagcuugcag
uaggguuge
<210> SEQ ID NO 9
<211> LENGTH: 69
<212> TYPE: RNA
<213> ORGANISM: Rattus sp.
<400> SEQUENCE: 9
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuuaauuaa aacguugcag
uaggguuge
<210> SEQ ID NO 10
<211> LENGTH: 69
<212> TYPE: RNA
<213> ORGANISM: Canis sp.
<400> SEQUENCE: 10
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuuaauuaa aacguugcag
uaggguuge
<210>
<211>
<212>
<213>
SEQ ID NO 11
LENGTH: 69
TYPE: RNA
ORGANISM: Gallus sp.
<400> SEQUENCE: 11
uucuugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuuaauuaa aacguugcag
uaggguuge
<210> SEQ ID NO 12
<211> LENGTH: 72
<212> TYPE: RNA
<213> ORGANISM: Takifugu
<400> SEQUENCE: 12
uuccugcuuu aagcaauugg uugaaaauau auguauguaa uggucuuaau uaaaaaaaca
aacuaagaca aa
<210> SEQ ID NO 13
<211> LENGTH: 69
<212> TYPE: RNA
<213> ORGANISM: Danio sp.
<400> SEQUENCE: 13
uuccugcuuu aaagcaauug gucuaaaaua uauguaaucg ucuucauuac aaaaacgaac
caucaaacg
<210> SEQ ID NO 14
<211> LENGTH: 71
<212> TYPE: DNA
69
60
69
60
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69
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<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 14
acgggegage ttttggeccg ggttatacct gatgctcacg tataagacga gcaaaaaget
tgttggtcag a
<210> SEQ ID NO 15
<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Mus sp.
<400> SEQUENCE: 15
acgggtgage ttttggceccg ggttatacct gactctcacg tataagacga gcaaaaaget
tgttggtcag a
<210> SEQ ID NO 16
<211> LENGTH: 71
<212> TYPE: DNA
<213> ORGANISM: Rattus sp.
<400> SEQUENCE: 16
acgggtgage ttttggceccg ggttatacct gactctcacg tataagacga gcaaaaaget
tgttggtcag a
<210>
<211>
<212>
<213>
SEQ ID NO 17
LENGTH: 71
TYPE: DNA
ORGANISM: Canis sp.
<400> SEQUENCE: 17
acgcatgage ttttggctcg ggttatacct gatgctcacg tataagacga gcaaaaaget
tgttggtcag a
<210> SEQ ID NO 18
<211> LENGTH: 76
<212> TYPE: DNA
<213> ORGANISM: Mus sp.
<400> SEQUENCE: 18
tecctgtgte ttgggtggge agctgttaag acttgcagtg atgtttaget cctctgcatg
tgaacatcac agcaag
<210> SEQ ID NO 19
<211> LENGTH: 74
<212> TYPE: DNA
<213> ORGANISM: Rattus sp.
<400> SEQUENCE: 19
tecetgtctt gggtgggcag ctgttaagac ttgcagtgat gtttagetce tctccatgtg
aacatcacag caag
<210> SEQ ID NO 20
<211> LENGTH: 76
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 20
cecetgtgee ttgggeggge ggctgttaag acttgcagtg atgtttaact cctctccacg
tgaacatcac agcaag
60
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<210>
<211>
<212>
<213>
<400>
SEQ ID NO 21
LENGTH: 76
TYPE: DNA
ORGANISM: Canis sp.
SEQUENCE: 21
cecttgcace ctgggeggge ggecgttaag acttgcagtg atgtttaact cctctccacg
tgaacatcac agcaag
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 22
LENGTH: 76
TYPE: DNA
ORGANISM: Monodelphis sp.
SEQUENCE: 22
cecetgecte ceeggeggge agetgttaag acttgcagtg atgtttaatt cttctctatg
tgaacatcac aacaag
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 23
LENGTH: 62
TYPE: DNA
ORGANISM: Gallus sp.
SEQUENCE: 23
ggageggeag ttaagacttg tagtgatgtt tagataatgt attacatgga catcacttta
ag
<210>
<211>
<212>
<213>
<400>
SEQ ID NO 24
LENGTH: 68
TYPE: DNA
ORGANISM: Xenopus tropicalis
SEQUENCE: 24
gtcttagega ggcagttaag acttgcagtg atgtttagtt aaaatctttt catgaacatc
actttaag
<210>
<211>
<212>
<213>
<220>
<223>
<400>
SEQ ID NO 25
LENGTH: 79
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Pre-miR-499 sequence
SEQUENCE: 25
gggugggeag cuguuaagac uugcagugau guuuagcuce ucugcaugug aacaucacag
caagucugug cugcugecu
<210>
<211>
<212>
<213>
<220>
<223>
<400>
SEQ ID NO 26
LENGTH: 21
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: miR-499 sequence
SEQUENCE: 26
uuaagacuug cagugauguu u
<210>
<211>
<212>
SEQ ID NO 27
LENGTH: 22
TYPE: RNA
60
76
60
76
60
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<213> ORGANISM: Unknown
<220> FEATURE:
<223> OTHER INFORMATION: miR-208b sequence
<400> SEQUENCE: 27
auaagacgaa caaaagguuu gu
<210> SEQ ID NO 28
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Unknown
<220> FEATURE:
<223> OTHER INFORMATION: U6 forward primer
<400> SEQUENCE: 28
gtgetegett cggcage
<210> SEQ ID NO 29
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Unknown
<220> FEATURE:
<223> OTHER INFORMATION: U6 reverse primer
<400> SEQUENCE: 29
aaaatatgga acgcttcacg aatttgceg
<210> SEQ ID NO 30
<211> LENGTH: 43
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 30
tttctgatce gaatataaga cgaacaaaag gtttgtctga ggg
<210> SEQ ID NO 31
<211> LENGTH: 43
<212> TYPE: DNA
<213> ORGANISM: Mus sp.
<400> SEQUENCE: 31
tttctgatce gaatataaga cgaacaaaag gtttgtctga ggg
<210> SEQ ID NO 32
<211> LENGTH: 43
<212> TYPE: DNA
<213> ORGANISM: Rattus sp.
<400> SEQUENCE: 32
tttctgatce gaatataaga cgaacaaaag gtttgtctga ggg
<210> SEQ ID NO 33
<211> LENGTH: 43
<212> TYPE: DNA
<213> ORGANISM: Canis sp.
<400> SEQUENCE: 33
tttctgatcc gaatataaga cgaacaaaag gtttgtctga ggg
<210> SEQ ID NO 34
<211> LENGTH: 43
<212> TYPE: DNA
<213> ORGANISM: Monodelphis sp.
<400> SEQUENCE: 34
22
17
28
43
43
43
43
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ttttggatct gaatataaga cgaacaaaag gtttgtctgt gtg
<210> SEQ ID NO 35
<211> LENGTH: 43
<212> TYPE: DNA
<213> ORGANISM: Xenopus tropicalis
<400> SEQUENCE: 35
ttttctgttg ttgtataaga cgagcataaa gcttgtttgt tag
<210>
<211>
<212>
<213>
<220>
<223>
SEQ ID NO 36
LENGTH: 77
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Pre miR-208b sequence
<400> SEQUENCE: 36
ccucucaggg aagcuuuuug cucgcguuau guuucucauc cgaauauaag acgaacaaaa
gguuugucug agggcug
<210>
<211>
<212>
<213>
<220>
<223>
SEQ ID NO 37
LENGTH: 71
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Pre miR-208 sequence
<400> SEQUENCE: 37
ugacgggega gcuuuuggee cggguuauac cugaugcuca cguauaagac gagcaaaaag
cuuguugguc a
<210>
<211>
<212>
<213>
<220>
<223>
SEQ ID NO 38
LENGTH: 24
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: miR-208 sequence
<400> SEQUENCE: 38
auaagacgag caaaaageuu guuu
<210>
<211>
<212>
<213>
<220>
<223>
SEQ ID NO 39
LENGTH: 23
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: miR-499 sequence
<400> SEQUENCE: 39
uuaagacuug cagugauguu uaa
43
43
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The invention claimedis:
1. A methodfor treating pathologic cardiac hypertrophy,
heart failure, or myocardial infarction in a subject in need
thereof comprising administering to the subject:
a miR-499 inhibitor, wherein the miR-499 inhibitor is an
antisense oligonucleotide comprising a sequencethatis
at least 85% complementary to amiR-499 sequence over
the entire length of the antisense oligonucleotide; and
a miR-208/miR-208b inhibitor, wherein the miR-208/
miR-208b inhibitoris an antisense oligonucleotide com-
prising a sequencethatis at least 85% complementary to
amiR-208 or miR-208b sequenceoverthe entire length
ofthe antisense oligonucleotide, wherein the expression
or activity of miR-499 and miR-208 or miR-208b is
inhibited in the heart cells of the subject following
administration of the miR-499 inhibitor and the miR-
208/miR-208b inhibitor.
2. The methodofclaim 1, wherein the miR-499 inhibitoris
65 anantisense oligonucleotide comprising a sequencethat is at
least 95% complementary to SEQ ID NO:26 overthe entire
length of the antisense oligonucleotide.
60
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3. The method ofclaim 1, wherein the miR-499inhibitoris
an antisense oligonucleotide comprising a sequence that is
100% complementary to SEQ ID NO: 26 over the entire
length of the antisense oligonucleotide.
4. The methodofclaim 1, wherein the miR-208/miR-208b
inhibitor is an antisense oligonucleotide comprising a
sequencethatis at least 95% complementary to SEQ ID NO:
5 or SEQ ID NO:27 over the entire length of the antisense
oligonucleotide.
5. The methodofclaim 1, wherein the miR-208/miR-208b
inhibitor is an antisense oligonucleotide comprising a
sequencethat is 100% complementary to SEQ ID NO: 5 or
SEQ ID NO:27 over the entire length of the antisense oligo-
nucleotide.
6. The methodofclaim 1, wherein the miR-208/miR-208b
inhibitor is an antisense oligonucleotide comprising a
sequencethat is at least 95% complementary to a pre-miR-
208 sequence over the entire length of the antisense oligo-
nucleotide.
7. The method of claim 6, wherein the pre-miR-208
sequence is SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO:
16, or SEQ ID NO:17.
8. The method ofclaim 1, wherein the miR-208/miR-208b
inhibitor is an antisense oligonucleotide comprising a
sequencethat is at least 95% complementary to a pre-miR-
208b sequence.
9. The method of claim 8, wherein the pre-miR-208b
sequence is SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO:
32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, or SEQ
ID NO:36.
10. The method of claim 1, wherein the miR-499 inhibitor
is an antisense oligonucleotide comprising a sequencethatis
at least 95% complementary to a pre-miR-499 sequence.
11. The method of claim 10, wherein the pre-miR-499
sequence is SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:
20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO:23, or SEQ
ID NO:24.
12. The method of claim 1, wherein the miR-499 inhibitor
and/or the miR-208/miR-208b inhibitor is about 15 to about
50 nucleotides in length.
13. The method of claim 1, wherein the miR-499 inhibitor
and/or the miR-208/miR-208b inhibitor is about 19 to about
25 nucleotides in length.
14. The method of claim 1, wherein the miR-499 inhibitor
and/or the miR-208/miR-208b inhibitor comprises at least
one chemical modification.
15. The method of claim 14, wherein the chemical modi-
fication is a sugar and/or backbone modification.
16. The method of claim 15, wherein the sugar modifica-
tion is a modification selected from the group consisting of
2'-O-alkyl, 2'-O-methyl, 2'-O-methoxyethyl, 2'-fluoro, and a
locked nucleic acid.
17. The method of claim 15, wherein the backbone modi-
fication is a phosphorothioate linkage.
18. The method of claim 1, wherein the miR-499 inhibitor
and/or the miR-208/miR-208b inhibitor is conjugated to cho-
lesterol.
19. The method of claim 1, wherein the miR-499 inhibitor
and/or the miR-208/miR-208b inhibitor is administered by
intradermal, subcutaneous, intramuscular, intraperitoneal,
intravenous, oral, transdermal, sustained release, controlled
release, delayed release, suppository, catheter, or sublingual
administration or direct injection into cardiac tissue.
20. A method of preventing pathologic cardiac hypertro-
phyor heart failure in a subject identified as being atrisk of
developing pathologic cardiac hypertrophy or heart failure
comprising:
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administering to the subject a miR-499 inhibitor, wherein
the miR-499 inhibitor is an antisense oligonucleotide
comprising a sequencethatis at least 85% complemen-
tary to amiR-499 sequenceoverthe entire length ofthe
antisense oligonucleotide; and
administering to the subject a miR-208/miR-208b inhibi-
tor, wherein the miR-208/miR-208b inhibitor is an anti-
sense oligonucleotide comprising a sequence that is at
least 85% complementary to a miR-208 or miR-208b
sequence over the entire length of the antisense oligo-
nucleotide, wherein the expression or activity of miR-
499 and miR-208 or miR-208b is inhibited in the heart
cells ofthe subject following administration ofthe miR-
499 inhibitor and the miR-208/miR-208b inhibitor.
21. The method ofclaim 20, wherein the subject identified
as being at risk exhibits one or morerisk factors selected from
the group consisting of long standing uncontrolled hyperten-
sion, uncorrected valvular disease, chronic angina, recent
myocardial infarction, or congenital predisposition to heart
disease.
22. The method ofclaim 20, wherein the subject identified
as being at risk has been diagnosed as having a genetic pre-
disposition to cardiac hypertrophy.
23. The method ofclaim 20, wherein the subject identified
as being at risk has a familial history of cardiac hypertrophy.
24. The method ofclaim 20, wherein the miR-499 inhibitor
is an antisense oligonucleotide comprising a sequencethatis
at least 95% complementary to SEQ ID NO:26 overthe entire
length of the antisense oligonucleotide.
25. The method ofclaim 20, wherein the miR-499 inhibitor
is an antisense oligonucleotide comprising a sequencethatis
100% complementary to SEQ ID NO: 26 over the entire
length of the antisense oligonucleotide.
26. The method of claim 20, wherein the miR-208/miR-
208b inhibitor is an antisense oligonucleotide comprising a
sequencethatis at least 95% complementary to SEQ ID NO:
5 or SEQ ID NO:27 over the entire length of the antisense
oligonucleotide.
27. The method of claim 20, wherein the miR-208/miR-
208b inhibitor is an antisense oligonucleotide comprising a
sequence that is 100% complementary to SEQ ID NO: 5 or
SEQ ID NO:27 over the entire length of the antisense oligo-
nucleotide.
28. The method of claim 20, wherein the miR-208/miR-
208b inhibitor is an antisense oligonucleotide comprising a
sequence that is at least 95% complementary to a pre-miR-
208 sequence over the entire length of the antisense oligo-
nucleotide.
29. The method of claim 28, wherein the pre-miR-208
sequence is SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO:
16, or SEQ ID NO:17.
30. The method of claim 20, wherein the miR-208/miR-
208b inhibitor is an antisense oligonucleotide comprising a
sequence that is at least 95% complementary to a pre-miR-
208b sequence over the entire length of the antisense oligo-
nucleotide.
31. The method of claim 30, wherein the pre-miR-208b
sequence is SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO:
32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, or SEQ
ID NO:36.
32. The method ofclaim 20, wherein the miR-499 inhibitor
is an antisense oligonucleotide comprising a sequencethatis
at least 95% complementary to a pre-miR-499 sequence over
the entire length of the antisense oligonucleotide.
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33. The method of claim 32, wherein the pre-miR-499
sequence is SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO:
20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO:23, or SEQ
ID NO:24.
34. The method ofclaim 20, wherein the miR-499 inhibitor
and/or the miR-208/miR-208b inhibitor is about 15 to about
50 nucleotides in length.
35. The method ofclaim 20, wherein the miR-499 inhibitor
and/or the miR-208/miR-208b inhibitor is about 19 to about
25 nucleotides in length.
36. The methodofclaim 20, wherein the miR-499inhibitor
and/or the miR-208b /miR-208b inhibitor comprises at least
one chemical modification.
37. The method of claim 36, wherein the chemical modi-
fication is a sugar and/or backbone modification.
38. The methodof claim 37, wherein the sugar modifica-
tion is a modification selected from the group consisting of
2'-O-alkyl, 2'-O-methyl, 2'-O-methoxyethyl, 2'-fluoro, and a
locked nucleic acid.
39. The method of claim 37, wherein the backbone modi-
fication is a phosphorothioate linkage.
40. The method ofclaim 20, wherein the miR-499 inhibitor
and/or the miR-208/miR-208b inhibitor is conjugated to cho-
lesterol.
41. The method ofclaim 20, wherein the miR-499 inhibitor
and/or the miR-208/miR-208b inhibitor is administered by
intradermal, subcutaneous, intramuscular, intraperitoneal,
intravenous, oral, transdermal, sustained release, controlled
release, delayed release, suppository, catheter, or sublingual
administration or direct injection into cardiac tissue.
* * * * *
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